Modified AAV vectors for gene therapy for hemophilia
Modified AAV vectors with capsid protein and ITR D-sequence substitutions improve transduction efficiency and transgene expression, effectively treating hemophilia A and B by enhancing delivery of coagulation factors.
Patent Information
- Application Number
- PCT/US2026/027295
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing AAV vectors face limitations in transduction efficiency and transgene expression, hindering effective gene therapy applications, particularly for conditions like hemophilia A and B.
Development of AAV vectors with modified AAV capsid proteins and nucleic acid sequences, including substitutions in the ITR D-sequence and incorporation of heterologous sequences like glucocorticoid receptor binding elements (GRE), to enhance transduction efficiency and transgene expression.
The modified AAV vectors demonstrate improved delivery and expression of coagulation factors, such as FIX and FVIII, effectively treating hemophilia A and B by enhancing transduction efficiency and transgene expression.
Smart Images

Figure US2026027295_12112026_PF_FP_ABST
Abstract
Description
T19749Attorney Docket No. U1202.70169WO00MODIFIED AAV VECTORS FOR GENE THERAPY FOR HEMOPHILIARELATED APPLICATIONS
[0001] This application claims the benefit under 35 U. S. C. § 119(e) of U. S. Provisional Patent Application No. 63 / 802,047, filed May 8, 2025, entitled “MODIFIED AAV VECTORS FOR GENE THERAPY FOR HEMOPHILIA”, the entire contents of which are hereby incorporated by reference.FIELD OF THE INVENTION
[0002] The application relates to AAV based gene therapy vectors.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0003] The contents of the electronic sequence listing (U120270169WO00-SEQ-COB.xml; Size: 159,047 bytes; and Date of Creation: May 5, 2026) are herein incorporated by reference in their entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0004] This invention was made with government support under Grant No. R01 HL177230, awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND
[0005] Gene therapy has the potential to treat subjects suffering from or at risk of suffering from various diseases. Improved adeno-associated virus (AAV) vectors for carrying genetic payloads would be beneficial to the development of gene therapies. Many AAV vectors are limited by low transduction efficiency and transgene expression.SUMMARY
[0006] The present disclosure is based at least in part on the development of adeno-associated virus (AAV) vectors with favorable properties for the treatment of hemophilia (e.g., hemophilia A or hemophilia B).1#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0007] Accordingly, aspects of the present disclosure provide AAV particles useful in the treatment of hemophilia. According to some aspects, an adeno-associated virus (AAV) particle comprises (i) an AAV capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an inverted terminal repeat (ITR) with a heterologous sequence, and (b) a transgene coding sequence encoding a coagulation factor.
[0008] In some embodiments, the AAV capsid protein is an AAV3 capsid protein.
[0009] In some embodiments, the heterologous sequence comprises an S-sequence. In some embodiments, the S-sequence comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15).
[0010] In some embodiments, the heterologous sequence comprises a glucocorticoid receptor binding element (GRE). In some embodiments, the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
[0011] In some embodiments, the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
[0012] In some embodiments, the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement.
[0013] In some embodiments, the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its2#15239971vlT19749Attorney Docket No. U1202.70169WO00 reverse or reverse complement. In some embodiments, the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement.
[0014] In some embodiments, the heterologous sequence comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous sequence comprises, consists essentially of, or consists of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).
[0015] In some embodiments, the AAV capsid protein comprises amino acid substitutions at positions corresponding to S663 and / or T492 of SEQ ID NO: 3. In some embodiments, the AAV capsid protein comprises amino acid substitutions corresponding to S663V and / or T492V substitutions in SEQ ID NO: 3.
[0016] In some embodiments, the AAV capsid protein comprises one or more amino acid substitutions at positions corresponding to S262, Y444, T492, K545, S663, and / or Y731 of SEQ ID NO: 3. In some embodiments, the AAV capsid protein comprises amino acid substitutions corresponding to S262D, S262G, or S262F; Y444F; T492V; K545R; S663R or S663V; and / or Y731F substitutions in SEQ ID NO: 3.
[0017] In some embodiments, the coagulation factor comprises coagulation factor IX (FIX). In some embodiments, the coagulation factor comprises human FIX (hFIX).
[0018] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of factor IX-Padua amino acid sequence (SEQ ID NO: 32). In some embodiments, the transgene coding sequence encodes the amino acid sequence of factor IX-Padua amino acid sequence (SEQ ID NO: 32).
[0019] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of codon-optimized factor IX-Padua coding sequence (SEQ ID NO: 31). In some embodiments, the transgene coding sequence comprises the sequence of codon-optimized factor IX-Padua coding sequence (SEQ ID NO: 31).
[0020] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_000124.1 (SEQ ID NO:3#15239971vlT19749Attorney Docket No. U1202.70169WO00 35). In some embodiments, the transgene coding sequence encodes the amino acid sequence of NP_000124.1 (SEQID NO: 35).
[0021] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_000133.4 (SEQ ID NO: 33) or the coding sequence thereof (nucleotides 27-1412 (SEQ ID NO: 34)). In some embodiments, the transgene coding sequence comprises the sequence of NM_000133.4 (SEQ ID NO: 33) or the coding sequence thereof (nucleotides 27-1412 (SEQ ID NO: 34)).
[0022] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_001300842.1 (SEQ ID NO: 38). In some embodiments, the transgene coding sequence encodes the amino acid sequence of NP_001300842.1 (SEQ ID NO: 38).
[0023] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_001313913.2 (SEQ ID NO: 36) or the coding sequence thereof (nucleotides 27-1298 (SEQ ID NO: 37)). In some embodiments, the transgene coding sequence comprises the sequence of NM_001313913.2 (SEQ ID NO: 36) or the coding sequence thereof (nucleotides 27-1298 (SEQ ID NO: 37)).
[0024] In some embodiments, the nucleic acid vector comprises the sequence of pscAAV3-TTR-FIX-Padua (SEQ ID NO: 49) or pscAAV3-GRE-TTR-FIX-Padua (SEQ ID NO: 50).
[0025] In some embodiments, the coagulation factor comprises coagulation factor VIII (FVIII). In some embodiments, the coagulation factor comprises human FVIII (hFVIII).
[0026] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40). In some embodiments, the transgene coding sequence encodes the amino acid sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40).
[0027] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39). In some embodiments, the transgene coding sequence comprises the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39).
[0028] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_000123.1 (SEQ ID NO: 43). In some embodiments, the transgene coding sequence encodes the amino acid sequence of NP_000123.1 (SEQID NO: 43).4#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0029] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_000132.4 (SEQ ID NO: 41) or the coding sequence thereof (nucleotides 172-7227 (SEQ ID NO: 42)). In some embodiments, the transgene coding sequence comprises the sequence of NM_000132.4 (SEQ ID NO: 41) or the coding sequence thereof (nucleotides 172-7227 (SEQ ID NO: 42)).
[0030] In some embodiments, the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_063916.1 (SEQ ID NO: 46). In some embodiments, the transgene coding sequence encodes the amino acid sequence of NP_063916.1 (SEQ ID NO: 46).
[0031] In some embodiments, the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_019863.3 (SEQ ID NO: 44) or the coding sequence thereof (nucleotides 161-811 (SEQ ID NO: 45)). In some embodiments, the transgene coding sequence comprises the sequence of NM_019863.3 (SEQ ID NO: 44) or the coding sequence thereof (nucleotides 161-811 (SEQ ID NO: 45)).
[0032] In some embodiments, the nucleic acid vector comprises the sequence of pscAAV3-TTR-BDD-FVIII (SEQ ID NO: 47) or pscAAV3-GRE-TTR-BDD-FVIII (SEQ ID NO: 48).
[0033] According to some aspects, provided herein are pharmaceutical compositions. In some embodiments, a pharmaceutical composition comprises an AAV particle provided herein and a pharmaceutically-acceptable carrier.
[0034] According to some aspects, provided herein are methods of treating a subject. In some embodiments, a method of treating a subject in need thereof comprises administering to the subject an AAV particle provided herein.
[0035] In some embodiments, the subject has been diagnosed with a coagulopathy. In some embodiments, the coagulopathy is a hemophilia.
[0036] According to some aspects, provided herein are methods of treating hemophilia B in a subject. In some embodiments, a method of treating hemophilia B in a subject comprises administering to the subject an AAV particle or a pharmaceutical composition provided herein.
[0037] According to some aspects, provided herein are methods of treating hemophilia A in a subject. In some embodiments, a method of treating hemophilia A comprises administering to the subject an AAV particle or a pharmaceutical composition provided herein.5#15239971vlT19749Attorney Docket No. U1202.70169WO00 BRIEF DESCRIPTION OF THE DRAWINGS
[0038] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0039] FIGs. 1A-1C show transduction efficiencies of AAV5, AAV6, and AAV3 vectors in human Huh7 hepatic cells (FIG. 1A), in human SK-Hepl liver sinusoidal endothelial cells (LSECs) (FIG. IB), and in primary human LSECs (FIG. 1C). For Huh7 and SK-Hepl, cells were transduced in triplicates with each vector at 3xl03viral genomes (vgs) / cell. For primary human LSECs, cells were transduced in triplicates with each vector at 3xl04vgs / cell. Each of the vectors used expressed an EGFP reporter gene. Transgene expression was determined 72 hours post-transduction and quantitated using a KEYENCE microscope.
[0040] FIG. 2A shows transduction efficiencies of AAV5, AAVrh74, and AAV3 vectors in human hepatic cell line, Huh7. Cells were transduced in triplicates with 3xl03vgs / cell, and each of the vectors expressed an EGFP reporter gene. Transgene expression was visualized and quantitated 72 hours post-transduction using a KEYENCE microscope. FIG. 2B shows transduction efficiencies of AAV5 and AAV3 vectors in primary human hepatocytes. Cells were transduced with 3xl04vgs / cell, and each of the vectors expressed an EGFP reporter gene. Transgene expression was visualized and quantitated 72 hours post-transduction using a KEYENCE microscope.
[0041] FIGs. 3A and 3B show improved efficacy of FIX gene therapy in hemophilia B mice using GRE-ITR element, as measured by chromogenic FIX activity assay (FIG. 3A) or by ELISA for hFIX antigen (FIG. 3B).
[0042] FIG. 4 shows improved efficacy of FVIII gene therapy in hemophilia A mice using GRE-ITR element.
[0043] FIGs. 5A-5B show transduction efficiency of AAV3 vectors expressing the mApple and EGFP reporter genes under the control of TTR and Stab2 promoter, respectively in (FIG.5A) human hepatic (Huh7) and (FIG. 5B) LSEC (SK-Hepl) cells.
[0044] FIG. 6A shows schematic structures of the 5'-ITR of the AAV genome. Various deletions in the A-stem are denoted by arrows. FIG. 6B shows schematic structures of WT scAAV-EGFP vector genome as well as those containing various deletions in the A-stem in 5'-ITR.6#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0045] FIG. 7A shows transduction efficiencies of scAAV-EGFP vectors in mouse hepatocytes in vivo. C57BL / 6 mice (n=5 / group) were administered intravenously either with PBS (Mock), or with 5 x IO10vgs each of WT scAAV-EGFP vectors or those containing various deletions in the A-stem in the 5'-ITRs. Two weeks post vector administration, livers were harvested, sectioned and transgene expression was visualized under a fluorescence microscope. FIG. 7B shows data that were quantitated and analyzed using the ImageJ software.
[0046] FIGs. 8A-8B show transgene expression from linear (L) and no-end (NE-DNA) from human TTR and Stab2 promoters in human hepatic cells. FIG. 8A shows that human Huh7 cells were mock-transfected or transfected with linear- or NE-DNA expressing EGFP under the control of the two promoters. Transgene expression was visualized by fluorescence microscopy. FIG. 8B shows quantitation of the data from triplicate cultures.
[0047] FIGs. 9A-9B show transgene expression from linear (L) and no-end (NE-DNA) from human TTR and Stab2 promoters in human liver sinusoidal endothelial cells. FIG. 9A shows that human SK-Hepl cells were mock-transfected or transfected with linear- or NE-DNA expressing EGFP under the control of the two promoters. FIG. 9B shows that transgene was visualized and quantitated as described under the legend to FIGs. 8A-8B.
[0048] FIG. 10 shows hFVIII expression from plasmid (P), linear (L), and no-end (NE) DNA in human liver sinusoidal endothelial cells, as measured by western blot.DETAILED DESCRIPTION
[0049] The present disclosure is based at least in part on the development of adeno-associated virus (AAV) genomes and particles useful in the delivery of various cargoes to cells, facilitating efficient transgene expression therein. The disclosure relates, at least in part, to the development of AAV vectors that have beneficial properties in the context of hemophilia (e.g., hemophilia A or hemophilia B), such as such vectors that are useful in the treatment of hemophilia. Certain of the AAV vectors described herein incorporate sequence modifications into AAV genomes, resulting in improvements in various characteristics of AAVs, such as packaging, transduction efficiency, transgene expression, etc. These improvements may result from increased second- strand synthesis of the AAV genome, resulting from modifications therein. Certain of the AAV vectors described herein incorporate modifications into capsid proteins comprised within the AAV viral particle. Such capsid protein modifications can7#15239971vlT19749Attorney Docket No. U1202.70169WO00 facilitate beneficial properties, including improved delivery of the AAV vectors into certain cells and / or tissues of interest, improved transgene expression from the AAV vectors, amongst other beneficial properties. The AAV genomes, particles, etc., disclosed herein may be used in a variety of applications including but not limited to compositions and methods (e.g., therapeutic and diagnostic methods). Therapeutic and diagnostic methods disclosed herein include those useful in the treatment and diagnosis of various diseases, disorders, and conditions, in subjects in need thereof. For example, compositions disclosed herein may be useful in the treatment of hemophilia (e.g., hemophilia A or hemophilia B).
[0050] Provided herein are compositions comprising AAV particles (e.g., infectious AAV particles), AAV genomes (e.g., genomes comprising sequence modifications), and methods of using the compositions for transducing cells of interest (e.g., for treating or diagnosing a disease or condition in a subject).Nucleic Acid Vectors (e.g., A A V Genomes)
[0051] According to some aspects, provided herein are nucleic acid vectors (e.g., AAV genomes, e.g., recombinant AAV (rAAV) genomes) that may be encapsidated by wild-type AAV capsids or any other AAV capsids (e.g., comprising a capsid protein comprising one or more amino acid substitutions) as provided herein.
[0052] A nucleic acid vector (e.g., an AAV genome) provided herein may comprise AAV inverted terminal repeat(s) modified to improve properties of the nucleic acid vector, e.g., to improve second-strand synthesis (e.g., increase the rate, efficiency, etc., of second-strand synthesis). In some embodiments, an ITR as provided herein is a 5' ITR, i.e. an ITR that is 5' from a transgene in a nucleic acid vector (e.g., an AAV genome). An ITR serves as an origin of replication and is comprised of two arm palindromes (B-B1and C-C) embedded in a larger stem palindrome (A-A1). An AAV ITR can be in flip or flop configurations. See e.g., Mroske, et al., Human Gene Therapy Methods 23(2): 128-36 (2012). In some embodiments, an ITR has the B-B' and the C-C palindrome closest to the 3' end. In wild-type ITRs, the D-sequence is present only once at each end of the genome thus remaining single-stranded. The D-sequence is also referred to as the “D-element” in the art. The D-sequence consists of 20 or approximately 20 (e.g., 19, 20, 21, 22, 23, 24, etc.) nucleotides adjacent to the terminal resolution site (trs), and generally consists or consists essentially of the medial 20 (or approximately 20) nucleotides of the ITR (where “medial” indicates the segment of the ITR8#15239971vlT19749Attorney Docket No. U1202.70169WO00 that is adjacent to the center of the AAV genome). The first nucleotide of the D-sequence is generally at position 126 or approximately position 126 from the terminus of the AAV genome. See, e.g., Yan, et al., “Inverted Terminal Repeat Sequences Are Important for Intermolecular Recombination and Circularization of Adeno-Associated Virus Genomes” J Virol. 79( 1):364-379 (2005); Earley, et al., “Adeno-Associated Virus Serotype- Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression” Hum Gene Ther. 31(3-4): 151- 162 (2020); Shitik, et al., “AAV- based vector improvements unrelated to capsid protein modification” Front Med. 10:1106085 (2023), doi: 10.3389 / fmed.2023.1106085; Savy, et al., “Impact of Inverted Terminal Repeat Integrity on rAAV8 Production Using the Baculovirus / Sf9 Cells System” Hum Gene Ther Methods 28(5): 277-289 (2017); Wilmott, et al., “A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus” Hum Gene Ther Methods 30(6): 206-213 (2019); and Zhou, et al., “Deletion of the B-B’ and C-C’ regions of inverted terminal repeats reduces rAAV productivity but increases transgene expression” Sci Rep. 7:5432 (2017), doi: 10.1038 / s41598-017-04054-4; the entire contents of each of which are herein incorporated by reference.
[0053] In some embodiments, a nucleic acid vector (e.g., an AAV genome) as provided herein comprises a first inverted terminal repeat (ITR) and a second ITR. In some embodiments, the first ITR is modified. In some embodiments, the second ITR is modified. In some embodiments, a modification of an ITR comprises substitution of the entire D-sequence or substitution of part of a D-sequence. In some embodiments, a modification of an ITR comprises deletion of an entire D-sequence (e.g., the D-sequence of the left ITR or the right ITR) or deletion of part of a D-sequence (e.g., the proximal 10 nucleotides of the ITR, relative to the terminus of the nucleic acid vector). For example, a modification of an ITR may in some embodiments comprise deletion or substitution of 1-20 nucleotides of the D-sequence. In some embodiments, the proximal 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides of the D-sequence, relative to the terminus of the nucleic acid vector, are deleted or substituted. In some embodiments, the proximal 10 nucleotides of the D-sequence, relative to the terminus of the nucleic acid vector, are deleted or substituted. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides in the middle of the D-sequence are deleted or substituted (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides beginning 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 3' or 5' end of the D-sequence). In some embodiments, the distal 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides of the D-9#15239971vlT19749Attorney Docket No. U1202.70169WO00 sequence, relative to the terminus of the nucleic acid vector, are deleted or substituted. In some embodiments, the distal 10 nucleotides of the D-sequence, relative to the terminus of the nucleic acid vector, are deleted or substituted. In some embodiments, a D-sequence comprises the sequence CTCCATCACTAGGGGTTCCT (SEQ ID NO: 22) of the wild-type AAV2 ITR, or a corresponding sequence of a different serotype ITR. In some embodiments, a D-sequence is defined by the sequence CTCCATCACTAGGGGTTCCT (SEQ ID NO: 22). In embodiments in which a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR or of the right ITR of a nucleic acid vector described herein) is substituted, the substituted sequence may be any alternative sequence described herein, such as a sequence described as a “heterologous nucleotide sequence.”
[0054] As used herein, a “heterologous” nucleotide sequence or nucleic acid sequence refers to a sequence that is not native to an AAV or naturally-occurring in an AAV. A heterologous sequence can be a short sequence (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides in length, or of a similar length), or can be a longer sequence (e.g., about 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 nucleotides in length, or longer). A heterologous sequence can comprise a coding sequence (e.g., encoding a gene of interest) or can be a non-coding sequence (e.g., inserted in or replacing a regulatory or structural portion of an AAV nucleic acid, such as an AAV genome).
[0055] A nucleic acid vector (e.g., an AAV genome) may comprise one or more heterologous nucleic acid sequences comprising a gene of interest (e.g., encoding a protein or polypeptide of interest) and one or more sequences comprising inverted terminal repeat (ITR) sequences (e.g., wild-type ITR sequences or modified ITR sequences) flanking the one or more heterologous nucleic acid sequences. In some embodiments, a nucleic acid vector (e.g., an AAV genome) is encapsidated within an AAV capsid forming an AAV particle. In some embodiments, a nucleic acid vector disclosed herein is encapsidated by a wild-type AAV capsid (e.g., a wild- type AAV3 capsid) or another AAV capsid disclosed herein, such as an AAV capsid comprising one or more amino acid substitutions (e.g., a modified AAV3 capsid).
[0056] In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises native AAV genes or native AAV nucleotide sequences. In some embodiments, one or more native AAV genes or native AAV nucleotide sequences may be removed from a nucleic acid vector (e.g., an AAV genome). In some embodiments, one or more native AAV genes or native AAV10#15239971vlT19749Attorney Docket No. U1202.70169WO00 nucleotide sequences may be removed from a nucleic acid vector (e.g., an AAV genome) and replaced with a gene or interest.
[0057] A nucleic acid vector (e.g., an AAV genome) can be of any AAV serotype, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrhlO, or AAVrh74, or a combination of serotypes. In some embodiments, a nucleic acid vector (e.g., an AAV genome) encapsidated within an AAV capsid forms a pseudotyped AAV particle, such that the genome is of a serotype distinct from the capsid in which it is encapsidated. For example, a nucleic acid vector (e.g., an AAV genome) of serotype AAV2 may be encapsidated within a capsid of serotype AAV3.
[0058] In some embodiments, a nucleic acid vector (e.g., an AAV genome) is single- stranded and comprises a first inverted terminal repeat (ITR) and a second ITR. As disclosed herein, the first ITR refers to the ITR at the 5' terminus of the nucleic acid vector (e.g., AAV genome), and the second ITR refers to the ITR at the 3' terminus of the nucleic acid vector (e.g., AAV genome). Each ITR in its native or wild-type form is or is about 145 nucleotides in length (e.g., about 140 nucleotides, about 145 nucleotides, about 150 nucleotides, about 155 nucleotides, about 160 nucleotides, or about 165 nucleotides) and comprises a D-sequence. Each ITR can independently be of any AAV serotype (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrhlO, or AAVrh74), or both ITRs may be of the same serotype. ITRs are described, for example, in Grimm et al. J. Virol.80(l):426-439 (2006). Exemplary left ITR sequences are provided below. In each ITR sequence, the D-sequence is underlined. A right ITR has a nucleotide sequence which is the reverse complement of the corresponding left ITR (e.g., the AAV2 right ITR has a nucleotide sequence which is the reverse complement of the AAV2 left ITR).
[0059] Example of wild-type AAV 1 left ITR:TTGCCCACTCCCTCTCTGCGCGCTCGCTCGCTCGGTGGGGCCTGCGGACCAAAGGTCCGCAGACGGCAG AGGTCTCCTCTGCCGGCCCCACCGAGCGAGCGAGCGCGCAGAGAGGGAGTGGGCAACTCCATCACTAGG GGTAA (SEQ ID NO: 23)
[0060] Example of wild- type AAV2 left ITR:TTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCG GGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGG GGTTCCT (SEQ ID NO: 24)
[0061] Example of wild-type AAV3 left ITR:TTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCTGGCGACCAAAGGTCGCCAGACGGACG11#15239971vlT19749Attorney Docket No. U1202.70169WO00 TGCTTTGCACGTCCGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGGAGTGGCCAACTCCATCACTAGA GGTATGGC (SEQ ID NO: 25)
[0062] Example of wild-type AAV4 left ITR:TTGGCCACTCCCTCTATGCGCGCTCGCTCACTCACTCGGCCCTGGAGACCAAAGGTCTCCAGACTGCCG GCCTCTGGCCGGCAGGGCCGAGTGAGTGAGCGAGCGCGCATAGAGGGAGTGGCCAACTCCATCATCTAG GTTTGCCC (SEQ ID NO: 26)
[0063] Example of wild- type AAV5 left ITR:CTCTCCCCCCTGTCGCGTTCGCTCGCTCGCTGGCTCGTTTGGGGGGGTGGCAGCTCAAAGAGCTGCCAG ACGACGGCCCTCTGGCCGTCGCCCCCCCAAACGAGCCAGCGAGCGAGCGAACGCGACAGGGGGGAGAGT GCCACACTCTCAAGCAAGGGGGTTTTGTA (SEQ ID NO: 27)
[0064] Example of wild- type AAV6 left ITR:TTGCCCACTCCCTCTATGCGCGCTCGCTCGCTCGGTGGGGCCTGCGGACCAAAGGTCCGCAGACGGCAG AGCTCTGCTCTGCCGGCCCCACCGAGCGAGCGAGCGCGCATAGAGGGAGTGGGCAACTCCATCACTAGG GGTA (SEQ ID NO: 28 )
[0065] Example of wild-type AAVrh74 left ITR:TTGCCCACTCCCTCTCTGCGCGCTCGCTCGCTCGGTGGGGCCTGCGGACCAAAGGTCCGCAGACGGCAG AGGTCTCCTCTGCCGGCCCCACCGAGCGAGCGAGCGCGCAGAGAGGGAGTGGGCAACTCCATCACTAGG GGTAA (SEQ ID NO: 29)
[0066] In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises a modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of an ITR. In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises a modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of a left ITR. In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises a modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of a right ITR. In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises a modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of both a left ITR and a right ITR. In some embodiments, a nucleic acid vector (e.g., an AAV genome) comprises a modification (e.g., a deletion, a substitution, or an insertion) of either a left ITR or a right ITR, but not both (i.e., the nucleic acid vector comprises a modification of only one ITR).
[0067] The ITR sequence comprises a terminal sequence at the 5' or 3' end of the nucleic acid vector (e.g., AAV genome) which forms a palindromic double- stranded T-shaped hairpin structure, and an additional sequence which remains single- stranded (i.e., is not part of the T-shaped hairpin structure), termed the D-sequence. The D-sequence of an ITR is typically approximately 20 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides located 12#15239971vlT19749Attorney Docket No. U1202.70169WO00at the distal (relative to the terminus of the nucleic acid vector) end of the ITR (e.g., the 3' end of the ITR at the 5' end of the genome, or the 5' end of the ITR at the 3' end of the genome), and corresponds to the sequence of CTCCATCACTAGGGGTTCCT (SEQ ID NO: 22) of the wild- type AAV2 left ITR or a corresponding sequence in an ITR of another serotype. The D-sequence of an ITR in some embodiments comprises, consists essentially of, or consists of the nucleic acid sequence CTCCATCACTAGGGGTTCCT (SEQ ID NO: 22) of the wild-type AAV2 left ITR or a corresponding sequence in an ITR of another serotype.
[0068] In some embodiments, substitution of a D-sequence comprises substitution of at least 5 nucleotides (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides) of the D-sequence with a different nucleotide sequence (e.g., an S-sequence or portion thereof, or a GRE or portion thereof, or another heterologous sequence). In some embodiments, substitution of a D-sequence comprises substitution of 10 nucleotides of the D-sequence. In some embodiments, substitution of a D-sequence comprises substitution of the 3'-most 10 nucleotides of the D-sequence. In some embodiments, substitution of a D-sequence comprises substitution of the 5'-most 10 nucleotides of the D-sequence. In some embodiments, substitution of a D-sequence comprises substitution of an internal portion that does not comprise a terminal nucleotide of the D-sequence, such as 10 nucleotides of the internal portion of the D-sequence.
[0069] In some embodiments, deletion of a D-sequence comprises deletion of at least 5 nucleotides (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides) of the D-sequence. In some embodiments, deletion of a D-sequence comprises deletion of 10 nucleotides of the D-sequence. In some embodiments, deletion of a D-sequence comprises deletion of the 3'-most 10 nucleotides of the D-sequence. In some embodiments, deletion of a D-sequence comprises deletion of the 5'-most 10 nucleotides of the D-sequence. In some embodiments, deletion of a D-sequence comprises deletion of an internal portion that does not comprise a terminal nucleotide of the D-sequence, such as 10 nucleotides of the internal portion of the D-sequence.
[0070] In some embodiments, a heterologous nucleotide sequence is inserted into a nucleic acid vector (e.g., an AAV genome) instead of substituting a portion of an ITR. For example, a heterologous nucleotide sequence may be inserted inside the D-sequence of an ITR, upstream of the D-sequence of an ITR, or downstream of the D-sequence of an ITR.13#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0071] In some embodiments, substitution of a D-sequence comprises substitution of at least 5 nucleotides (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides) of the D-sequence with a different nucleotide sequence (e.g., a heterologous nucleotide sequence or portion thereof). In some embodiments, substitution of a D-sequence comprises substitution of 10 nucleotides of the D-sequence. In some embodiments, substitution of a D-sequence comprises substitution of the 3'-most 10 nucleotides of the D-sequence (e.g., of the D-sequence of the ITR at the 3' end of the nucleic acid vector (e.g., AAV genome)). In some embodiments, substitution of a D-sequence comprises substitution of the 5 '-most 10 nucleotides of the D-sequence (e.g., of the D-sequence of the ITR at the 5' end of the nucleic acid vector (e.g., AAV genome)). In some embodiments, substitution of a D-sequence comprises substitution of an internal portion that does not comprise a terminal nucleotide of the D-sequence, such as 10 nucleotides of the internal portion of the D-sequence.
[0072] In some embodiments, an ITR comprising a substitution, insertion, or deletion as disclosed herein comprises one or more additional modifications, such as an additional substitution, modification, or deletion in another portion of the ITR.
[0073] In some embodiments, modification of a nucleic acid vector (e.g., an AAV genome) as provided herein results in the generation of a nucleic acid vector with increased capacity. For example, wild-type AAV genomes are approximately 4.7 kilobases (kb) in length; recombinant AAV genomes have typically been limited to approximately this same length. See, e.g., Wu, et al., Mol Ther. (2010) 18(1): 80-86. Self-complementary AAV genomes are often even more limited, with maximum packaging capacities of about 2.3 kb. The modifications provided herein can, in some embodiments, enable substantially larger AAV genomes (comprising the modification(s)) to be useful in generating AAV particles for delivery of genes of interest.
[0074] In some embodiments, an AAV genome disclosed herein comprising a modification can be generated having a length greater than a corresponding AAV genome not comprising the modification, without substantial negative impacts on AAV genome rescue, replication, and / or packaging.
[0075] In some embodiments, an AAV genome disclosed herein is about 4 kilobases (kb), 4.5 kb, 5 kb, 5.5 kb, 6 kb, 6.5 kb, 7 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 10 kb, 10.5 kb, 11 kb, 11.5 kb, 12 kb, 12.5 kb, 13 kb, 13.5 kb, 14 kb, 14.5 kb, 15 kb, 15.5 kb, 16 kb, 16.5 kb, 17 kb, 17.5 kb, or more in length. In some embodiments, an AAV genome disclosed herein is at least 4 kilobases (kb), 4.5 kb, 5 kb, 5.5 kb, 6 kb, 6.5 kb, 7 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 1014#15239971vlT19749Attorney Docket No. U1202.70169WO00 kb, 10.5 kb, 11 kb, 11.5 kb, 12 kb, 12.5 kb, 13 kb, 13.5 kb, 14 kb, 14.5 kb, 15 kb, 15.5 kb, 16 kb, 16.5 kb, 17 kb, 17.5 kb, or more in length. In some embodiments, an AAV genome disclosed herein is less than 4 kilobases (kb), 4.5 kb, 5 kb, 5.5 kb, 6 kb, 6.5 kb, 7 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 10 kb, 10.5 kb, 11 kb, 11.5 kb, 12 kb, 12.5 kb, 13 kb, 13.5 kb, 14 kb, 14.5 kb, 15 kb, 15.5 kb, 16 kb, 16.5 kb, 17 kb, or 17.5 kb in length. It should be understood that an AAV genome disclosed herein can be of any size or size range within the kb values disclosed herein (e.g., an AAV genome can be 4-17.5 kb in length, 7-10 kb in length, 6-9.5 kb in length, or any range or combination of lengths disclosed herein).
[0076] A nucleic acid vector (e.g., an AAV genome) as disclosed herein in some embodiments comprises one or more regulatory elements, such as regulatory elements operably linked to a transgene. In some embodiments, a regulatory element is located between two ITRs, a 5' ITR and a 3' ITR. In some embodiments, a regulatory element is located upstream of or 5' relative to a transgene. In some embodiments, a regulatory element is located downstream of or 3' relative to the 5' ITRs as described herein. In some embodiments, a regulatory element is located upstream of or 5' relative to a transgene and downstream of or 3' relative to a 5' ITR. A regulatory element refers to a nucleotide sequence or structural component of a nucleic acid vector which is involved in the regulation of expression of components of the nucleic acid vector (e.g., a gene of interest comprised therein). Regulatory elements include, but are not limited to, promoters, enhancers, silencers, insulators, response elements, initiation sites, termination signals, and ribosome binding sites.
[0077] Promoters include constitutive promoters, inducible promoters, tissue-specific promoters, cell type-specific promoters, and synthetic promoters. For example, a nucleic acid vector disclosed herein may include viral promoters or promoters from mammalian genes that are generally active in promoting transcription. Non-limiting examples of constitutive viral promoters include the Herpes Simplex virus (HSV), thymidine kinase (TK), Rous Sarcoma Virus (RSV), Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV), Ad E1A and cytomegalovirus (CMV) promoters. Non-limiting examples of constitutive mammalian promoters include various housekeeping gene promoters, as exemplified by the P-actin promoter.
[0078] In some embodiments, a nucleic acid vector comprises a liver sinusoidal endothelial cell (LSEC)-specific promoter(s), e.g., to control the expression of coagulation factor VIII. Examples of LSEC-specific promoters include Oit3, hFVIII (also known as F8, or pF8),15#15239971vlT19749Attorney Docket No. U1202.70169WO00 STAB2, EPAS1, LIFR, NIDI, CEEC4M, CLEC1B, CRHBP, FCN3, C-MAF, GATA4, and MEIS2 promoters. Preferred LSEC-specific promoters are hFVIII and STAB2 promoters.
[0079] An example of a STAB 2 promoter sequence is:ATCTTTCTACTTCTCTCTGAGGCAAAATTTCAGTCTGGAAACCCTCCCATTCCTGCAGAGACCACAGCTTCTGATT AC AAGC C C C AGT T C AAGGT T T C AT C AC T GAAC C AGAC AGAAAT AAAAGC AAAGAGAGC AAGAC AC CTGCCCTTGCC AATTCACAGACACCCTGCAAGTAAAGTGGGGAAAGGGACGTGAATTTATACAGTTCAAGGTCAAATTATCTCTTTC TGCCTCTGGCACCAAAGAACTTGAGTTTGGTTTTGTTTGATTTTGTTTTTACCTGAAACAGCAGGAAGGAAGTGAG T GC C C T C AT AAAAGAAAGAAT GT GT C GC AC C AAAAGGC T C T T C AAC AAC GAC AGC T C C T GGAAAC AT AC C C T GT T C GAGC C AC AC T GGAGT GAAT T C GAAC TGGGCAATGGCTC C AAT AGAT C T C AGC C AGAT AAGAC AC AGGC AC AC AC AG TAACGGGAGTGATGCGGATCAATTTCTTTGTCCCTCTCATTCTTCTGCTTCTTGTCAAAAGGATACAATAATTAAT TCCTGAGGCTTTGAAAGTGGATTATCTCATTGCTAA ( SEQ ID NO: 30 )
[0080] In some embodiments, a nucleic acid vector does not comprise a liver-specific promoter (i.e., the vector is completely devoid of liver- specific promoters).
[0081] Inducible promoters or other inducible regulatory elements may also be used to achieve desired expression levels of a gene of interest (e.g., a protein or polypeptide of interest). Nonlimiting examples of suitable inducible promoters include those from genes such as cytochrome P450 genes, heat shock protein genes, metallothionein genes, and hormone-inducible genes, such as the estrogen gene promoter. Another example of an inducible promoter is the tetVP16 promoter that is responsive to tetracycline.
[0082] Tissue-specific promoters or other tissue-specific regulatory elements are also contemplated herein.
[0083] Synthetic promoters are also contemplated herein. A synthetic promoter may comprise, for example, regions of known promoters, regulatory elements, transcription factor binding sites, enhancer elements, repressor elements, and the like.
[0084] In some embodiments, a nucleic acid vector (e.g., an AAV genome) provided herein comprises a nucleotide sequence encoding a product (e.g., a protein or polypeptide product). In some embodiments, a nucleotide sequence comprises a nucleotide sequence of a gene of interest. In some embodiments, a gene of interest encodes a therapeutic and / or diagnostic agent (e.g., protein or polypeptide). In some embodiments, a therapeutic or diagnostic agent is an antibody, a peptibody, a growth factor, a clotting factor, a hormone, a membrane protein, a cytokine, a chemokine, an activating or inhibitory peptide acting on cell surface receptors or ion channels, a cell-permeant peptide targeting intracellular processes, a thrombolytic agent, an enzyme, a bone morphogenetic protein, a nuclease, a protein used for gene editing, an Fc-fusion protein, an anticoagulant, or a protein or polypeptide that can be detected using a16#15239971vlT19749Attorney Docket No. U1202.70169WO00 laboratory test. In some embodiments, a nucleic acid vector (e.g., an AAV genome) provided herein comprises a nucleotide sequence encoding a guide RNA or other nucleic acid used for gene editing, optionally in addition to a protein used for gene editing.
[0085] In some embodiments, a product encoded by a nucleic acid vector (e.g., an AAV genome) disclosed herein is a detectable molecule. A detectable molecule is a molecule that can be visualized (e.g., using a naked eye, under a microscope, or using a light detection device such as a camera). In some embodiments, the detectable molecule is a fluorescent molecule, a bioluminescent molecule, or a molecule that provides color (e.g., P-galactosidase, P-lactamase, P-glucuronidase, or spheroidenone). In some embodiments, the detectable molecule is a fluorescent, bioluminescent or enzymatic protein or functional peptide or polypeptide thereof.
[0086] In some embodiments, fluorescent protein is a blue fluorescent protein, a cyan fluorescent protein, a green fluorescent protein, a yellow fluorescent protein, an orange fluorescent protein, a red fluorescent protein, or a functional peptide or polypeptide thereof. A blue fluorescent protein may be azurite, EBFP, EBFP2, mTagBFP, or Y66H. A cyan fluorescent protein may be ECFP, AmCyanl, Cerulean, CyPet, mECFP, Midori-ishi Cyan, mTFPl, or TagCFP. A Green fluorescent protein may be AcGFP, Azami Green, EGFP, Emarald, GFP or a mutated form of GFP (e.g., GFP-S65T, mWasabi, Stemmer, Superfolder GFP, TagGFP, TurboGFP, or ZsGreen). A yellow fluorescent protein may be EYFP, mBanana, mCitrine, PhiYFp, TagYFP, Topaz, Venus, YPet, or ZsYellowl. An orange fluorescent protein may be DsRed, RFP, DsRed2, DsRed-Express, Ds-Red-monomer, Tomato, tdTomato, Kusabira Orange, mK02, mOrange, mOrange2, mTangerine, TagRFP, or TagRFP-T. A red fluorescent protein may be AQ142, AsRed2, dKeima-Tandem, HcRedl, tHcRed, Jred, mApple, mCherry, mPlum, mRasberry, mRFPl, mRuby or mStrawberry.
[0087] In some embodiments, a detectable molecule is a bioluminescent protein or a functional peptide or polypeptide thereof. Non-limiting examples of bioluminescent proteins are firefly luciferase, click-beetle luciferase, Renilla luciferase, and luciferase from Oplophorus gracilirostris.
[0088] In some embodiments, a detectable molecule may be any polypeptide or protein that can be detected using methods known in the art. Non-limiting methods of detection are fluorescence imaging, luminescent imaging, bright filed imaging, and include imaging facilitated by immunofluorescence or immunohistochemical staining.17#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0089] Additional features of AAV particles, nucleic acid vectors, and capsid proteins are described in Patent Application Publication No. US2017 / 0356009, the contents of which are incorporated herein by reference in their entirety.
[0090] In some embodiments, a nucleic acid vector (e.g., an AAV genome) is comprised within or encoded by a plasmid.
[0091] Nucleic acid vectors as disclosed herein, e.g., comprising modified ITRs, can be prepared by one of ordinary skill in the art by known methods.S-sequences
[0092] In some embodiments, the D-sequence of an ITR (e.g., the first ITR or the second ITR) of a nucleic acid vector disclosed herein is entirely or partially removed. In some embodiments, the D-sequence of both ITRs of a nucleic acid vector disclosed herein is entirely or partially removed. In some embodiments, the D-sequence of an ITR (e.g., the first ITR or the second ITR) is entirely or partially replaced with a non- AAV sequence (i.e., a nucleotide sequence that is not from an AAV nucleic acid, or a heterologous sequence). In some embodiments, the D-sequence of an ITR (e.g., the first ITR or the second ITR) is entirely or partially replaced with an S-sequence. In some embodiments, the S-sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence18#15239971vlAttorney Docket No. U1202.70169WO00 has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has a length of or about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides.Glucocorticoid receptor-binding elements
[0093] In some embodiments, the D-sequence of an ITR (e.g., the first ITR or the second ITR) is entirely or partially substituted with a glucocorticoid receptor-binding element (GRE). In some embodiments, a GRE is inserted into a nucleic acid vector instead of substituting a portion of an ITR. For example, a GRE may be inserted inside the D-sequence of an ITR, upstream of the D-sequence of an ITR, or downstream of the D-sequence of an ITR.
[0094] Glucocorticoid receptor-binding elements are also known as glucocorticoid responsive elements or glucocorticoid response elements. GREs are nucleotide sequences that glucocorticoid receptor binds, which in their native loci are generally about 100 to 2,000 base pairs upstream from the transcription initiation site of a gene. The present disclosure is based in part on the discovery that a portion of the AAV2 D-sequence shares partial homology to the consensus half-site of the GRE, and that the glucocorticoid receptor signaling pathway is activated following AAV2 infection or transduction. In some embodiments, substitution of a portion or all of a D-sequence of an AAV ITR with a GRE increases expression of a transgene encoded by a nucleic acid vector encapsidated within an AAV particle.
[0095] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of19#15239971vlAttorney Docket No. U1202.70169WO00 the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
[0096] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence20#15239971vlAttorney Docket No. U1202.70169WO00 GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
[0097] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse21#15239971vlT19749Attorney Docket No. U1202.70169WO00 complement. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement.
[0098] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some22#15239971vlT19749Attorney Docket No. U1202.70169WO00 embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement.Other heterologous sequences
[0099] In some embodiments, the D-sequence of an ITR (e.g., the first ITR or the second ITR) is entirely or partially replaced with a heterologous nucleotide sequence. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with the sequence 5'-23#15239971vlT19749Attorney Docket No. U1202.70169WO00 ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has a length of or about 10 nucleotides (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides).Transgenes
[0100] In some embodiments, a nucleic acid vector disclosed herein comprises a transgene sequence. This transgene sequence may be expressed within a cell (e.g., after administration to a subject, or after contacting a cell in vitro), e.g., to produce a desired product, such as a diagnostic product or a therapeutic product.
[0101] In some embodiments, a transgene comprises a sequence encoding coagulation factor IX (e.g., human coagulation factor IX, “hFIX”). Exemplary sequences encoding hFIX, and exemplary amino acid sequences of hFIX, are provided below:Homo sapiens coagulation factor IX-Padua coding sequence ("hFIX- Padua") (codon-optimized)1 ATGCAGAGGG TCAATATGAT CATGGCTGAA TCTCCTGGGC TGATCACCAT TTGCCTGCTG 61 GGATACCTGC TGTCTGCTGA GTGTACAGTG TTCCTGGACC ATGAGAATGC CAATAAGATC 121 CTGAACAGGC CCAAAAGATA CAATTCTGGA AAGCTGGAGG AATTTGTGCA GGGCAACCTG 181 GAGAGGGAAT GCATGGAGGA AAAGTGTAGC TTTGAGGAAG CTAGGGAGGT GTTTGAAAAC 241 ACAGAGAGGA CCACAGAATT CTGGAAGCAG TATGTGGATG GAGATCAGTG TGAGTCCAAC 301 CCCTGTCTGA ATGGAGGGTC TTGCAAAGAT GATATCAACT CCTATGAGTG CTGGTGTCCT 361 TTTGGATTTG AAGGCAAAAA TTGTGAGCTG GATGTGACCT GTAACATCAA GAATGGCAGG 421 TGTGAGCAGT TCTGTAAAAA CTCTGCTGAT AATAAGGTGG TCTGCAGCTG TACAGAAGGC 481 TATAGGCTGG CTGAGAACCA GAAGAGCTGT GAACCAGCTG TGCCCTTCCC TTGTGGGAGG 541 GTGTCTGTCA GCCAGACCTC TAAGCTGACC AGAGCTGAGA CTGTGTTCCC AGATGTGGAT 601 TATGTCAACT CCACAGAGGC TGAAACCATC CTGGACAACA TCACCCAGTC TACCCAGTCC 661 TTCAATGACT TTACCAGAGT GGTGGGAGGA GAGGATGCCA AACCAGGCCA GTTCCCCTGG 721 CAGGTGGTCC TGAATGGGAA GGTGGATGCT TTTTGTGGGG GATCCATTGT GAATGAGAAA 781 TGGATTGTCA CAGCTGCTCA CTGTGTGGAG ACAGGGGTCA AGATCACTGT GGTGGCTGGA 841 GAGCACAACA TTGAGGAAAC AGAACATACT GAGCAGAAGA GGAATGTGAT CAGAATCATC 901 CCTCACCATA ACTACAATGC TGCTATCAAC AAATATAATC ATGACATTGC CCTGCTGGAA 961 CTGGATGAGC CTCTGGTGCT GAACAGCTAT GTCACCCCAA TCTGCATTGC TGACAAAGAG 24#15239971vlT19749Attorney Docket No. U1202.70169WO00 1021 TATACCAATA TCTTCCTGAA GTTTGGATCT GGATATGTGT CTGGATGGGG AAGGGTCTTC 1081 CACAAGGGCA GGTCTGCCCT GGTGCTGCAG TATCTGAGGG TGCCTCTGGT GGACAGAGCT 1141 ACCTGCCTGC TGTCTACCAA GTTCACCATC TACAACAATA TGTTCTGTGC TGGATTTCAT 1201 GAGGGAGGCA GGGACTCCTG TCAGGGGGAT TCTGGAGGCC CACATGTGAC AGAGGTGGAA 1261 GGCACCAGCT TCCTGACTGG CATCATCTCT TGGGGGGAGG AATGTGCTAT GAAGGGGAAA 1321 TATGGAATCT ACACCAAAGT GAGCAGGTAT GTGAACTGGA TCAAAGAGAA GACCAAACTG 1381 ACCTGA ( SEQ ID NO: 31 )Homo sapiens coagulation factor IX-Padua amino acid sequence (“hFIX-Padua”)1 MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG51 KLEEFVQGNL ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN101 PCLNGGSCKD DINSYECWCP FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD151 NKWCSCTEG YRLAENQKSC EPAVPFPCGR VSVSQTSKLT RAETVFPDVD201 YVNSTEAETI LDNITQSTQS FNDFTRWGG EDAKPGQFPW QWLNGKVDA251 FCGGSIVNEK WIVTAAHCVE TGVKITWAG EHNIEETEHT EQKRNVIRII301 PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS351 GYVSGWGRVF HKGRSALVLQ YLRVPLVDRA TCLLSTKFTI YNNMFCAGFH401 EGGRDSCQGD SGGPHVTEVE GTSFLTGIIS WGEECAMKGK YGIYTKVSRY451 VNWIKEKTKL T ( SEQ ID NO: 32 )Homo sapiens coagulation factor IX (F9), transcript variant 1, mRNA (NCBIRef. Seq. NM_000133.4)1 ACTTTCACAA TCTGCTAGCA AAGGTTATGC AGCGCGTGAA CATGATCATG GCAGAATCAC 61 CAGGCCTCAT CACCATCTGC CTTTTAGGAT ATCTACTCAG TGCTGAATGT ACAGTTTTTC 121 TTGATCATGA AAACGCCAAC AAAATTCTGA ATCGGCCAAA GAGGTATAAT TCAGGTAAAT 181 TGGAAGAGTT TGTTCAAGGG AACCTTGAGA GAGAATGTAT GGAAGAAAAG TGTAGTTTTG 241 AAGAAGCACG AGAAGTTTTT GAAAACACTG AAAGAACAAC TGAATTTTGG AAGCAGTATG 301 TTGATGGAGA TCAGTGTGAG TCCAATCCAT GTTTAAATGG CGGCAGTTGC AAGGATGACA 361 TTAATTCCTA TGAATGTTGG TGTCCCTTTG GATTTGAAGG AAAGAACTGT GAATTAGATG 421 TAACATGTAA CATTAAGAAT GGCAGATGCG AGCAGTTTTG TAAAAATAGT GCTGATAACA 481 AGGTGGTTTG CTCCTGTACT GAGGGATATC GACTTGCAGA AAACCAGAAG TCCTGTGAAC 541 CAGCAGTGCC ATTTCCATGT GGAAGAGTTT CTGTTTCACA AACTTCTAAG CTCACCCGTG 601 CTGAGACTGT TTTTCCTGAT GTGGACTATG TAAATTCTAC TGAAGCTGAA ACCATTTTGG 661 ATAACATCAC TCAAAGCACC CAATCATTTA ATGACTTCAC TCGGGTTGTT GGTGGAGAAG 721 ATGCCAAACC AGGTCAATTC CCTTGGCAGG TTGTTTTGAA TGGTAAAGTT GATGCATTCT 781 GTGGAGGCTC TATCGTTAAT GAAAAATGGA TTGTAACTGC TGCCCACTGT GTTGAAACTG 841 GTGTTAAAAT TACAGTTGTC GCAGGTGAAC ATAATATTGA GGAGACAGAA CATACAGAGC 901 AAAAGCGAAA TGTGATTCGA ATTATTCCTC ACCACAACTA CAATGCAGCT ATTAATAAGT 961 ACAACCATGA CATTGCCCTT CTGGAACTGG ACGAACCCTT AGTGCTAAAC AGCTACGTTA 1021 CACCTATTTG CATTGCTGAC AAGGAATACA CGAACATCTT CCTCAAATTT GGATCTGGCT 1081 ATGTAAGTGG CTGGGGAAGA GTCTTCCACA AAGGGAGATC AGCTTTAGTT CTTCAGTACC 1141 TTAGAGTTCC ACTTGTTGAC CGAGCCACAT GTCTTCGATC TACAAAGTTC ACCATCTATA 1201 ACAACATGTT CTGTGCTGGC TTCCATGAAG GAGGTAGAGA TTCATGTCAA GGAGATAGTG 1261 GGGGACCCCA TGTTACTGAA GTGGAAGGGA CCAGTTTCTT AACTGGAATT ATTAGCTGGG 1321 GTGAAGAGTG TGCAATGAAA GGCAAATATG GAATATATAC CAAGGTATCC CGGTATGTCA 1381 ACTGGATTAA GGAAAAAACA AAGCTCACTT AATGAAAGAT GGATTTCCAA GGTTAATTCA 1441 TTGGAATTGA AAATTAACAG GGCCTCTCAC TAACTAATCA CTTTCCCATC TTTTGTTAGA 1501 TTTGAATATA TACATTCTAT GATCATTGCT TTTTCTCTTT ACAGGGGAGA ATTTCATATT 1561 TTACCTGAGC AAATTGATTA GAAAATGGAA CCACTAGAGG AATATAATGT GTTAGGAAAT 1621 TACAGTCATT TCTAAGGGCC CAGCCCTTGA CAAAATTGTG AAGTTAAATT CTCCACTCTG 1681 TCCATCAGAT ACTATGGTTC TCCACTATGG CAACTAACTC ACTCAATTTT CCCTCCTTAG 1741 CAGCATTCCA TCTTCCCGAT CTTCTTTGCT TCTCCAACCA AAACATCAAT GTTTATTAGT 1801 TCTGTATACA GTACAGGATC TTTGGTCTAC TCTATCACAA GGCCAGTACC ACACTCATGA 1861 AGAAAGAACA CAGGAGTAGC TGAGAGGCTA AAACTCATCA AAAACACTAC TCCTTTTCCT 1921 CTACCCTATT CCTCAATCTT TTACCTTTTC CAAATCCCAA TCCCCAAATC AGTTTTTCTC 25#15239971vlT19749Attorney Docket No. U1202.70169WO00 1981 TTTCTTACTC CCTCTCTCCC TTTTACCCTC CATGGTCGTT AAAGGAGAGA TGGGGAGCAT 2041 CATTCTGTTA TACTTCTGTA CACAGTTATA CATGTCTATC AAACCCAGAC TTGCTTCCGT 2101 AGTGGAGACT TGCTTTTCAG AACATAGGGA TGAAGTAAGG TGCCTGAAAA GTTTGGGGGA 2161 AAAGTTTCTT TCAGAGAGTT AAGTTATTTT ATATATATAA TATATATATA AAATATATAA 2221 TATACAATAT AAATATATAG TGTGTGTGTA TGCGTGTGTG TAGACACACA CGCATACACA 2281 CATATAATGG AAGCAATAAG CCATTCTAAG AGCTTGTATG GTTATGGAGG TCTGACTAGG 2341 CATGATTTCA CGAAGGCAAG ATTGGCATAT CATTGTAACT AAAAAAGCTG ACATTGACCC 2401 AGACATATTG TACTCTTTCT AAAAATAATA ATAATAATGC TAACAGAAAG AAGAGAACCG 2461 TTCGTTTGCA ATCTACAGCT AGTAGAGACT TTGAGGAAGA ATTCAACAGT GTGTCTTCAG 2521 CAGTGTTCAG AGCCAAGCAA GAAGTTGAAG TTGCCTAGAC CAGAGGACAT AAGTATCATG 2581 TCTCCTTTAA CTAGCATACC CCGAAGTGGA GAAGGGTGCA GCAGGCTCAA AGGCATAAGT 2641 CATTCCAATC AGCCAACTAA GTTGTCCTTT TCTGGTTTCG TGTTCACCAT GGAACATTTT 2701 GATTATAGTT AATCCTTCTA TCTTGAATCT TCTAGAGAGT TGCTGACCAA CTGACGTATG 2761 TTTCCCTTTG TGAATTAATA AACTGGTGTT CTGGTTCATA ( SEQ ID NO: 33 ) Homo sapiens coagulation factor IX (F9), transcript variant 1, mRNA (NCBIRef. Seq. NM_000133.4, nucleotides 27-1412)- coding sequence1 ATGCAGCGCG TGAACATGAT CATGGCAGAA TCACCAGGCC TCATCACCAT CTGCCTTTTA 61 GGATATCTAC TCAGTGCTGA ATGTACAGTT TTTCTTGATC ATGAAAACGC CAACAAAATT 121 CTGAATCGGC CAAAGAGGTA TAATTCAGGT AAATTGGAAG AGTTTGTTCA AGGGAACCTT 181 GAGAGAGAAT GTATGGAAGA AAAGTGTAGT TTTGAAGAAG CACGAGAAGT TTTTGAAAAC 241 ACTGAAAGAA CAACTGAATT TTGGAAGCAG TATGTTGATG GAGATCAGTG TGAGTCCAAT 301 CCATGTTTAA ATGGCGGCAG TTGCAAGGAT GACATTAATT CCTATGAATG TTGGTGTCCC 361 TTTGGATTTG AAGGAAAGAA CTGTGAATTA GATGTAACAT GTAACATTAA GAATGGCAGA 421 TGCGAGCAGT TTTGTAAAAA TAGTGCTGAT AACAAGGTGG TTTGCTCCTG TACTGAGGGA 481 TATCGACTTG CAGAAAACCA GAAGTCCTGT GAACCAGCAG TGCCATTTCC ATGTGGAAGA 541 GTTTCTGTTT CACAAACTTC TAAGCTCACC CGTGCTGAGA CTGTTTTTCC TGATGTGGAC 601 TATGTAAATT CTACTGAAGC TGAAACCATT TTGGATAACA TCACTCAAAG CACCCAATCA 661 TTTAATGACT TCACTCGGGT TGTTGGTGGA GAAGATGCCA AACCAGGTCA ATTCCCTTGG 721 CAGGTTGTTT TGAATGGTAA AGTTGATGCA TTCTGTGGAG GCTCTATCGT TAATGAAAAA 781 TGGATTGTAA CTGCTGCCCA CTGTGTTGAA ACTGGTGTTA AAATTACAGT TGTCGCAGGT 841 GAACATAATA TTGAGGAGAC AGAACATACA GAGCAAAAGC GAAATGTGAT TCGAATTATT 901 CCTCACCACA ACTACAATGC AGCTATTAAT AAGTACAACC ATGACATTGC CCTTCTGGAA 961 CTGGACGAAC CCTTAGTGCT AAACAGCTAC GTTACACCTA TTTGCATTGC TGACAAGGAA 1021 TACACGAACA TCTTCCTCAA ATTTGGATCT GGCTATGTAA GTGGCTGGGG AAGAGTCTTC 1081 CACAAAGGGA GATCAGCTTT AGTTCTTCAG TACCTTAGAG TTCCACTTGT TGACCGAGCC 1141 ACATGTCTTC GATCTACAAA GTTCACCATC TATAACAACA TGTTCTGTGC TGGCTTCCAT 1201 GAAGGAGGTA GAGATTCATG TCAAGGAGAT AGTGGGGGAC CCCATGTTAC TGAAGTGGAA 1261 GGGACCAGTT TCTTAACTGG AATTATTAGC TGGGGTGAAG AGTGTGCAAT GAAAGGCAAA 1321 TATGGAATAT ATACCAAGGT ATCCCGGTAT GTCAACTGGA TTAAGGAAAA AACAAAGCTC 1381 ACTTAA ( SEQ ID NO: 34 )Homo sapiens coagulation factor IX isoform 1 preproprotein amino acid sequence (NCBI Ref Seq. NP_000124.1)1 MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL 61 ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP 121 FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKWCSCTEG YRLAENQKSC EPAVPFPCGR 181 VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRWGG EDAKPGQFPW 241 QWLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITWAG EHNIEETEHT EQKRNVIRII 301 PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF 361 HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE 421 GTSFLTGIIS WGEECAMKGK YGIYTKVSRY VNWIKEKTKL T ( SEQ ID NO: 35 )#15239971vlT19749Attorney Docket No. U1202.70169WO00 Homo sapiens coagulation factor IX (F9), transcript variant 2, mRNA (NCBIRef Seq. NM_001313913.2)1 ACTTTCACAA TCTGCTAGCA AAGGTTATGC AGCGCGTGAA CATGATCATG GCAGAATCAC 61 CAGGCCTCAT CACCATCTGC CTTTTAGGAT ATCTACTCAG TGCTGAATGT ACAGTTTTTC 121 TTGATCATGA AAACGCCAAC AAAATTCTGA ATCGGCCAAA GAGGTATAAT TCAGGTAAAT 181 TGGAAGAGTT TGTTCAAGGG AACCTTGAGA GAGAATGTAT GGAAGAAAAG TGTAGTTTTG 241 AAGAAGCACG AGAAGTTTTT GAAAACACTG AAAGAACAAC TGAATTTTGG AAGCAGTATG 301 TTGATGTAAC ATGTAACATT AAGAATGGCA GATGCGAGCA GTTTTGTAAA AATAGTGCTG 361 ATAACAAGGT GGTTTGCTCC TGTACTGAGG GATATCGACT TGCAGAAAAC CAGAAGTCCT 421 GTGAACCAGC AGTGCCATTT CCATGTGGAA GAGTTTCTGT TTCACAAACT TCTAAGCTCA 481 CCCGTGCTGA GACTGTTTTT CCTGATGTGG ACTATGTAAA TTCTACTGAA GCTGAAACCA 541 TTTTGGATAA CATCACTCAA AGCACCCAAT CATTTAATGA CTTCACTCGG GTTGTTGGTG 601 GAGAAGATGC CAAACCAGGT CAATTCCCTT GGCAGGTTGT TTTGAATGGT AAAGTTGATG 661 CATTCTGTGG AGGCTCTATC GTTAATGAAA AATGGATTGT AACTGCTGCC CACTGTGTTG 721 AAACTGGTGT TAAAATTACA GTTGTCGCAG GTGAACATAA TATTGAGGAG ACAGAACATA 781 CAGAGCAAAA GCGAAATGTG ATTCGAATTA TTCCTCACCA CAACTACAAT GCAGCTATTA 841 ATAAGTACAA CCATGACATT GCCCTTCTGG AACTGGACGA ACCCTTAGTG CTAAACAGCT 901 ACGTTACACC TATTTGCATT GCTGACAAGG AATACACGAA CATCTTCCTC AAATTTGGAT 961 CTGGCTATGT AAGTGGCTGG GGAAGAGTCT TCCACAAAGG GAGATCAGCT TTAGTTCTTC 1021 AGTACCTTAG AGTTCCACTT GTTGACCGAG CCACATGTCT TCGATCTACA AAGTTCACCA 1081 TCTATAACAA CATGTTCTGT GCTGGCTTCC ATGAAGGAGG TAGAGATTCA TGTCAAGGAG 1141 ATAGTGGGGG ACCCCATGTT ACTGAAGTGG AAGGGACCAG TTTCTTAACT GGAATTATTA 1201 GCTGGGGTGA AGAGTGTGCA ATGAAAGGCA AATATGGAAT ATATACCAAG GTATCCCGGT 1261 ATGTCAACTG GATTAAGGAA AAAACAAAGC TCACTTAATG AAAGATGGAT TTCCAAGGTT 1321 AATTCATTGG AATTGAAAAT TAACAGGGCC TCTCACTAAC TAATCACTTT CCCATCTTTT 1381 GTTAGATTTG AATATATACA TTCTATGATC ATTGCTTTTT CTCTTTACAG GGGAGAATTT 1441 CATATTTTAC CTGAGCAAAT TGATTAGAAA ATGGAACCAC TAGAGGAATA TAATGTGTTA 1501 GGAAATTACA GTCATTTCTA AGGGCCCAGC CCTTGACAAA ATTGTGAAGT TAAATTCTCC 1561 ACTCTGTCCA TCAGATACTA TGGTTCTCCA CTATGGCAAC TAACTCACTC AATTTTCCCT 1621 CCTTAGCAGC ATTCCATCTT CCCGATCTTC TTTGCTTCTC CAACCAAAAC ATCAATGTTT 1681 ATTAGTTCTG TATACAGTAC AGGATCTTTG GTCTACTCTA TCACAAGGCC AGTACCACAC 1741 TCATGAAGAA AGAACACAGG AGTAGCTGAG AGGCTAAAAC TCATCAAAAA CACTACTCCT 1801 TTTCCTCTAC CCTATTCCTC AATCTTTTAC CTTTTCCAAA TCCCAATCCC CAAATCAGTT 1861 TTTCTCTTTC TTACTCCCTC TCTCCCTTTT ACCCTCCATG GTCGTTAAAG GAGAGATGGG 1921 GAGCATCATT CTGTTATACT TCTGTACACA GTTATACATG TCTATCAAAC CCAGACTTGC 1981 TTCCGTAGTG GAGACTTGCT TTTCAGAACA TAGGGATGAA GTAAGGTGCC TGAAAAGTTT 2041 GGGGGAAAAG TTTCTTTCAG AGAGTTAAGT TATTTTATAT ATATAATATA TATATAAAAT 2101 ATATAATATA CAATATAAAT ATATAGTGTG TGTGTATGCG TGTGTGTAGA CACACACGCA 2161 TACACACATA TAATGGAAGC AATAAGCCAT TCTAAGAGCT TGTATGGTTA TGGAGGTCTG 2221 ACTAGGCATG ATTTCACGAA GGCAAGATTG GCATATCATT GTAACTAAAA AAGCTGACAT 2281 TGACCCAGAC ATATTGTACT CTTTCTAAAA ATAATAATAA TAATGCTAAC AGAAAGAAGA 2341 GAACCGTTCG TTTGCAATCT ACAGCTAGTA GAGACTTTGA GGAAGAATTC AACAGTGTGT 2401 CTTCAGCAGT GTTCAGAGCC AAGCAAGAAG TTGAAGTTGC CTAGACCAGA GGACATAAGT 2461 ATCATGTCTC CTTTAACTAG CATACCCCGA AGTGGAGAAG GGTGCAGCAG GCTCAAAGGC 2521 ATAAGTCATT CCAATCAGCC AACTAAGTTG TCCTTTTCTG GTTTCGTGTT CACCATGGAA 2581 CATTTTGATT ATAGTTAATC CTTCTATCTT GAATCTTCTA GAGAGTTGCT GACCAACTGA 2641 CGTATGTTTC CCTTTGTGAA TTAATAAACT GGTGTTCTGG TTCATA ( SEQ ID NO: 36 ) Homo sapiens coagulation factor IX (F9), transcript variant 2, mRNA (NCBIRef Seq. NM_001313913.2, nucleotides 27-1298) - coding sequence1 ATGCAGCGCG TGAACATGAT CATGGCAGAA TCACCAGGCC TCATCACCAT CTGCCTTTTA 61 GGATATCTAC TCAGTGCTGA ATGTACAGTT TTTCTTGATC ATGAAAACGC CAACAAAATT 121 CTGAATCGGC CAAAGAGGTA TAATTCAGGT AAATTGGAAG AGTTTGTTCA AGGGAACCTT 181 GAGAGAGAAT GTATGGAAGA AAAGTGTAGT TTTGAAGAAG CACGAGAAGT TTTTGAAAAC 241 ACTGAAAGAA CAACTGAATT TTGGAAGCAG TATGTTGATG TAACATGTAA CATTAAGAAT 301 GGCAGATGCG AGCAGTTTTG TAAAAATAGT GCTGATAACA AGGTGGTTTG CTCCTGTACT 27#15239971vlT19749Attorney Docket No. U1202.70169WO00 361 GAGGGATATC GACTTGCAGA AAACCAGAAG TCCTGTGAAC CAGCAGTGCC ATTTCCATGT 421 GGAAGAGTTT CTGTTTCACA AACTTCTAAG CTCACCCGTG CTGAGACTGT TTTTCCTGAT 481 GTGGACTATG TAAATTCTAC TGAAGCTGAA ACCATTTTGG ATAACATCAC TCAAAGCACC 541 CAATCATTTA ATGACTTCAC TCGGGTTGTT GGTGGAGAAG ATGCCAAACC AGGTCAATTC 601 CCTTGGCAGG TTGTTTTGAA TGGTAAAGTT GATGCATTCT GTGGAGGCTC TATCGTTAAT 661 GAAAAATGGA TTGTAACTGC TGCCCACTGT GTTGAAACTG GTGTTAAAAT TACAGTTGTC 721 GCAGGTGAAC ATAATATTGA GGAGACAGAA CATACAGAGC AAAAGCGAAA TGTGATTCGA 781 ATTATTCCTC ACCACAACTA CAATGCAGCT ATTAATAAGT ACAACCATGA CATTGCCCTT 841 CTGGAACTGG ACGAACCCTT AGTGCTAAAC AGCTACGTTA CACCTATTTG CATTGCTGAC 901 AAGGAATACA CGAACATCTT CCTCAAATTT GGATCTGGCT ATGTAAGTGG CTGGGGAAGA 961 GTCTTCCACA AAGGGAGATC AGCTTTAGTT CTTCAGTACC TTAGAGTTCC ACTTGTTGAC 1021 CGAGCCACAT GTCTTCGATC TACAAAGTTC ACCATCTATA ACAACATGTT CTGTGCTGGC 1081 TTCCATGAAG GAGGTAGAGA TTCATGTCAA GGAGATAGTG GGGGACCCCA TGTTACTGAA 1141 GTGGAAGGGA CCAGTTTCTT AACTGGAATT ATTAGCTGGG GTGAAGAGTG TGCAATGAAA 1201 GGCAAATATG GAATATATAC CAAGGTATCC CGGTATGTCA ACTGGATTAA GGAAAAAACA 1261 AAGCTCACTT AA ( SEQ ID NO: 37 )Homo sapiens coagulation factor IX isoform 2 precursor amino acid sequence (NCBI Ref Seq. NP_001300842.1)1 MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL 61 ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDVTCNIKN GRCEQFCKNS ADNKWCSCT 121 EGYRLAENQK SCEPAVPFPC GRVSVSQTSK LTRAETVFPD VDYVNSTEAE TILDNITQST 181 QSFNDFTRW GGEDAKPGQF PWQWLNGKV DAFCGGSIVN EKWIVTAAHC VETGVKITW 241 AGEHNIEETE HTEQKRNVIR IIPHHNYNAA INKYNHDIAL LELDEPLVLN SYVTPICIAD 301 KEYTNIFLKF GSGYVSGWGR VFHKGRSALV LQYLRVPLVD RATCLRSTKF TIYNNMFCAG 361 FHEGGRDSCQ GDSGGPHVTE VEGTSFLTGI ISWGEECAMK GKYGIYTKVS RYVNWIKEKT 421 KLT ( SEQ ID NO: 38 )
[0102] In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of codon-optimized hFIX-Padua coding sequence (SEQ ID NO: 31). In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of codon-optimized hFIX-Padua coding sequence (SEQ ID NO: 31). In some embodiments, a sequence encoding coagulation factor IX comprises the sequence of codon-optimized hFIX-Padua coding sequence (SEQ ID NO: 31). In some embodiments, a sequence encoding coagulation factor IX consists, or consists essentially of, the sequence of codon-optimized hFIX-Padua coding sequence (SEQ ID NO: 31).28#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0103] In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of hFIX-Padua amino acid sequence (SEQ ID NO: 32). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the sequence of hFIX-Padua amino acid sequence (SEQ ID NO: 32). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of hFIX-Padua amino acid sequence (SEQ ID NO: 32). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of hFIX-Padua amino acid sequence (SEQ ID NO: 32).
[0104] In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NM_000133.4 (SEQ ID NO: 33). In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of NM_000133.4 (SEQ ID NO: 33). In some embodiments, a sequence encoding coagulation factor IX comprises the sequence of NM_000133.4 (SEQ ID NO: 33). In some embodiments, a sequence encoding coagulation factor IX consists, or consists essentially of, the sequence of NM_000133.4 (SEQ ID NO: 33).
[0105] In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity,29#15239971vlT19749Attorney Docket No. U1202.70169WO00 at least 98% identity, or at least 99% identity) with the coding sequence portion of NM_000133.4 (nucleotides 27-1412 (SEQ ID NO: 34)). In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), nucleotide mismatches relative to the coding sequence portion of NM_000133.4 (nucleotides 27-1412 (SEQ ID NO: 34)). In some embodiments, a sequence encoding coagulation factor IX comprises the coding sequence portion of NM_000133.4 (nucleotides 27-1412 (SEQ ID NO: 34)). In some embodiments, a sequence encoding coagulation factor IX consists, or consists essentially of, the coding sequence portion of NM_000133.4 (nucleotides 27-1412 (SEQ ID NO: 34)).
[0106] In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NP_000124.1 (SEQ ID NO: 35). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the sequence of NP_000124.1 (SEQ ID NO: 35). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of NP_000124.1 (SEQ ID NO: 35). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of NP_000124.1 (SEQ ID NO: 35).
[0107] In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NM_001313913.2 (SEQ ID NO: 36). In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,30#15239971vlT19749Attorney Docket No. U1202.70169WO00 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of NM_001313913.2 (SEQ ID NO: 36). In some embodiments, a sequence encoding coagulation factor IX comprises the sequence of NM_001313913.2 (SEQ ID NO: 36). In some embodiments, a sequence encoding coagulation factor IX consists, or consists essentially of, the sequence of NM_001313913.2 (SEQ ID NO: 36).
[0108] In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the coding sequence portion of NM_001313913.2 (nucleotides 27-1298 (SEQ ID NO: 37)). In some embodiments, a sequence encoding coagulation factor IX comprises a sequence that has 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), nucleotide mismatches relative to the coding sequence portion of NM_001313913.2 (nucleotides 27-1298 (SEQ ID NO: 37)). In some embodiments, a sequence encoding coagulation factor IX comprises the coding sequence portion of NM_001313913.2 (nucleotides 27-1298 (SEQ ID NO: 37)). In some embodiments, a sequence encoding coagulation factor IX consists, or consists essentially of, the coding sequence portion of NM_001313913.2 (nucleotides 27-1298 (SEQ ID NO: 37)).
[0109] In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NP_001300842.1 (SEQ ID NO: 38). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the sequence of NP_001300842.1 (SEQ ID NO: 38). In some embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of NP_001300842.1 (SEQ ID NO: 38). In some31#15239971vlT19749Attorney Docket No. U1202.70169WO00 embodiments, a sequence encoding coagulation factor IX comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of NP_001300842.1 (SEQ ID NO: 38).
[0110] In some embodiments, a transgene comprises a sequence encoding coagulation factor VIII (e.g., human coagulation factor VIII, “hFVIII”). Exemplary sequences encoding hFVIII, and exemplary amino acid sequences of hFVIII, are provided below:Homo sapiens coagulation factor VIII (F8), codon-optimized coding sequence 1 (B domain-deleted)1 ATGCAAATAG AGCTCTCCAC CTGCTTCTTT CTGTGCCTTT TGCGATTCTG CTTTAGTGCC 61 ACCAGAAGAT ACTACCTGGG TGCAGTGGAA CTGTCATGGG ACTATATGCA AAGTGATCTC 121 GGTGAGCTGC CTGTGGACGC AAGATTTCCT CCTAGAGTGC CAAAATCTTT TCCATTCAAC 181 ACCTCAGTCG TGTACAAAAA GACTCTGTTT GTAGAATTCA CGGATCACCT TTTCAACATC 241 GCTAAGCCAA GGCCACCCTG GATGGGTCTG CTAGGTCCTA CCATCCAGGC TGAGGTTTAT 301 GATACAGTGG TCATTACACT TAAGAACATG GCTTCCCATC CTGTCAGTCT TCATGCTGTT 361 GGTGTATCCT ACTGGAAAGC TTCTGAGGGA GCTGAATATG ATGATCAGAC CAGTCAAAGG 421 GAGAAAGAAG ATGATAAAGT CTTCCCTGGT GGAAGCCATA CATATGTCTG GCAGGTCCTG 481 AAAGAGAATG GTCCAATGGC CTCTGACCCA CTGTGCCTTA CCTACTCATA TCTTTCTCAT 541 GTGGACCTGG TAAAAGACTT GAATTCAGGC CTCATTGGAG CCCTACTAGT ATGTAGAGAA 601 GGGAGTCTGG CCAAGGAAAA GACACAGACC TTGCACAAAT TTATACTACT TTTTGCTGTA 661 TTTGATGAAG GGAAAAGTTG GCACTCAGAA ACAAAGAACT CCTTGATGCA GGATAGGGAT 721 GCTGCATCTG CTCGGGCCTG GCCTAAAATG CACACAGTCA ATGGTTATGT AAACAGGTCT 781 CTGCCAGGTC TGATTGGATG CCACAGGAAA TCAGTCTATT GGCATGTGAT TGGAATGGGC 841 ACCACTCCTG AAGTGCACTC AATATTCCTC GAAGGTCACA CATTTCTTGT GAGGAACCAT 901 CGCCAGGCGT CCTTGGAAAT CTCGCCAATA ACTTTCCTTA CTGCTCAAAC ACTCTTGATG 961 GACCTTGGAC AGTTTCTACT GTTTTGTCAT ATCTCTTCCC ACCAACATGA TGGCATGGAA 1021 GCTTATGTCA AAGTAGACAG CTGTCCAGAG GAACCCCAAC TACGAATGAA AAATAATGAA 1081 GAAGCGGAAG ACTATGATGA TGATCTTACT GATTCTGAAA TGGATGTGGT CAGGTTTGAT 1141 GATGACAACT CTCCTTCCTT TATCCAAATT CGCTCAGTTG CCAAGAAGCA TCCTAAAACT 1201 TGGGTACATT ACATTGCTGC TGAAGAGGAG GACTGGGACT ATGCTCCCTT AGTCCTCGCC 1261 CCCGATGACA GAAGTTATAA AAGTCAATAT TTGAACAATG GCCCTCAGCG GATTGGTAGG 1321 AAGTACAAAA AAGTCCGATT TATGGCATAC ACAGATGAAA CCTTTAAGAC TCGTGAAGCT 1381 ATTCAGCATG AATCAGGAAT CTTGGGACCT TTACTTTATG GGGAAGTTGG AGACACACTG 1441 TTGATTATAT TTAAGAATCA AGCAAGCAGA CCATATAACA TCTACCCTCA CGGAATCACT 1501 GATGTCCGTC CTTTGTATTC AAGGAGATTA CCAAAAGGTG TAAAACATTT GAAGGATTTT 1561 CCAATTCTGC CAGGAGAAAT ATTCAAATAT AAATGGACAG TGACTGTAGA AGATGGGCCA 1621 ACTAAATCAG ATCCTCGGTG CCTGACCCGC TATTACTCTA GTTTCGTTAA TATGGAGAGA 1681 GATCTAGCTT CAGGACTCAT TGGCCCTCTC CTCATCTGCT ACAAAGAATC TGTAGATCAA 1741 AGAGGAAACC AGATAATGTC AGACAAGAGG AATGTCATCC TGTTTTCTGT ATTTGATGAG 1801 AACCGAAGCT GGTACCTCAC AGAGAATATA CAACGCTTTC TCCCCAATCC AGCTGGAGTG 1861 CAGCTTGAGG ATCCAGAGTT CCAAGCCTCC AACATCATGC ACAGCATCAA TGGCTATGTT 1921 TTTGATAGTT TGCAGTTGTC AGTTTGTTTG CATGAGGTGG CATACTGGTA CATTCTAAGC 1981 ATTGGAGCAC AGACTGACTT CCTTTCTGTC TTCTTCTCTG GATATACCTT CAAACACAAA 2041 ATGGTCTATG AAGACACACT CACCCTATTC CCATTCTCAG GAGAAACTGT CTTCATGTCG 2101 ATGGAAAACC CAGGTCTATG GATTCTGGGG TGCCACAACT CAGACTTTCG GAACAGAGGC 2161 ATGACCGCCT TACTGAAGGT TTCTAGTTGT GACAAGAACA CTGGTGATTA TTACGAGGAC 2221 AGTTATGAAG ATATTTCAGC ATACTTGCTG AGTAAAAACA ATGCCATTGA ACCAAGAAGC 2281 TTCTCTCAAA ACCCACCAGT CTTGAAACGC CATCAACGGG AAATAACTCG TACTACTCTT 2341 CAGTCAGATC AAGAGGAAAT TGACTATGAT GATACCATAT CAGTTGAAAT GAAGAAGGAA 2401 GATTTTGACA TTTATGATGA GGATGAAAAT CAGAGCCCCC GCAGCTTTCA AAAGAAAACA 2461 CGACACTATT TTATTGCTGC AGTGGAGAGG CTCTGGGATT ATGGGATGAG TAGCTCCCCA 2521 CATGTTCTAA GAAACAGGGC TCAGAGTGGC AGTGTCCCTC AGTTCAAGAA AGTTGTTTTC 2581 CAGGAATTTA CTGATGGCTC CTTTACTCAG CCCTTATACC GTGGAGAACT AAATGAACAT 32#15239971vlT19749Attorney Docket No. U1202.70169WO00 2641 TTGGGACTCC TGGGGCCATA TATAAGAGCA GAAGTTGAAG ATAATATCAT GGTAACTTTC 2701 AGAAATCAGG CCTCTCGTCC CTATTCCTTC TATTCTAGCC TTATTTCTTA TGAGGAAGAT 2761 CAGAGGCAAG GAGCAGAACC TAGAAAAAAC TTTGTCAAGC CTAATGAAAC CAAAACTTAC 2821 TTTTGGAAAG TGCAACATCA TATGGCACCC ACTAAAGATG AGTTTGACTG CAAAGCCTGG 2881 GCTTATTTCT CTGATGTTGA CCTGGAAAAA GATGTGCACT CAGGCCTGAT TGGACCCCTT 2941 CTGGTCTGCC ACACTAACAC ACTGAACCCT GCTCATGGGA GACAAGTGAC AGTACAGGAA 3001 TTTGCTCTGT TTTTCACCAT CTTTGATGAG ACCAAAAGCT GGTACTTCAC TGAAAATATG 3061 GAAAGAAACT GCAGGGCTCC CTGCAATATC CAGATGGAAG ATCCCACTTT TAAAGAGAAT 3121 TATCGCTTCC ATGCAATCAA TGGCTACATA ATGGATACAC TACCTGGCTT AGTAATGGCT 3181 CAGGATCAAA GGATTCGATG GTATCTGCTC AGCATGGGCA GCAATGAAAA CATCCATTCT 3241 ATTCATTTCA GTGGACATGT GTTCACTGTA CGAAAAAAAG AGGAGTATAA AATGGCACTG 3301 TACAATCTCT ATCCAGGTGT TTTTGAGACA GTGGAAATGT TACCATCCAA AGCTGGAATT 3361 TGGCGGGTGG AATGCCTTAT TGGCGAGCAT CTACATGCTG GGATGAGCAC ACTTTTTCTG 3421 GTGTACAGCA ATAAGTGTCA GACTCCCCTG GGAATGGCTT CTGGACACAT TAGAGATTTT 3481 CAGATTACAG CTTCAGGACA ATATGGACAG TGGGCCCCAA AGCTGGCCAG ACTTCATTAT 3541 TCCGGATCAA TCAATGCCTG GAGCACCAAG GAGCCCTTTT CTTGGATCAA GGTGGATCTG 3601 TTGGCACCAA TGATTATTCA CGGCATCAAG ACCCAGGGTG CCCGTCAGAA GTTCTCCAGC 3661 CTCTACATCT CTCAGTTTAT CATCATGTAT AGTCTTGATG GGAAGAAGTG GCAGACTTAT 3721 CGAGGAAATT CCACTGGAAC CTTAATGGTC TTCTTTGGCA ATGTGGATTC ATCTGGGATA 3781 AAACACAATA TTTTTAACCC TCCAATTATT GCTCGATACA TCCGTTTGCA CCCAACTCAT 3841 TATAGCATTC GCAGCACTCT TCGCATGGAG TTGATGGGCT GTGATTTAAA TAGTTGCAGC 3901 ATGCCATTGG GAATGGAGAG TAAAGCAATA TCAGATGCAC AGATTACTGC TTCATCCTAC 3961 TTTACCAATA TGTTTGCCAC CTGGTCTCCT TCAAAAGCTC GACTTCACCT CCAAGGGAGG 4021 AGTAATGCCT GGAGACCTCA GGTGAATAAT CCAAAAGAGT GGCTGCAAGT GGACTTCCAG 4081 AAGACAATGA AAGTCACAGG AGTAACTACT CAGGGAGTAA AATCTCTGCT TACCAGCATG 4141 TATGTGAAGG AGTTCCTCAT CTCCAGCAGT CAAGATGGCC ATCAGTGGAC TCTCTTTTTT 4201 CAGAATGGCA AAGTAAAGGT TTTTCAGGGA AATCAAGACT CCTTCACACC TGTGGTGAAC 4261 TCTCTAGACC CACCGTTACT GACTCGCTAC CTTCGAATTC ACCCCCAGAG TTGGGTGCAC 4321 CAGATTGCCC TGAGGATGGA GGTTCTGGGC TGCGAGGCAC AGGACCTCTA CTGA ( SEQ ID NO: 39 )Homo sapiens coagulation factor VIII (F8), amino acid sequence 1 (B domain-deleted) 1 MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL GELPVDARFP51 PRVPKSFPFN TSWYKKTLF VEFTDHLFNI AKPRPPWMGL LGPTIQAEVY101 DTWITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQR EKEDDKVFPG151 GSHTYVWQVL KENGPMASDP LCLTYSYLSH VDLVKDLNSG LIGALLVCRE201 GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD AASARAWPKM251 HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL EGHTFLVRNH301 RQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGME AYVKVDSCPE351 EPQLRMKNNE EAEDYDDDLT DSEMDWRFD DDNSPSFIQI RSVAKKHPKT401 WVHYIAAEEE DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR KYKKVRFMAY451 TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR PYNIYPHGIT501 DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP TKSDPRCLTR551 YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR NVILFSVFDE601 NRSWYLTENI QRFLPNPAGV QLEDPEFQAS NIMHSINGYV FDSLQLSVCL651 HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF PFSGETVFMS701 MENPGLWILG CHNSDFRNRG MTALLKVSSC DKNTGDYYED SYEDISAYLL751 SKNNAIEPRS FSQNPPVLKR HQREITRTTL QSDQEEIDYD DTISVEMKKE801 DFDIYDEDEN QSPRSFQKKT RHYFIAAVER LWDYGMSSSP HVLRNRAQSG851 SVPQFKKWF QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA EVEDNIMVTF901 RNQASRPYSF YSSLISYEED QRQGAEPRKN FVKPNETKTY FWKVQHHMAP951 TKDEFDCKAW AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP AHGRQVTVQE1001 FALFFTIFDE TKSWYFTENM ERNCRAPCNI QMEDPTFKEN YRFHAINGYI1051 MDTLPGLVMA QDQRIRWYLL SMGSNENIHS IHFSGHVFTV RKKEEYKMAL1101 YNLYPGVFET VEMLPSKAGI WRVECLIGEH LHAGMSTLFL VYSNKCQTPL1151 GMASGHIRDF QITASGQYGQ WAPKLARLHY SGSINAWSTK EPFSWIKVDL1201 LAPMIIHGIK TQGARQKFSS LYISQFIIMY SLDGKKWQTY RGNSTGTLMV1251 FFGNVDSSGI KHNIFNPPII ARYIRLHPTH YSIRSTLRME LMGCDLNSCS33#15239971vlT19749Attorney Docket No. U1202.70169WO00 1301 MPLGMESKAI SDAQITASSY FTNMFATWSP SKARLHLQGR SNAWRPQVNN1351 PKEWLQVDFQ KTMKVTGVTT QGVKSLLTSM YVKEFLISSS QDGHQWTLFF1401 QNGKVKVFQG NQDSFTPWN SLDPPLLTRY LRIHPQSWVH QIALRMEVLG1451 CEAQDLY ( SEQ ID NO: 40 )Homo sapiens coagulation factor VIII (F8), transcript variant 1, mRNA (NCBIRef. Seq. NM_000132.4)1 GCTTAGTGCT GAGCACATCC AGTGGGTAAA GTTCCTTAAA ATGCTCTGCA AAGAAATTGG 61 GACTTTTCAT TAAATCAGAA ATTTTACTTT TTTCCCCTCC TGGGAGCTAA AGATATTTTA 121 GAGAAGAATT AACCTTTTGC TTCTCCAGTT GAACATTTGT AGCAATAAGT CATGCAAATA 181 GAGCTCTCCA CCTGCTTCTT TCTGTGCCTT TTGCGATTCT GCTTTAGTGC CACCAGAAGA 241 TACTACCTGG GTGCAGTGGA ACTGTCATGG GACTATATGC AAAGTGATCT CGGTGAGCTG 301 CCTGTGGACG CAAGATTTCC TCCTAGAGTG CCAAAATCTT TTCCATTCAA CACCTCAGTC 361 GTGTACAAAA AGACTCTGTT TGTAGAATTC ACGGATCACC TTTTCAACAT CGCTAAGCCA 421 AGGCCACCCT GGATGGGTCT GCTAGGTCCT ACCATCCAGG CTGAGGTTTA TGATACAGTG 481 GTCATTACAC TTAAGAACAT GGCTTCCCAT CCTGTCAGTC TTCATGCTGT TGGTGTATCC 541 TACTGGAAAG CTTCTGAGGG AGCTGAATAT GATGATCAGA CCAGTCAAAG GGAGAAAGAA 601 GATGATAAAG TCTTCCCTGG TGGAAGCCAT ACATATGTCT GGCAGGTCCT GAAAGAGAAT 661 GGTCCAATGG CCTCTGACCC ACTGTGCCTT ACCTACTCAT ATCTTTCTCA TGTGGACCTG 721 GTAAAAGACT TGAATTCAGG CCTCATTGGA GCCCTACTAG TATGTAGAGA AGGGAGTCTG 781 GCCAAGGAAA AGACACAGAC CTTGCACAAA TTTATACTAC TTTTTGCTGT ATTTGATGAA 841 GGGAAAAGTT GGCACTCAGA AACAAAGAAC TCCTTGATGC AGGATAGGGA TGC TGC AT CT 901 GCTCGGGCCT GGCCTAAAAT GCACACAGTC AATGGTTATG TAAACAGGTC TCTGCCAGGT 961 CTGATTGGAT GCCACAGGAA ATCAGTCTAT TGGCATGTGA TTGGAATGGG CACCACTCCT 1021 GAAGTGCACT CAATATTCCT CGAAGGTCAC ACATTTCTTG TGAGGAACCA TCGCCAGGCG 1081 TCCTTGGAAA TCTCGCCAAT AACTTTCCTT ACTGCTCAAA CACTCTTGAT GGACCTTGGA 1141 CAGTTTCTAC TGTTTTGTCA TATCTCTTCC CACCAACATG ATGGCATGGA AGCTTATGTC 1201 AAAGTAGACA GCTGTCCAGA GGAACCCCAA CTACGAATGA AAAATAATGA AGAAGCGGAA 1261 GACTATGATG ATGATCTTAC TGATTCTGAA ATGGATGTGG TCAGGTTTGA TGATGACAAC 1321 TCTCCTTCCT TTATCCAAAT TCGCTCAGTT GCCAAGAAGC ATCCTAAAAC TTGGGTACAT 1381 TACATTGCTG CTGAAGAGGA GGACTGGGAC TATGCTCCCT TAGTCCTCGC CCCCGATGAC 1441 AGAAGTTATA AAAGTCAATA TTTGAACAAT GGCCCTCAGC GGATTGGTAG GAAGTACAAA 1501 AAAGTCCGAT TTATGGCATA CACAGATGAA ACCTTTAAGA CTCGTGAAGC TATTCAGCAT 1561 GAATCAGGAA TCTTGGGACC TTTACTTTAT GGGGAAGTTG GAGACACACT GTTGATTATA 1621 TTTAAGAATC AAGCAAGCAG ACCATATAAC ATCTACCCTC ACGGAATCAC TGATGTCCGT 1681 CCTTTGTATT CAAGGAGATT ACCAAAAGGT GTAAAACATT TGAAGGATTT TCCAATTCTG 1741 CCAGGAGAAA TATTCAAATA TAAATGGACA GTGACTGTAG AAGATGGGCC AACTAAATCA 1801 GATCCTCGGT GCCTGACCCG CTATTACTCT AGTTTCGTTA ATATGGAGAG AGATCTAGCT 1861 TCAGGACTCA TTGGCCCTCT CCTCATCTGC TACAAAGAAT CTGTAGATCA AAGAGGAAAC 1921 CAGATAATGT CAGACAAGAG GAATGTCATC CTGTTTTCTG TATTTGATGA GAACCGAAGC 1981 TGGTACCTCA CAGAGAATAT ACAACGCTTT CTCCCCAATC CAGCTGGAGT GCAGCTTGAG 2041 GATCCAGAGT TCCAAGCCTC CAACATCATG CACAGCATCA ATGGCTATGT TTTTGATAGT 2101 TTGCAGTTGT CAGTTTGTTT GCATGAGGTG GCATACTGGT ACATTCTAAG CATTGGAGCA 2161 CAGACTGACT TCCTTTCTGT CTTCTTCTCT GGATATACCT TCAAACACAA AATGGTCTAT 2221 GAAGACACAC TCACCCTATT CCCATTCTCA GGAGAAACTG TCTTCATGTC GATGGAAAAC 2281 CCAGGTCTAT GGATTCTGGG GTGCCACAAC TCAGACTTTC GGAACAGAGG CATGACCGCC 2341 TTACTGAAGG TTTCTAGTTG TGACAAGAAC ACTGGTGATT ATTACGAGGA CAGTTATGAA 2401 GATATTTCAG CATACTTGCT GAGTAAAAAC AATGCCATTG AACCAAGAAG CTTCTCCCAG 2461 AATTCAAGAC ACCCTAGCAC TAGGCAAAAG CAATTTAATG CCACCACAAT TCCAGAAAAT 2521 GACATAGAGA AGACTGACCC TTGGTTTGCA CACAGAACAC CTATGCCTAA AATACAAAAT 2581 GTCTCCTCTA GTGATTTGTT GATGCTCTTG CGACAGAGTC CTACTCCACA TGGGCTATCC 2641 T TAT CT GAT C TCCAAGAAGC CAAATATGAG ACTTTTTCTG ATGATCCATC ACCTGGAGCA 2701 ATAGACAGTA ATAACAGCCT GTCTGAAATG ACACACTTCA GGCCACAGCT CCATCACAGT 2761 GGGGACATGG TATTTACCCC TGAGTCAGGC CTCCAATTAA GATTAAATGA GAAACTGGGG 2821 ACAACTGCAG CAACAGAGTT GAAGAAACTT GATTTCAAAG TTTCTAGTAC ATCAAATAAT 2881 CTGATTTCAA CAATTCCATC AGACAATTTG GCAGCAGGTA CTGATAATAC AAGTTCCTTA 34#15239971vlT19749Attorney Docket No. U1202.70169WO00 2941 GGACCCCCAA GTATGCCAGT TCATTATGAT AGTCAATTAG ATACCACTCT ATTTGGCAAA 3001 AAGTCATCTC CCCTTACTGA GTCTGGTGGA CCTCTGAGCT TGAGTGAAGA AAATAATGAT 3061 TCAAAGTTGT TAGAATCAGG TTTAATGAAT AGCCAAGAAA GTTCATGGGG AAAAAATGTA 3121 TCGTCAACAG AGAGTGGTAG GTTATTTAAA GGGAAAAGAG CTCATGGACC TGCTTTGTTG 3181 ACTAAAGATA ATGCCTTATT CAAAGTTAGC ATCTCTTTGT TAAAGACAAA CAAAACTTCC 3241 AATAATTCAG CAACTAATAG AAAGACTCAC ATTGATGGCC CATCATTATT AATTGAGAAT 3301 AGTCCATCAG TCTGGCAAAA TATATTAGAA AGTGACACTG AGTTTAAAAA AGTGACACCT 3361 TTGATTCATG ACAGAATGCT TATGGACAAA AATGCTACAG CTTTGAGGCT AAATCATATG 3421 TCAAATAAAA CTACTTCATC AAAAAACATG GAAATGGTCC AGAGGGCCCC 3481 ATTCCACCAG ATGCACAAAA TCCAGATATG TCGTTCTTTA AGATGCTATT CTTGCCAGAA 3541 TCAGCAAGGT GGATACAAAG GACTCATGGA AAGAACTCTC TGAACTCTGG GCAAGGCCCC 3601 AGTCCAAAGC AATTAGTATC CTTAGGACCA GAAAAATCTG TGGAAGGTCA GAATTTCTTG 3661 TCTGAGAAAA ACAAAGTGGT AGTAGGAAAG GGTGAATTTA CAAAGGACGT AGGACTCAAA 3721 GAGATGGTTT TTCCAAGCAG CAGAAACCTA TTTCTTACTA ACTTGGATAA TTTACATGAA 3781 AATAATACAC ACAATCAAGA AAAAAAAATT CAGGAAGAAA TAGAAAAGAA GGAAACATTA 3841 ATCCAAGAGA ATGTAGTTTT GCCTCAGATA CATACAGTGA CTGGCACTAA GAATTTCATG 3901 AAGAACCTTT TCTTACTGAG CACTAGGCAA AATGTAGAAG GTTCATATGA CGGGGCATAT 3961 GCTCCAGTAC TTCAAGATTT TAGGTCATTA AATGATTCAA CAAATAGAAC AAAGAAACAC 4021 ACAGCTCATT TCTCAAAAAA AGGGGAGGAA GAAAACTTGG AAGGCTTGGG AAATCAAACC 4081 AAGCAAATTG TAGAGAAATA TGCATGCACC ACAAGGATAT CTCCTAATAC AAGCCAGCAG 4141 AATTTTGTCA CGCAACGTAG TAAGAGAGCT TTGAAACAAT TCAGACTCCC ACTAGAAGAA 4201 ACAGAACTTG AAAAAAGGAT AATTGTGGAT GACACCTCAA CCCAGTGGTC CAAAAACATG 4261 AAACATTTGA CCCCGAGCAC CCTCACACAG ATAGACTACA ATGAGAAGGA GAAAGGGGCC 4321 ATTACTCAGT CTCCCTTATC AGATTGCCTT ACGAGGAGTC ATAGCATCCC TCAAGCAAAT 4381 AGATCTCCAT TACCCATTGC AAAGGTATCA TCATTTCCAT CTATTAGACC TATATATCTG 4441 ACCAGGGTCC TATTCCAAGA CAACTCTTCT CATCTTCCAG CAGCATCTTA TAGAAAGAAA 4501 GATTCTGGGG TCCAAGAAAG CAGTCATTTC TTACAAGGAG CCAAAAAAAA TAACCTTTCT 4561 TTAGCCATTC TAACCTTGGA GATGACTGGT GATCAAAGAG AGGTTGGCTC CCTGGGGACA 4621 AGTGCCACAA ATTCAGTCAC ATACAAGAAA GTTGAGAACA CTGTTCTCCC GAAACCAGAC 4681 TTGCCCAAAA CATCTGGCAA AGTTGAATTG CTTCCAAAAG TTCACATTTA TCAGAAGGAC 4741 CTATTCCCTA CGGAAACTAG CAATGGGTCT CCTGGCCATC TGGATCTCGT GGAAGGGAGC 4801 CTTCTTCAGG GAACAGAGGG AGCGATTAAG TGGAATGAAG CAAACAGACC TGGAAAAGTT 4861 CCCTTTCTGA GAGTAGCAAC AGAAAGCTCT GCAAAGACTC CCTCCAAGCT ATTGGATCCT 4921 CTTGCTTGGG ATAACCACTA TGGTACTCAG ATACCAAAAG AAGAGTGGAA ATCCCAAGAG 4981 AAGTCACCAG AAAAAACAGC TTTTAAGAAA AAGGATACCA TTTTGTCCCT GAACGCTTGT 5041 GAAAGCAATC ATGCAATAGC AGCAATAAAT GAGGGACAAA ATAAGCCCGA AATAGAAGTC 5101 ACCTGGGCAA AGCAAGGTAG GACTGAAAGG CTGTGCTCTC AAAACCCACC AGTCTTGAAA 5161 CGCCATCAAC GGGAAATAAC TCGTACTACT CTTCAGTCAG ATCAAGAGGA AATTGACTAT 5221 GAT GAT ACC A TATCAGTTGA AATGAAGAAG GAAGATTTTG ACATTTATGA TGAGGATGAA 5281 AATCAGAGCC CCCGCAGCTT TCAAAAGAAA ACACGACACT ATTTTATTGC TGCAGTGGAG 5341 AGGCTCTGGG ATTATGGGAT GAGTAGCTCC CCACATGTTC TAAGAAACAG GGCTCAGAGT 5401 GGCAGTGTCC CTCAGTTCAA GAAAGTTGTT TTCCAGGAAT T TACT GAT GG CTCCTTTACT 5461 CAGCCCTTAT ACCGTGGAGA ACTAAATGAA CATTTGGGAC TCCTGGGGCC ATATATAAGA 5521 GCAGAAGTTG AAGATAATAT CATGGTAACT TTCAGAAATC AGGCCTCTCG TCCCTATTCC 5581 TTCTATTCTA GCCTTATTTC TTATGAGGAA GATCAGAGGC AAGGAGCAGA ACCTAGAAAA 5641 AACTTTGTCA AGCCTAATGA AACCAAAACT TACTTTTGGA AAGTGCAACA TCATATGGCA 5701 CCCACTAAAG ATGAGTTTGA CTGCAAAGCC TGGGCTTATT TCTCTGATGT TGACCTGGAA 5761 AAAGATGTGC ACTCAGGCCT GATTGGACCC CTTCTGGTCT GCCACACTAA CACACTGAAC 5821 CCTGCTCATG GGAGACAAGT GACAGTACAG GAATTTGCTC TGTTTTTCAC CATCTTTGAT 5881 GAGACCAAAA GCTGGTACTT CACTGAAAAT ATGGAAAGAA ACTGCAGGGC TCCCTGCAAT 5941 ATCCAGATGG AAGATCCCAC TTTTAAAGAG AATTATCGCT TCCATGCAAT CAATGGCTAC 6001 ATAATGGATA CACTACCTGG CTTAGTAATG GCTCAGGATC AAAGGATTCG ATGGTATCTG 6061 CTCAGCATGG GCAGCAATGA AAACATCCAT TCTATTCATT TCAGTGGACA TGTGTTCACT 6121 GTACGAAAAA AAGAGGAGTA TAAAATGGCA CTGTACAATC TCTATCCAGG TGTTTTTGAG 6181 ACAGTGGAAA TGTTACCATC CAAAGCTGGA ATTTGGCGGG TGGAATGCCT TATTGGCGAG 6241 CATCTACATG CTGGGATGAG CACACTTTTT CTGGTGTACA GCAATAAGTG TCAGACTCCC 6301 CTGGGAATGG CTTCTGGACA CATTAGAGAT TTTCAGATTA CAGCTTCAGG ACAATATGGA 6361 CAGTGGGCCC CAAAGCTGGC CAGACTTCAT TATTCCGGAT CAATCAATGC CTGGAGCACC 6421 AAGGAGCCCT TTTCTTGGAT CAAGGTGGAT CTGTTGGCAC CAATGATTAT TCACGGCATC #15239971vlT19749Attorney Docket No. U1202.70169WO00 6481 AAGACCCAGG GTGCCCGTCA GAAGTTCTCC AGCCTCTACA TCTCTCAGTT TATCATCATG 6541 TATAGTCTTG ATGGGAAGAA GTGGCAGACT TATCGAGGAA ATTCCACTGG AACCTTAATG 6601 GTCTTCTTTG GCAATGTGGA TTCATCTGGG ATAAAACACA ATATTTTTAA CCCTCCAATT 6661 ATTGCTCGAT ACATCCGTTT GCACCCAACT CATTATAGCA TTCGCAGCAC TCTTCGCATG 6721 GAGTTGATGG GCTGTGATTT AAATAGTTGC AGCATGCCAT TGGGAATGGA GAGTAAAGCA 6781 ATATCAGATG CACAGATTAC TGCTTCATCC TACTTTACCA ATATGTTTGC CACCTGGTCT 6841 CCTTCAAAAG CTCGACTTCA CCTCCAAGGG AGGAGTAATG CCTGGAGACC TCAGGTGAAT 6901 AATCCAAAAG AGTGGCTGCA AGTGGACTTC CAGAAGACAA TGAAAGTCAC AGGAGTAACT 6961 ACTCAGGGAG TAAAATCTCT GCTTACCAGC ATGTATGTGA AGGAGTTCCT CATCTCCAGC 7021 AGTCAAGATG GCCATCAGTG GACTCTCTTT TTTCAGAATG GCAAAGTAAA GGTTTTTCAG 7081 GGAAATCAAG ACTCCTTCAC ACCTGTGGTG AACTCTCTAG ACCCACCGTT ACTGACTCGC 7141 TACCTTCGAA TTCACCCCCA GAGTTGGGTG CACCAGATTG CCCTGAGGAT GGAGGTTCTG 7201 GGCTGCGAGG CACAGGACCT CTACTGAGGG TGGCCACTGC AGCACCTGCC ACTGCCGTCA 7261 CCTCTCCCTC CTCAGCTCCA GGGCAGTGTC CCTCCCTGGC TTGCCTTCTA CCTTTGTGCT 7321 AAATCCTAGC AGACACTGCC TTGAAGCCTC CTGAATTAAC TATCATCAGT CCTGCATTTC 7381 TTTGGTGGGG GGCCAGGAGG GTGCATCCAA TTTAACTTAA CTCTTACCTA TTTTCTGCAG 7441 CTGCTCCCAG ATTACTCCTT CCTTCCAATA TAACTAGGCA AAAAGAAGTG AGGAGAAACC 7501 TGCATGAAAG CATTCTTCCC TGAAAAGTTA GGCCTCTCAG AGTCACCACT TCCTCTGTTG 7561 TAGAAAAACT ATGTGATGAA ACTTTGAAAA AGATATTTAT GATGTTAACA TTTCAGGTTA 7621 AGCCTCATAC GTTTAAAATA AAACTCTCAG TTGTTTATTA TCCTGATCAA GCATGGAACA 7681 AAGCATGTTT CAGGATCAGA TCAATACAAT CTTGGAGTCA AAAGGCAAAT CATTTGGACA 7741 ATCTGCAAAA TGGAGAGAAT ACAATAACTA CTACAGTAAA GTCTGTTTCT GCTTCCTTAC 7801 ACATAGATAT AATTATGTTA TTTAGTCATT ATGAGGGGCA CATTCTTATC TCCAAAACTA 7861 GCATTCTTAA ACTGAGAATT ATAGATGGGG TTCAAGAATC CCTAAGTCCC CTGAAATTAT 7921 ATAAGGCATT CTGTATAAAT GCAAAT GTGC ATTTTTCTGACGAGTGTCCA TAGATATAAA7981 GCCATTTGGT CTTAATTCTG ACCAATAAAA AAATAAGTCA GGAGGATGCA ATTGTTGAAA 8041 GCTTTGAAAT AAAATAACAA TGTCTTCTTG AAATTTGTGA TGGCCAAGAA AGAAAATGAT 8101 GATGACATTA GGCTTCTAAA GGACATACAT TTAATATTTC TGTGGAAATA TGAGGAAAAT 8161 CCATGGTTAT CTGAGATAGG AGATACAAAC TTTGTAATTC TAATAATGCA CTCAGTTTAC 8221 TCTCTCCCTC TACTAATTTC CTGCTGAAAA TAACACAACA AAAATGTAAC AGGGGAAATT 8281 ATATACCGTG ACTGAAAACT AGAGTCCTAC TTACATAGTT GAAATATCAA GGAGGTCAGA 8341 AGAAAATTGG ACTGGTGAAACACTCCAGTC TGCCATATCA CCACACAATA 8401 GGATCCCCCT TCTTGCCCTC CACCCCCATA AGATTGTGAA GGGTTTACTG CTCCTTCCAT 8461 CTGCCTGACC CCTTCACTAT GACTACACAG AATCTCCTGA TAGTAAAGGG GGCTGGAGAC 8521 AAGGATAAGT TATAGAGCAG TTGGAGGAAG CATCCAAAGA TTGCAACCCA GGGCAAATGG 8581 AAAACAGGAG ATCCTAATAT GAAAGAAAAA TGGATCCCAA TCTGAGAAAA GGCAAAAGAA 8641 TGGCTACTTT TTTCTATGCT GGAGTATTTT CTAATAATCC TGCTTGACCC TTATCTGACC 8701 TCTTTGGAAA CTATAACATA GCTGTCACAG TATAGTCACA ATCCACAAAT GATGCAGGTG 8761 CAAATGGTTT ATAGCCCTGT GAAGTTCTTA AAGTTTAGAG GCTAACTTAC AGAAATGAAT 8821 AAGTTGTTTT GTTTTATAGC CCGGTAGAGG AGTTAACCCC AAAGGTGATA TGGTTTTATT 8881 TCCTGTTATG TTTAACTTGA TAATCTTATT TTGGCATTCT TTTCCCATTG AC TAT AT AC A 8941 TCTCTATTTC TCAAATGTTC ATGGAACTAG CTCTTTTATT TTCCTGCTGG TTTCTTCAGT 9001 AATGAGTTAA ATAAAACATT GACACATACA AA ( SEQ ID NO: 41 )Homo sapiens coagulation factor VIII (F8), transcript variant 1, mRNA (NCBIRef. Seq. NM_000132.4, nucleotides 172-7227) - coding sequence1 ATGCAAATAG AGCTCTCCAC CTGCTTCTTT CTGTGCCTTT TGCGATTCTG CTTTAGTGCC 61 ACCAGAAGAT ACTACCTGGG TGCAGTGGAA CTGTCATGGG ACTATATGCA AAGTGATCTC 121 GGTGAGCTGC CTGTGGACGC AAGATTTCCT CCTAGAGTGC CAAAATCTTT TCCATTCAAC 181 ACCTCAGTCG TGTACAAAAA GACTCTGTTT GTAGAATTCA CGGATCACCT TTTCAACATC 241 GCTAAGCCAA GGCCACCCTG GATGGGTCTG CTAGGTCCTA CCATCCAGGC TGAGGTTTAT 301 GATACAGTGG TCATTACACT TAAGAACATG GCTTCCCATC CTGTCAGTCT TCATGCTGTT 361 GGTGTATCCT ACTGGAAAGC TTCTGAGGGA GCTGAATATG ATGATCAGAC CAGTCAAAGG 421 GAGAAAGAAG ATGATAAAGT CTTCCCTGGT GGAAGCCATA CATATGTCTG GCAGGTCCTG 481 AAAGAGAATG GTCCAATGGC CTCTGACCCA CTGTGCCTTA CCTACTCATA TCTTTCTCAT 541 GTGGACCTGG TAAAAGACTT GAATTCAGGC CTCATTGGAG CCCTACTAGT ATGTAGAGAA 36#15239971vlT19749Attorney Docket No. U1202.70169WO00 601 GGGAGTCTGG CCAAGGAAAA GACACAGACC TTGCACAAAT T TAT AC TACT TTTTGCTGTA 661 TTTGATGAAG GGAAAAGTTG GCACTCAGAA ACAAAGAACT CCTTGATGCA GGATAGGGAT 721 GCTGCATCTG CTCGGGCCTG GCCTAAAATG CACACAGTCA ATGGTTATGT AAACAGGTCT 781 CTGCCAGGTC TGATTGGATG CCACAGGAAA TCAGTCTATT GGCATGTGAT TGGAATGGGC 841 ACCACTCCTG AAGTGCACTC AATATTCCTC GAAGGTCACA CATTTCTTGT GAGGAACCAT 901 CGCCAGGCGT CCTTGGAAAT CTCGCCAATA ACTTTCCTTA CTGCTCAAAC ACTCTTGATG 961 GACCTTGGAC AGTTTCTACT GTTTTGTCAT ATCTCTTCCC ACCAACATGA TGGCATGGAA 1021 GCTTATGTCA AAGTAGACAG CTGTCCAGAG GAACCCCAAC TACGAATGAA AAATAATGAA 1081 GAAGCGGAAG AC TAT GAT GA TGATCTTACT GATTCTGAAA TGGATGTGGT CAGGTTTGAT 1141 GATGACAACT CTCCTTCCTT TATCCAAATT CGCTCAGTTG CCAAGAAGCA TCCTAAAACT 1201 TGGGTACATT ACATTGCTGC TGAAGAGGAG GACTGGGACT ATGCTCCCTT AGTCCTCGCC 1261 CCCGATGACA GAAGTTATAA AAGTCAATAT TTGAACAATG GCCCTCAGCG GATTGGTAGG 1321 AAGTACAAAA AAGTCCGATT TATGGCATAC ACAGATGAAA CCTTTAAGAC TCGTGAAGCT 1381 ATTCAGCATG AATCAGGAAT CTTGGGACCT TTACTTTATG GGGAAGTTGG AGACACACTG 1441 TTGATTATAT TTAAGAATCA AGCAAGCAGA CCATATAACA TCTACCCTCA CGGAATCACT 1501 GATGTCCGTC CTTTGTATTC AAGGAGATTA CCAAAAGGTG TAAAACATTT GAAGGATTTT 1561 CCAATTCTGC CAGGAGAAAT ATTCAAATAT AAATGGACAG TGACTGTAGA AGATGGGCCA 1621 ACTAAATCAG ATCCTCGGTG CCTGACCCGC TATTACTCTA GTTTCGTTAA TATGGAGAGA 1681 GATCTAGCTT CAGGACTCAT TGGCCCTCTC CTCATCTGCT ACAAAGAATC TGTAGATCAA 1741 AGAGGAAACC AGATAATGTC AGACAAGAGG AATGTCATCC TGTTTTCTGT AT TT GAT GAG 1801 AACCGAAGCT GGTACCTCAC AGAGAATATA CAACGCTTTC TCCCCAATCC AGCTGGAGTG 1861 CAGCTTGAGG ATCCAGAGTT CCAAGCCTCC AACATCATGC ACAGCATCAA TGGCTATGTT 1921 TTTGATAGTT TGCAGTTGTC AGTTTGTTTG CATGAGGTGG CATACTGGTA CATTCTAAGC 1981 ATTGGAGCAC AGACTGACTT CCTTTCTGTC TTCTTCTCTG GATATACCTT CAAACACAAA 2041 ATGGTCTATG AAGACACACT CACCCTATTC CCATTCTCAG GAGAAACTGT CTTCATGTCG 2101 ATGGAAAACC CAGGTCTATG GATTCTGGGG TGCCACAACT CAGACTTTCG GAACAGAGGC 2161 ATGACCGCCT TACTGAAGGT TTCTAGTTGT GACAAGAACA CTGGTGATTA TTACGAGGAC 2221 AGTTATGAAG ATATTTCAGC ATACTTGCTG AGTAAAAACA ATGCCATTGA ACCAAGAAGC 2281 TTCTCCCAGA ATTCAAGACA CCCTAGCACT AGGCAAAAGC AATTTAATGC CACCACAATT 2341 CCAGAAAATG ACATAGAGAA GACTGACCCT TGGTTTGCAC ACAGAACACC TATGCCTAAA 2401 ATACAAAATG TCTCCTCTAG TGATTTGTTG ATGCTCTTGC GACAGAGTCC TACTCCACAT 2461 GGGCTATCCT TATCTGATCT CCAAGAAGCC AAATATGAGA CTTTTTCTGA TGATCCATCA 2521 CCTGGAGCAA TAGACAGTAA TAACAGCCTG TCTGAAATGA CACACTTCAG GCCACAGCTC 2581 CATCACAGTG GGGACATGGT ATTTACCCCT GAGTCAGGCC TCCAATTAAG ATTAAATGAG 2641 AAACTGGGGA CAACTGCAGC AACAGAGTTG AAGAAACTTG ATTTCAAAGT TTCTAGTACA 2701 TCAAATAATC TGATTTCAAC AATTCCATCA GACAATTTGG CAGCAGGTAC TGATAATACA 2761 AGTTCCTTAG GACCCCCAAG TATGCCAGTT CATTATGATA GTCAATTAGA TACCACTCTA 2821 TTTGGCAAAA AGTCATCTCC CCTTACTGAG TCTGGTGGAC CTCTGAGCTT GAGTGAAGAA 2881 AATAATGATT CAAAGTTGTT AGAATCAGGT TTAATGAATA GCCAAGAAAG TTCATGGGGA 2941 AAAAATGTAT CGTCAACAGA GAGTGGTAGG TTATTTAAAG GGAAAAGAGC TCATGGACCT 3001 GCTTTGTTGA CTAAAGATAA TGCCTTATTC AAAGTTAGCA TCTCTTTGTT AAAGACAAAC 3061 AAAACTTCCA ATAATTCAGC AACTAATAGA AAGACTCACA TTGATGGCCC ATCATTATTA 3121 ATTGAGAATA GTCCATCAGT CTGGCAAAAT ATATTAGAAA GTGACACTGA GTTTAAAAAA 3181 GTGACACCTT T GATT CAT GA CAGAATGCTT ATGGACAAAA ATGCTACAGC TTTGAGGCTA 3241 AATCATATGT CAAATAAAAC TACTTCATCA AAAAACATGG AAATGGTCCA3301 GAGGGCCCCA TTCCACCAGA TGCACAAAAT CCAGATATGT CGTTCTTTAA GATGCTATTC 3361 TTGCCAGAAT CAGCAAGGTG GATACAAAGG ACTCATGGAA AGAACTCTCT GAACTCTGGG 3421 CAAGGCCCCA GTCCAAAGCA ATTAGTATCC TTAGGACCAG AAAAATCTGT GGAAGGTCAG 3481 AATTTCTTGT CTGAGAAAAA CAAAGTGGTA GTAGGAAAGG GTGAATTTAC AAAGGACGTA 3541 GGACTCAAAG AGATGGTTTT TCCAAGCAGC AGAAACCTAT TTCTTACTAA CTTGGATAAT 3601 TTACATGAAA ATAATACACA CAATCAAGAA AAAAAAATTC AGGAAGAAAT AGAAAAGAAG 3661 GAAACATTAA TCCAAGAGAA TGTAGTTTTG CCTCAGATAC ATACAGTGAC TGGCACTAAG 3721 AATTTCATGA AGAACCTTTT CTTACTGAGC ACTAGGCAAA ATGTAGAAGG TTCATATGAC 3781 GGGGCATATG CTCCAGTACT TCAAGATTTT AGGTCATTAA ATGATTCAAC AAATAGAACA 3841 AAGAAACACA CAGCTCATTT CTCAAAAAAA GGGGAGGAAG AAAACTTGGA AGGCTTGGGA 3901 AATCAAACCA AGCAAATTGT AGAGAAATAT GCATGCACCA CAAGGATATC TCCTAATACA 3961 AGCCAGCAGA ATTTTGTCAC GCAACGTAGT AAGAGAGCTT TGAAACAATT CAGACTCCCA 4021 CTAGAAGAAA CAGAACTTGA AAAAAGGATA ATTGTGGATG ACACCTCAAC CCAGTGGTCC 4081 AAAAACATGA AACATTTGAC CCCGAGCACC CTCACACAGA TAGACTACAA TGAGAAGGAG 37#15239971vlT19749Attorney Docket No. U1202.70169WO00 4141 AAAGGGGCCA TTACTCAGTC TCCCTTATCA GATTGCCTTA CGAGGAGTCA TAGCATCCCT 4201 CAAGCAAATA GATCTCCATT ACCCATTGCA AAGGTATCAT CATTTCCATC TATTAGACCT 4261 ATATATCTGA CCAGGGTCCT ATTCCAAGAC AACTCTTCTC ATCTTCCAGC AGCATCTTAT 4321 AGAAAGAAAG ATTCTGGGGT CCAAGAAAGC AGTCATTTCT TACAAGGAGC CAAAAAAAAT 4381 AACCTTTCTT TAGCCATTCT AACCTTGGAG ATGACTGGTG ATCAAAGAGA GGTTGGCTCC 4441 CTGGGGACAA GTGCCACAAA TTCAGTCACA TACAAGAAAG TTGAGAACAC TGTTCTCCCG 4501 AAACCAGACT TGCCCAAAAC ATCTGGCAAA GTTGAATTGC TTCCAAAAGT TCACATTTAT 4561 CAGAAGGACC TATTCCCTAC GGAAACTAGC AATGGGTCTC CTGGCCATCT GGATCTCGTG 4621 GAAGGGAGCC TTCTTCAGGG AACAGAGGGA GCGATTAAGT GGAATGAAGC AAACAGACCT 4681 GGAAAAGTTC CCTTTCTGAG AGTAGCAACA GAAAGCTCTG CAAAGACTCC CTCCAAGCTA 4741 TTGGATCCTC TTGCTTGGGA TAACCACTAT GGTACTCAGA TACCAAAAGA AGAGTGGAAA 4801 TCCCAAGAGA AGTCACCAGA AAAAACAGCT TTTAAGAAAA AGGATACCAT TTTGTCCCTG 4861 AACGCTTGTG AAAGCAATCA TGCAATAGCA GCAATAAATG AGGGACAAAA TAAGCCCGAA 4921 ATAGAAGTCA CCTGGGCAAA GCAAGGTAGG ACTGAAAGGC TGTGCTCTCA AAACCCACCA 4981 GTCTTGAAAC GCCATCAACG GGAAATAACT CGTACTACTC TTCAGTCAGA TCAAGAGGAA 5041 ATTGACTATG ATGATACCAT ATCAGTTGAA ATGAAGAAGG AAGATTTTGA CAT T TAT GAT 5101 GAGGATGAAA ATCAGAGCCC CCGCAGCTTT CAAAAGAAAA CACGACACTA TTTTATTGCT 5161 GCAGTGGAGA GGCTCTGGGA TTATGGGATG AGTAGCTCCC CACATGTTCT AAGAAACAGG 5221 GCTCAGAGTG GCAGTGTCCC TCAGTTCAAG AAAGTTGTTT TCCAGGAATT TACTGATGGC 5281 TCCTTTACTC AGCCCTTATA CCGTGGAGAA CTAAATGAAC ATTTGGGACT CCTGGGGCCA 5341 TATATAAGAG CAGAAGTTGA AGATAATATC ATGGTAACTT TCAGAAATCA GGCCTCTCGT 5401 CCCTATTCCT TCTATTCTAG CCTTATTTCT TATGAGGAAG ATCAGAGGCA AGGAGCAGAA 5461 CCTAGAAAAA ACTTTGTCAA GCCTAATGAA ACCAAAACTT ACTTTTGGAA AGTGCAACAT 5521 CATATGGCAC CCACTAAAGA TGAGTTTGAC TGCAAAGCCT GGGCTTATTT CTCTGATGTT 5581 GACCTGGAAA AAGATGTGCA CTCAGGCCTG ATTGGACCCC TTCTGGTCTG CCACACTAAC 5641 ACACTGAACC CTGCTCATGG GAGACAAGTG ACAGTACAGG AATTTGCTCT GTTTTTCACC 5701 ATCTTTGATG AGACCAAAAG CTGGTACTTC ACTGAAAATA TGGAAAGAAA CTGCAGGGCT 5761 CCCTGCAATA TCCAGATGGA AGATCCCACT TTTAAAGAGA ATTATCGCTT CCATGCAATC 5821 AATGGCTACA TAATGGATAC ACTACCTGGC TTAGTAATGG CTCAGGATCA AAGGATTCGA 5881 TGGTATCTGC TCAGCATGGG CAGCAATGAA AACATCCATT CTATTCATTT CAGTGGACAT 5941 GTGTTCACTG TACGAAAAAA AGAGGAGTAT AAAATGGCAC TGTACAATCT CTATCCAGGT 6001 GTTTTTGAGA CAGTGGAAAT GTTACCATCC AAAGCTGGAA TTTGGCGGGT GGAATGCCTT 6061 ATTGGCGAGC ATCTACATGC TGGGATGAGC ACACTTTTTC TGGTGTACAG CAATAAGTGT 6121 CAGACTCCCC TGGGAATGGC TTCTGGACAC ATTAGAGATT TTCAGATTAC AGCTTCAGGA 6181 CAATATGGAC AGTGGGCCCC AAAGCTGGCC AGACTTCATT ATTCCGGATC AATCAATGCC 6241 TGGAGCACCA AGGAGCCCTT TTCTTGGATC AAGGTGGATC TGTTGGCACC AATGATTATT 6301 CACGGCATCA AGACCCAGGG TGCCCGTCAG AAGTTCTCCA GCCTCTACAT CTCTCAGTTT 6361 ATCATCATGT ATAGTCTTGA TGGGAAGAAG TGGCAGACTT ATCGAGGAAA TTCCACTGGA 6421 ACCTTAATGG TCTTCTTTGG CAATGTGGAT TCATCTGGGA TAAAACACAA TATTTTTAAC 6481 CCTCCAATTA TTGCTCGATA CATCCGTTTG CACCCAACTC ATTATAGCAT TCGCAGCACT 6541 CTTCGCATGG AGTTGATGGG CTGTGATTTA AATAGTTGCA GCATGCCATT GGGAATGGAG 6601 AGTAAAGCAA TATCAGATGC ACAGATTACT GCTTCATCCT ACTTTACCAA TATGTTTGCC 6661 ACCTGGTCTC CTTCAAAAGC TCGACTTCAC CTCCAAGGGA GGAGTAATGC CTGGAGACCT 6721 CAGGTGAATA ATCCAAAAGA GTGGCTGCAA GTGGACTTCC AGAAGACAAT GAAAGTCACA 6781 GGAGTAACTA CTCAGGGAGT AAAATCTCTG CTTACCAGCA TGTATGTGAA GGAGTTCCTC 6841 ATCTCCAGCA GTCAAGATGG CCATCAGTGG ACTCTCTTTT TTCAGAATGG CAAAGTAAAG 6901 GTTTTTCAGG GAAATCAAGA CTCCTTCACA CCTGTGGTGA ACTCTCTAGA CCCACCGTTA 6961 CTGACTCGCT ACCTTCGAAT TCACCCCCAG AGTTGGGTGC ACCAGATTGC CCTGAGGATG 7021 GAGGTTCTGG GCTGCGAGGC ACAGGACCTC TACTGA ( SEQ ID NO: 42 )Homo sapiens coagulation factor VIII isoform a preproprotein amino acid sequence (NCBI Ref Seq. NP_000123.1)1 MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL GELPVDARFP PRVPKSFPFN 61 TSWYKKTLF VEFTDHLFNI AKPRPPWMGL LGPTIQAEVY DTWITLKNM ASHPVSLHAV 121 GVSYWKASEG AEYDDQTSQR EKEDDKVFPG GSHTYVWQVL KENGPMASDP LCLTYSYLSH 181 VDLVKDLNSG LIGALLVCRE GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD#15239971vlT19749Attorney Docket No. U1202.70169WO00 241 AASARAWPKM HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL EGHTFLVRNH 301 RQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGME AYVKVDSCPE EPQLRMKNNE 361 EAEDYDDDLT DSEMDWRFD DDNSPSFIQI RSVAKKHPKT WVHYIAAEEE DWDYAPLVLA 421 PDDRSYKSQY LNNGPQRIGR KYKKVRFMAY TDETFKTREA IQHESGILGP LLYGEVGDTL 481 LIIFKNQASR PYNIYPHGIT DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP 541 TKSDPRCLTR YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR NVILFSVFDE 601 NRSWYLTENI QRFLPNPAGV QLEDPEFQAS NIMHSINGYV FDSLQLSVCL HEVAYWYILS 661 IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF PFSGETVFMS MENPGLWILG CHNSDFRNRG 721 MTALLKVSSC DKNTGDYYED SYEDISAYLL SKNNAIEPRS FSQNSRHPST RQKQFNATTI 781 PENDIEKTDP WFAHRTPMPK IQNVSSSDLL MLLRQSPTPH GLSLSDLQEA KYETFSDDPS 841 PGAIDSNNSL SEMTHFRPQL HHSGDMVFTP ESGLQLRLNE KLGTTAATEL KKLDFKVSST 901 SNNLISTIPS DNLAAGTDNT SSLGPPSMPV HYDSQLDTTL FGKKSSPLTE SGGPLSLSEE 961 NNDSKLLESG LMNSQESSWG KNVSSTESGR LFKGKRAHGP ALLTKDNALF KVSISLLKTN 1021 KTSNNSATNR KTHIDGPSLL IENSPSVWQN ILESDTEFKK VTPLIHDRML MDKNATALRL 1081 NHMSNKTTSS KNMEMVQQKK EGPIPPDAQN PDMSFFKMLF LPESARWIQR THGKNSLNSG 1141 QGPSPKQLVS LGPEKSVEGQ NFLSEKNKW VGKGEFTKDV GLKEMVFPSS RNLFLTNLDN 1201 LHENNTHNQE KKIQEEIEKK ETLIQENWL PQIHTVTGTK NFMKNLFLLS TRQNVEGSYD 1261 GAYAPVLQDF RSLNDSTNRT KKHTAHFSKK GEEENLEGLG NQTKQIVEKY ACTTRISPNT 1321 SQQNFVTQRS KRALKQFRLP LEETELEKRI IVDDTSTQWS KNMKHLTPST LTQIDYNEKE 1381 KGAITQSPLS DCLTRSHSIP QANRSPLPIA KVSSFPSIRP IYLTRVLFQD NSSHLPAASY 1441 RKKDSGVQES SHFLQGAKKN NLSLAILTLE MTGDQREVGS LGTSATNSVT YKKVENTVLP 1501 KPDLPKTSGK VELLPKVHIY QKDLFPTETS NGSPGHLDLV EGSLLQGTEG AIKWNEANRP 1561 GKVPFLRVAT ESSAKTPSKL LDPLAWDNHY GTQIPKEEWK SQEKSPEKTA FKKKDTILSL 1621 NACESNHAIA AINEGQNKPE IEVTWAKQGR TERLCSQNPP VLKRHQREIT RTTLQSDQEE 1681 IDYDDTISVE MKKEDFDIYD EDENQSPRSF QKKTRHYFIA AVERLWDYGM SSSPHVLRNR 1741 AQSGSVPQFK KWFQEFTDG SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI MVTFRNQASR 1801 PYSFYSSLIS YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH HMAPTKDEFD CKAWAYFSDV 1861 DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV TVQEFALFFT IFDETKSWYF TENMERNCRA 1921 PCNIQMEDPT FKENYRFHAI NGYIMDTLPG LVMAQDQRIR WYLLSMGSNE NIHSIHFSGH 1981 VFTVRKKEEY KMALYNLYPG VFETVEMLPS KAGIWRVECL IGEHLHAGMS TLFLVYSNKC 2041 QTPLGMASGH IRDFQITASG QYGQWAPKLA RLHYSGSINA WSTKEPFSWI KVDLLAPMII 2101 HGIKTQGARQ KFSSLYISQF IIMYSLDGKK WQTYRGNSTG TLMVFFGNVD SSGIKHNIFN 2161 PPIIARYIRL HPTHYSIRST LRMELMGCDL NSCSMPLGME SKAISDAQIT ASSYFTNMFA 2221 TWSPSKARLH LQGRSNAWRP QVNNPKEWLQ VDFQKTMKVT GVTTQGVKSL LTSMYVKEFL 2281 ISSSQDGHQW TLFFQNGKVK VFQGNQDSFT PWNSLDPPL LTRYLRIHPQ SWVHQIALRM 2341 EVLGCEAQDL Y ( SEQ ID NO: 43 )Homo sapiens coagulation factor VIII (F8), transcript variant 2, mRNA (NCBIRef. Seq. NMJH9863.3)1 GGGGCGACGT GCCCTGCGTC CCCCTCGGCG GGCTGCCGCC GTGCCCGCGC CGGCTCCCCA 61 GCCCGAGCCT GCCCCTTGCC CTGATGAGGT GCAAAGAGCG GGATCGGAGG CGGGGCCTGG 121 CCGGGCTGTG AGCGGCGTAT GCAAATCGAG GGTCTCGGGG ATGCGGATCC AAGACCCTGG 181 GAAGGTCTTC TTTGGCAATG TGGATTCATC TGGGATAAAA CACAATATTT TTAACCCTCC 241 AATTATTGCT CGATACATCC GTTTGCACCC AACTCATTAT AGCATTCGCA GCACTCTTCG 301 CATGGAGTTG ATGGGCTGTG ATTTAAATAG TTGCAGCATG CCATTGGGAA TGGAGAGTAA 361 AGCAATATCA GATGCACAGA TTACTGCTTC ATCCTACTTT ACCAATATGT TTGCCACCTG 421 GTCTCCTTCA AAAGCTCGAC TTCACCTCCA AGGGAGGAGT AATGCCTGGA GACCTCAGGT 481 GAATAATCCA AAAGAGTGGC TGCAAGTGGA CTTCCAGAAG ACAATGAAAG TCACAGGAGT 541 AACTACTCAG GGAGTAAAAT CTCTGCTTAC CAGCATGTAT GTGAAGGAGT TCCTCATCTC 601 CAGCAGTCAA GATGGCCATC AGTGGACTCT CTTTTTTCAG AATGGCAAAG TAAAGGTTTT 661 TCAGGGAAAT CAAGACTCCT TCACACCTGT GGTGAACTCT CTAGACCCAC CGTTACTGAC 721 TCGCTACCTT CGAATTCACC CCCAGAGTTG GGTGCACCAG ATTGCCCTGA GGATGGAGGT 781 TCTGGGCTGC GAGGCACAGG ACCTCTACTG AGGGTGGCCA CTGCAGCACC TGCCACTGCC 841 GTCACCTCTC CCTCCTCAGC TCCAGGGCAG TGTCCCTCCC TGGCTTGCCT TCTACCTTTG 901 TGCTAAATCC TAGCAGACAC TGCCTTGAAG CCTCCTGAAT TAACTATCAT CAGTCCTGCA 961 TTTCTTTGGT GGGGGGCCAG GAGGGTGCAT CCAATTTAAC TTAACTCTTA CCTATTTTCT 39#15239971vlT19749Attorney Docket No. U1202.70169WO00 1021 GCAGCTGCTC CCAGATTACT CCTTCCTTCC AATATAACTA GGCAAAAAGA AGTGAGGAGA 1081 AACCTGCATG AAAGCATTCT TCCCTGAAAA GTTAGGCCTC TCAGAGTCAC CACTTCCTCT 1141 GTTGTAGAAA AACTATGTGA TGAAACTTTG AAAAAGATAT TTATGATGTT AACATTTCAG 1201 GTTAAGCCTC ATACGTTTAA AATAAAACTC TCAGTTGTTT ATTATCCTGA TCAAGCATGG 1261 AACAAAGCAT GTTTCAGGAT CAGATCAATA CAATCTTGGA GTCAAAAGGC AAATCATTTG 1321 GACAATCTGC AAAATGGAGA GAATACAATA ACTACTACAG TAAAGTCTGT TTCTGCTTCC 1381 TT AC AC AT AG ATATAATTAT GTTATTTAGT CATTATGAGG GGCACATTCT TATCTCCAAA 1441 AC TAGCAT TC TTAAACTGAG AATTATAGAT GGGGTTCAAG AATCCCTAAG TCCCCTGAAA 1501 TTATATAAGG CATTCTGTAT AAATGCAAAT GTGCATTTTT CTGACGAGTG TCCATAGATA 1561 TAAAGCCATT TGGTCTTAAT TCTGACCAAT AAAAAAATAA GTCAGGAGGA TGCAATTGTT 1621 GAAAGCTTTG AAATAAAATA ACAATGTCTT CTTGAAATTT GTGATGGCCA AGAAAGAAAA 1681 TGATGATGAC ATTAGGCTTC TAAAGGACAT ACATTTAATA TTTCTGTGGA AATATGAGGA 1741 AAATCCATGG T TAT CT GAGA TAGGAGATAC AAACTTTGTA ATTCTAATAA TGCACTCAGT 1801 TTACTCTCTC CCTCTACTAA TTTCCTGCTG AAAATAACAC AACAAAAATG TAACAGGGGA 1861 AATTATATAC CGTGACTGAA AACTAGAGTC CTACTTACAT AGTTGAAATA TCAAGGAGGT 1921 CAGAAGAAAA TTGGACTGGT GAAAACAGAA AAAACACTCC AGTCTGCCAT ATCACCACAC 1981 AATAGGATCC CCCTTCTTGC CCTCCACCCC CATAAGATTG TGAAGGGTTT ACTGCTCCTT 2041 CCATCTGCCT GACCCCTTCA CTATGACTAC ACAGAATCTC CTGATAGTAA AGGGGGCTGG 2101 AGACAAGGAT AAGTTATAGA GCAGTTGGAG GAAGCATCCA AAGATTGCAA CCCAGGGCAA 2161 ATGGAAAACA GGAGATCCTA ATATGAAAGA AAAATGGATC CCAATCTGAG AAAAGGCAAA 2221 AGAATGGCTA CTTTTTTCTA TGCTGGAGTA TTTTCTAATA ATCCTGCTTG ACCCTTATCT 2281 GACCTCTTTG GAAACTATAA CATAGCTGTC ACAGTATAGT CACAATCCAC AAATGATGCA 2341 GGTGCAAATG GTTTATAGCC CTGTGAAGTT CTTAAAGTTT AGAGGCTAAC TTACAGAAAT 2401 GAATAAGTTG TTTTGTTTTA TAGCCCGGTA GAGGAGTTAA CCCCAAAGGT GATATGGTTT 2461 TATTTCCTGT TATGTTTAAC TTGATAATCT TATTTTGGCA TTCTTTTCCC ATTGACTATA 2521 TACATCTCTA TTTCTCAAAT GTTCATGGAA CTAGCTCTTT TATTTTCCTG CTGGTTTCTT 2581 CAGTAATGAG TTAAATAAAA CATTGACACA TACAAA ( SEQ ID NO: 44 )Homo sapiens coagulation factor VIII (F8), transcript variant 2, mRNA (NCBIRef. Seq. NM_019863.3, nucleotides 161-811)- coding sequence1 ATGCGGATCC AAGACCCTGG GAAGGTCTTC TTTGGCAATG TGGATTCATC TGGGATAAAA 61 CACAATATTT TTAACCCTCC AATTATTGCT CGATACATCC GTTTGCACCC AACTCATTAT 121 AGCATTCGCA GCACTCTTCG CATGGAGTTG ATGGGCTGTG ATTTAAATAG TTGCAGCATG 181 CCATTGGGAA TGGAGAGTAA AGCAATATCA GATGCACAGA TTACTGCTTC ATCCTACTTT 241 ACCAATATGT TTGCCACCTG GTCTCCTTCA AAAGCTCGAC TTCACCTCCA AGGGAGGAGT 301 AATGCCTGGA GACCTCAGGT GAATAATCCA AAAGAGTGGC TGCAAGTGGA CTTCCAGAAG 361 ACAATGAAAG TCACAGGAGT AACTACTCAG GGAGTAAAAT CTCTGCTTAC CAGCATGTAT 421 GTGAAGGAGT TCCTCATCTC CAGCAGTCAA GATGGCCATC AGTGGACTCT CTTTTTTCAG 481 AATGGCAAAG TAAAGGTTTT TCAGGGAAAT CAAGACTCCT TCACACCTGT GGTGAACTCT 541 CTAGACCCAC CGTTACTGAC TCGCTACCTT CGAATTCACC CCCAGAGTTG GGTGCACCAG 601 ATTGCCCTGA GGATGGAGGT TCTGGGCTGC GAGGCACAGG ACCTCTACTG A ( SEQ ID NO: 45 )Homo sapiens coagulation factor VIII isoform b amino acid sequence (NCBIRef Seq. NPJD63916.1)1 MRIQDPGKVF FGNVDSSGIK HNIFNPPIIA RYIRLHPTHY SIRSTLRMEL MGCDLNSCSM 61 PLGMESKAIS DAQITASSYF TNMFATWSPS KARLHLQGRS NAWRPQVNNP KEWLQVDFQK 121 TMKVTGVTTQ GVKSLLTSMY VKEFLISSSQ DGHQWTLFFQ NGKVKVFQGN QDSFTPWNS 181 LDPPLLTRYL RIHPQSWVHQ IALRMEVLGC EAQDLY ( SEQ ID NO: 46 )
[0111] In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least40#15239971vlT19749Attorney Docket No. U1202.70169WO00 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39). In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39). In some embodiments, a sequence encoding coagulation factor VIII comprises the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39). In some embodiments, a sequence encoding coagulation factor VIII consists, or consists essentially of, the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39).
[0112] In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40).
[0113] In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity,41#15239971vlT19749Attorney Docket No. U1202.70169WO00 at least 98% identity, or at least 99% identity) with the sequence of NM_000132.4 (SEQ ID NO: 41). In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of NM_000132.4 (SEQ ID NO: 41). In some embodiments, a sequence encoding coagulation factor VIII comprises the sequence of NM_000132.4 (SEQ ID NO: 41). In some embodiments, a sequence encoding coagulation factor VIII consists, or consists essentially of, the sequence of NM_000132.4 (SEQ ID NO: 41).
[0114] In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the coding sequence portion of NM_000132.4 (nucleotides 172-7227 (SEQ ID NO: 42)). In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), nucleotide mismatches relative to the coding sequence portion of NM_000132.4 (nucleotides 172-7227 (SEQ ID NO: 42)). In some embodiments, a sequence encoding coagulation factor VIII comprises the coding sequence portion of NM_000132.4 (nucleotides 172-7227 (SEQ ID NO: 42)). In some embodiments, a sequence encoding coagulation factor VIII consists, or consists essentially of, the coding sequence portion of NM_000132.4 (nucleotides 172-7227 (SEQ ID NO: 42)).
[0115] In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NP_000123.1 (SEQ ID NO: 43). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the42#15239971vlT19749Attorney Docket No. U1202.70169WO00 sequence of NP_000123.1 (SEQ ID NO: 43). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of NP_000123.1 (SEQ ID NO: 43). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of NP_000123.1 (SEQ ID NO: 43).
[0116] In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NM_019863.3 (SEQ ID NO: 44). In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has 0-60 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60), nucleotide mismatches relative to the sequence of NM_019863.3 (SEQ ID NO: 44). In some embodiments, a sequence encoding coagulation factor VIII comprises the sequence of NM_019863.3 (SEQ ID NO: 44). In some embodiments, a sequence encoding coagulation factor VIII consists, or consists essentially of, the sequence of NM_019863.3 (SEQ ID NO: 44).
[0117] In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the coding sequence portion of NM_019863.3 (nucleotides 161-811 (SEQ ID NO: 45)). In some embodiments, a sequence encoding coagulation factor VIII comprises a sequence that has 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), nucleotide mismatches relative to the coding sequence portion of NM_019863.3 (nucleotides 161-811 (SEQ ID NO: 45)). In some embodiments, a sequence encoding coagulation factor VIII comprises the coding sequence portion of NM_019863.3 (nucleotides 161-811 (SEQ ID NO: 45)). In some embodiments, a sequence encoding coagulation factor VIII consists, or43#15239971vlT19749Attorney Docket No. U1202.70169WO00 consists essentially of, the coding sequence portion of NM_019863.3 (nucleotides 161-811 (SEQ ID NO: 45)).
[0118] In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence of NP_063916.1 (SEQ ID NO: 46). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence having 0-30 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30), amino acid mismatches relative to the sequence of NP_063916.1 (SEQ ID NO: 46). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of NP_063916.1 (SEQ ID NO: 46). In some embodiments, a sequence encoding coagulation factor VIII comprises a nucleotide sequence that encodes an amino acid sequence consisting, or consisting essentially of, the amino acid sequence of NP_063916.1 (SEQ ID NO: 46).Examples of nucleic acid vectors
[0119] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence and (b) a nucleotide sequence encoding a transgene. In some embodiments, the S-sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has about 70% to about 95% identity (e.g., about 95% identity,44#15239971vlT19749Attorney Docket No. U1202.70169WO00 about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, the S-sequence has a length of or about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15) and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15) and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0120] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene.
[0121] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In45#15239971vlT19749Attorney Docket No. U1202.70169WO00 some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
[0122] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the46#15239971vlT19749Attorney Docket No. U1202.70169WO00 GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
[0123] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than47#15239971vlT19749Attorney Docket No. U1202.70169WO00 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement.
[0124] In some embodiments, the GRE comprises, consists essentially of, or consists of at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80%48#15239971vlAttorney Docket No. U1202.70169WO00 identity, about 75% identity, or about 70% identity) with at least 8 contiguous nucleotides (e.g., 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides) of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement. In some embodiments, the GRE has a length of or about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the GRE has a length of 15 nucleotides. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement.
[0125] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein49#15239971vlAttorney Docket No. U1202.70169WO00 each N is independently a T, C, G, or A and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0126] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0127] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-50#15239971vlAttorney Docket No. U1202.70169WO00 AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0128] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0129] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence and (b) a nucleotide sequence encoding a transgene. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91%51#15239971vlT19749Attorney Docket No. U1202.70169WO00 identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity) with the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has less than 95% identity (e.g., less than 90% identity, less than 85% identity, less than 80% identity, less than 75% identity, or less than 70% identity) with the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has about 70% to about 95% identity (e.g., about 95% identity, about 90% identity, about 85% identity, about 80% identity, about 75% identity, or about 70% identity) with the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has fewer than 6 mismatches (e.g., fewer than 5, fewer than 4, fewer than 3, fewer than 2, 1, or no mismatches) relative to the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has 1, 2, 3, 4, 5, or 6 mismatches relative to the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, the heterologous nucleotide sequence has a length of or about 10 nucleotides (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-52#15239971vlT19749Attorney Docket No. U1202.70169WO00 ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0130] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5 '-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-53#15239971vlT19749Attorney Docket No. U1202.70169WO00 3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0131] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence54#15239971vlT19749Attorney Docket No. U1202.70169WO00 comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0132] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-55#15239971vlT19749Attorney Docket No. U1202.70169WO00 AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5 '-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0133] In some embodiments, a nucleic acid vector provided herein (e.g., to be encapsidated in an rAAV capsid) comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising,56#15239971vlT19749Attorney Docket No. U1202.70169WO00 consisting essentially of, or consisting of the nucleic acid sequence 5'- GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'- TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, a nucleic acid vector provided herein comprises (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0134] Examples of nucleic acid vectors encoding human FVIII are provided below. The vectors can be used in AAV preparations, and include the entire sequence of an AAV nucleic acid vector, from left ITR to right ITR. The coding sequence in each example nucleic acid vector below is bolded and underlined.pscAA V3-TTR-BDD-FVHI (from Left ITR to right ITR) TTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCTGGCGACCAAAGGTCGCCAGACGGACGTGCTTTG CACGTCCGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGGAGTGGCCAACTCCATCACTAGAGGTATGGCACCGGT GGGGAGGCTGCAGGTGAACATTAACCAAGGTCACCCCAGTTATCAGAGGAGCAAACAGGAGCTAAGTCCACGTCTG TCTGCACATTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTA TTCTCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGG T T GGAAGGAGGGGGT AT AAAAGC C C C T T C AC C AGGAGAAGC C GT C AC AC AGAT C C AC AAGC T C C T GGT C GAC T T AA TTAAAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAA AT C AC T T T T T T T C AGGT T GGC T C GAgt acggccgccac catgcaaatagagctctccacctgcttctttctgtgcc ttttgcgattctgctttagtgccaccagaagatactacctgggtgcagtggaactgtcatgggactatatgcaaag tgatctcggtgagctgcctgtggacgcaagatttcctcctagagtgccaaaatcttttccattcaacacctcagtc gtgtacaaaaagactctgtttgtagaattcacggatcaccttttcaacatcgctaagccaaggccaccctggatgg gtctgctaggtcctaccatccaggctgaggtttatgatacagtggtcattacacttaagaacatggcttcccatcc tgtcagtcttcatgctgttggtgtatcctactggaaagcttctgagggagctgaatatgatgatcagaccagtcaa agggagaaagaagatgataaagtcttccctggtggaagccatacatatgtctggcaggtcctgaaagagaatggtc caatggcctctgacccactgtgccttacctactcatatctttctcatgtggacctggtaaaagacttgaattcagg cctcattggagccctactagtatgtagagaagggagtctggccaaggaaaagacacagaccttgcacaaatttata ctactttttgctgtatttgatgaagggaaaagttggcactcagaaacaaagaactccttgatgcaggatagggatg ctgcatctgctcgggcctggcctaaaatgcacacagtcaatggttatgtaaacaggtctctgccaggtctgattgg atgccacaggaaatcagtctattggcatgtgattggaatgggcaccactcctgaagtgcactcaatattcctcgaa ggtcacacatttcttgtgaggaaccatcgccaggcgtccttggaaatctcgccaataactttccttactgctcaaa 57#15239971vlT19749Attorney Docket No. U1202.70169WO00 cactcttgatggaccttggacagtttctactgttttgtcatatctcttcccaccaacatgatggcatggaagctta tgtcaaagtagacagctgtccagaggaaccccaactacgaatgaaaaataatgaagaagcggaagactatgatgat gatcttactgattctgaaatggatgtggtcaggtttgatgatgacaactctccttcctttatccaaattcgctcag ttgccaagaagcatcctaaaacttgggtacattacattgctgctgaagaggaggactgggactatgctcccttagt cctcgcccccgatgacagaagttataaaagtcaatatttgaacaatggccctcagcggattggtaggaagtacaaa aaagtccgatttatggcatacacagatgaaacctttaagactcgtgaagctattcagcatgaatcaggaatcttgg gacctttactttatggggaagttggagacacactgttgattatatttaagaatcaagcaagcagaccatataacat ctaccctcacggaatcactgatgtccgtcctttgtattcaaggagattaccaaaaggtgtaaaacatttgaaggat tttccaattctgccaggagaaatattcaaatataaatggacagtgactgtagaagatgggccaactaaatcagatc ctcggtgcctgacccgctattactctagtttcgttaatatggagagagatctagcttcaggactcattggccctct cctcatctgctacaaagaatctgtagatcaaagaggaaaccagataatgtcagacaagaggaatgtcatcctgttt tctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctggagtgc agcttgaggatccagagttccaagcctccaacatcatgcacagcatcaatggctatgtttttgatagtttgcagtt gtcagtttgtttgcatgaggtggcatactggtacattctaagcattggagcacagactgacttcctttctgtcttc ttctctggatataccttcaaacacaaaatggtctatgaagacacactcaccctattcccattctcaggagaaactg tcttcatgtcgatggaaaacccaggtctatggattctggggtgccacaactcagactttcggaacagaggcatgac cgccttactgaaggtttctagttgtgacaagaacactggtgattattacgaggacagttatgaagatatttcagca tacttgctgagtaaaaacaatgccattgaaccaagaagcttctctcaaaacccaccagtcttgaaacgccatcaac gggaaataactcgtactactcttcagtcagatcaagaggaaattgactatgatgataccatatcagttgaaatgaa gaaggaagattttgacatttatgatgaggatgaaaatcagagcccccgcagctttcaaaagaaaacacgacactat tttattgctgcagtggagaggctctgggattatgggatgagtagctccccacatgttctaagaaacagggctcaga gtggcagtgtccctcagttcaagaaagttgttttccaggaatttactgatggctcctttactcagcccttataccg tggagaactaaatgaacatttgggactcctggggccatatataagagcagaagttgaagataatatcatggtaact ttcagaaatcaggcctctcgtccctattccttctattctagccttatttcttatgaggaagatcagaggcaaggag cagaacctagaaaaaactttgtcaagcctaatgaaaccaaaacttacttttggaaagtgcaacatcatatggcacc cactaaagatgagtttgactgcaaagcctgggcttatttctctgatgttgacctggaaaaagatgtgcactcaggc ctgattggaccccttctggtctgccacactaacacactgaaccctgctcatgggagacaagtgacagtacaggaat ttgctctgtttttcaccatctttgatgagaccaaaagctggtacttcactgaaaatatggaaagaaactgcagggc tccctgcaatatccagatggaagatcccacttttaaagagaattatcgcttccatgcaatcaatggctacataatg gatacactacctggcttagtaatggctcaggatcaaaggattcgatggtatctgctcagcatgggcagcaatgaaa acatccattctattcatttcagtggacatgtgttcactgtacgaaaaaaagaggagtataaaatggcactgtacaa tctctatccaggtgtttttgagacagtggaaatgttaccatccaaagctggaatttggcgggtggaatgccttatt ggcgagcatctacatgctgggatgagcacactttttctggtgtacagcaataagtgtcagactcccctgggaatgg cttctggacacattagagattttcagattacagcttcaggacaatatggacagtgggccccaaagctggccagact tcattattccggatcaatcaatgcctggagcaccaaggagcccttttcttggatcaaggtggatctgttggcacca atgattattcacggcatcaagacccagggtgcccgtcagaagttctccagcctctacatctctcagtttatcatca tgtatagtcttgatgggaagaagtggcagacttatcgaggaaattccactggaaccttaatggtcttctttggcaa tgtggattcatctgggataaaacacaatatttttaaccctccaattattgctcgatacatccgtttgcacccaact cattatagcattcgcagcactcttcgcatggagttgatgggctgtgatttaaatagttgcagcatgccattgggaa tggagagtaaagcaatatcagatgcacagattactgcttcatcctactttaccaatatgtttgccacctggtctcc ttcaaaagctcgacttcacctccaagggaggagtaatgcctggagacctcaggtgaataatccaaaagagtggctg caagtggacttccagaagacaatgaaagtcacaggagtaactactcagggagtaaaatctctgcttaccagcatgt atgtgaaggagttcctcatctccagcagtcaagatggccatcagtggactctcttttttcagaatggcaaagtaaa ggtttttcagggaaatcaagactccttcacacctgtggtgaactctctagacccaccgttactgactcgctacctt cgaattcacccccagagttgggtgcaccagattgccctgaggatggaggttctgggctgcgaggcacaggacctct actgagcggccgctcgaGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGCAAT TGGCCATACCTCTAGTGATGGAGTTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCGGACGTGCAAA GCACGTCCGTCTGGCGACCTTTGGTCGCCAGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGGAGTGGCCAA( SEQ ID NO: 47 )pscAAV3-GRE-TTR-BDD-FVIH (from Left ITR to right ITR)GRE is shown [boxed and in bold italics^.TTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCTGGCGACCAAAGGTCGCCAGACGGACGTGCTTTG CACGTCCGGCCCCACC GAGC GAGC GAGT GC GC AT AGAGGGAGT GGC C AAC T C C AT C AC T[AGAACAGGATGTTC!z|AC CGGTGGGGAGGCTGCAGGTGAACATTAACCAAGGTCACCCCAGTTATCAGAGGAGCAAACAGGAGCTAAGTCCACG TCTGTCTGCACATTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTA58#15239971vlT19749Attorney Docket No. U1202.70169WO00 CTTATTCTCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCC T GGGT T GGAAGGAGGGGGT AT AAAAGC C C C T T C AC C AGGAGAAGC C GT C AC AC AGAT C C AC AAGC T C C T GGT C GAC TTAATTAAAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCC T GAAAT C AC T T T T T T T C AGGT T GGC T C GAgt acggccgccac catgcaaatagagctctccacctgcttctttctg tgccttttgcgattctgctttagtgccaccagaagatactacctgggtgcagtggaactgtcatgggactatatgc aaagtgatctcggtgagctgcctgtggacgcaagatttcctcctagagtgccaaaatcttttccattcaacacctc agtcgtgtacaaaaagactctgtttgtagaattcacggatcaccttttcaacatcgctaagccaaggccaccctgg atgggtctgctaggtcctaccatccaggctgaggtttatgatacagtggtcattacacttaagaacatggcttccc atcctgtcagtcttcatgctgttggtgtatcctactggaaagcttctgagggagctgaatatgatgatcagaccag tcaaagggagaaagaagatgataaagtcttccctggtggaagccatacatatgtctggcaggtcctgaaagagaat ggtccaatggcctctgacccactgtgccttacctactcatatctttctcatgtggacctggtaaaagacttgaatt caggcctcattggagccctactagtatgtagagaagggagtctggccaaggaaaagacacagaccttgcacaaatt tatactactttttgctgtatttgatgaagggaaaagttggcactcagaaacaaagaactccttgatgcaggatagg gatgctgcatctgctcgggcctggcctaaaatgcacacagtcaatggttatgtaaacaggtctctgccaggtctga ttggatgccacaggaaatcagtctattggcatgtgattggaatgggcaccactcctgaagtgcactcaatattcct cgaaggtcacacatttcttgtgaggaaccatcgccaggcgtccttggaaatctcgccaataactttccttactgct caaacactcttgatggaccttggacagtttctactgttttgtcatatctcttcccaccaacatgatggcatggaag cttatgtcaaagtagacagctgtccagaggaaccccaactacgaatgaaaaataatgaagaagcggaagactatga tgatgatcttactgattctgaaatggatgtggtcaggtttgatgatgacaactctccttcctttatccaaattcgc tcagttgccaagaagcatcctaaaacttgggtacattacattgctgctgaagaggaggactgggactatgctccct tagtcctcgcccccgatgacagaagttataaaagtcaatatttgaacaatggccctcagcggattggtaggaagta caaaaaagtccgatttatggcatacacagatgaaacctttaagactcgtgaagctattcagcatgaatcaggaatc ttgggacctttactttatggggaagttggagacacactgttgattatatttaagaatcaagcaagcagaccatata acatctaccctcacggaatcactgatgtccgtcctttgtattcaaggagattaccaaaaggtgtaaaacatttgaa ggattttccaattctgccaggagaaatattcaaatataaatggacagtgactgtagaagatgggccaactaaatca gatcctcggtgcctgacccgctattactctagtttcgttaatatggagagagatctagcttcaggactcattggcc ctctcctcatctgctacaaagaatctgtagatcaaagaggaaaccagataatgtcagacaagaggaatgtcatcct gttttctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctgga gtgcagcttgaggatccagagttccaagcctccaacatcatgcacagcatcaatggctatgtttttgatagtttgc agttgtcagtttgtttgcatgaggtggcatactggtacattctaagcattggagcacagactgacttcctttctgt cttcttctctggatataccttcaaacacaaaatggtctatgaagacacactcaccctattcccattctcaggagaa actgtcttcatgtcgatggaaaacccaggtctatggattctggggtgccacaactcagactttcggaacagaggca tgaccgccttactgaaggtttctagttgtgacaagaacactggtgattattacgaggacagttatgaagatatttc agcatacttgctgagtaaaaacaatgccattgaaccaagaagcttctctcaaaacccaccagtcttgaaacgccat caacgggaaataactcgtactactcttcagtcagatcaagaggaaattgactatgatgataccatatcagttgaaa tgaagaaggaagattttgacatttatgatgaggatgaaaatcagagcccccgcagctttcaaaagaaaacacgaca ctattttattgctgcagtggagaggctctgggattatgggatgagtagctccccacatgttctaagaaacagggct cagagtggcagtgtccctcagttcaagaaagttgttttccaggaatttactgatggctcctttactcagcccttat accgtggagaactaaatgaacatttgggactcctggggccatatataagagcagaagttgaagataatatcatggt aactttcagaaatcaggcctctcgtccctattccttctattctagccttatttcttatgaggaagatcagaggcaa ggagcagaacctagaaaaaactttgtcaagcctaatgaaaccaaaacttacttttggaaagtgcaacatcatatgg cacccactaaagatgagtttgactgcaaagcctgggcttatttctctgatgttgacctggaaaaagatgtgcactc aggcctgattggaccccttctggtctgccacactaacacactgaaccctgctcatgggagacaagtgacagtacag gaatttgctctgtttttcaccatctttgatgagaccaaaagctggtacttcactgaaaatatggaaagaaactgca gggctccctgcaatatccagatggaagatcccacttttaaagagaattatcgcttccatgcaatcaatggctacat aatggatacactacctggcttagtaatggctcaggatcaaaggattcgatggtatctgctcagcatgggcagcaat gaaaacatccattctattcatttcagtggacatgtgttcactgtacgaaaaaaagaggagtataaaatggcactgt acaatctctatccaggtgtttttgagacagtggaaatgttaccatccaaagctggaatttggcgggtggaatgcct tattggcgagcatctacatgctgggatgagcacactttttctggtgtacagcaataagtgtcagactcccctggga atggcttctggacacattagagattttcagattacagcttcaggacaatatggacagtgggccccaaagctggcca gacttcattattccggatcaatcaatgcctggagcaccaaggagcccttttcttggatcaaggtggatctgttggc accaatgattattcacggcatcaagacccagggtgcccgtcagaagttctccagcctctacatctctcagtttatc atcatgtatagtcttgatgggaagaagtggcagacttatcgaggaaattccactggaaccttaatggtcttctttg gcaatgtggattcatctgggataaaacacaatatttttaaccctccaattattgctcgatacatccgtttgcaccc aactcattatagcattcgcagcactcttcgcatggagttgatgggctgtgatttaaatagttgcagcatgccattg ggaatggagagtaaagcaatatcagatgcacagattactgcttcatcctactttaccaatatgtttgccacctggt ctccttcaaaagctcgacttcacctccaagggaggagtaatgcctggagacctcaggtgaataatccaaaagagtg gctgcaagtggacttccagaagacaatgaaagtcacaggagtaactactcagggagtaaaatctctgcttaccagc atgtatgtgaaggagttcctcatctccagcagtcaagatggccatcagtggactctcttttttcagaatggcaaag 59#15239971vlT19749Attorney Docket No. U1202.70169WO00 taaaggtttttcagggaaatcaagactccttcacacctgtggtgaactctctagacccaccgttactgactcgcta ccttcgaattcacccccagagttgggtgcaccagattgccctgaggatggaggttctgggctgcgaggcacaggac ctctactgagcggccgctcgaGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTG CAATTGGCCATACCTCTAGTGATGGAGTTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCGGACGTG CAAAGCACGTCCGTCTGGCGACCTTTGGTCGCCAGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGGAGTGGCCAA(SEQ ID NO: 48 )
[0135] Examples of nucleic acid vectors encoding human FIX are provided below. The vectors can be used in AAV preparations, and include the entire sequence of an AAV nucleic acid vector, from left ITR to right ITR. The coding sequence in each example nucleic acid vector below is bolded and underlined.pscAAV3-TTR-FIX-Padua (from Left ITR to right ITR) TTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCTGGCGACCAAAGGTCGCCAGACGGACGTGCTTTG CACGTCCGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGGAGTGGCCAACTCCATCACTAGAGGTATGGCACCGGT GGGGAGGCTGCAGGTGAACATTAACCAAGGTCACCCCAGTTATCAGAGGAGCAAACAGGAGCTAAGTCCACGTCTG TCTGCACATTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTA TTCTCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGG T T GGAAGGAGGGGGT AT AAAAGC C C C T T C AC C AGGAGAAGC C GT C AC AC AGAT C C AC AAGC T C C T GGT C GAC T T AA TTAAAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAA ATCACTTTTTTTCAGGTTGGCTC GAGC C AC C ATGCAGAGGGTCAATATGATCATGGCTGAATCTCCTGGGCTGATC ACCATTTGCCTGCTGGGATACCTGCTGTCTGCTGAGTGTACAGTGTTCCTGGACCATGAGAATGCCAATAAGATCC TGAACAGGCCCAAAAGATACAATTCTGGAAAGCTGGAGGAATTTGTGCAGGGCAACCTGGAGAGGGAATGCATGGA GGAAAAGTGTAGCTTTGAGGAAGCTAGGGAGGTGTTTGAAAACACAGAGAGGACCACAGAATTCTGGAAGCAGTAT GTGGATGGAGATCAGTGTGAGTCCAACCCCTGTCTGAATGGAGGGTCTTGCAAAGATGATATCAACTCCTATGAGT GCTGGTGTCCTTTTGGATTTGAAGGCAAAAATTGTGAGCTGGATGTGACCTGTAACATCAAGAATGGCAGGTGTGA GCAGTTCTGTAAAAACTCTGCTGATAATAAGGTGGTCTGCAGCTGTACAGAAGGCTATAGGCTGGCTGAGAACCAG AAGAGCTGTGAACCAGCTGTGCCCTTCCCTTGTGGGAGGGTGTCTGTCAGCCAGACCTCTAAGCTGACCAGAGCTG AGACTGTGTTCCCAGATGTGGATTATGTCAACTCCACAGAGGCTGAAACCATCCTGGACAACATCACCCAGTCTAC CCAGTCCTTCAATGACTTTACCAGAGTGGTGGGAGGAGAGGATGCCAAACCAGGCCAGTTCCCCTGGCAGGTGGTC CTGAATGGGAAGGTGGATGCTTTTTGTGGGGGATCCATTGTGAATGAGAAATGGATTGTCACAGCTGCTCACTGTG TGGAGACAGGGGTCAAGATCACTGTGGTGGCTGGAGAGCACAACATTGAGGAAACAGAACATACTGAGCAGAAGAG GAATGTGATCAGAATCATCCCTCACCATAACTACAATGCTGCTATCAACAAATATAATCATGACATTGCCCTGCTG GAACTGGATGAGCCTCTGGTGCTGAACAGCTATGTCACCCCAATCTGCATTGCTGACAAAGAGTATACCAATATCT TCCTGAAGTTTGGATCTGGATATGTGTCTGGATGGGGAAGGGTCTTCCACAAGGGCAGGTCTGCCCTGGTGCTGCA GTATCTGAGGGTGCCTCTGGTGGACAGAGCTACCTGCCTGCTGTCTACCAAGTTCACCATCTACAACAATATGTTC TGTGCTGGATTTCATGAGGGAGGCAGGGACTCCTGTCAGGGGGATTCTGGAGGCCCACATGTGACAGAGGTGGAAG GCACCAGCTTCCTGACTGGCATCATCTCTTGGGGGGAGGAATGTGCTATGAAGGGGAAATATGGAATCTACACCAA AGTGAGCAGGTATGTGAACTGGATCAAAGAGAAGACCAAACTGACCTGAGC GGC C GC AAT AAAAT AT CTTTATTTT CATTACATCTGTGTGTTGGTTTTTTGTGTGCAATTGTTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGG CCGGACGTGCAAAGCACGTCCGTCTGGCGACCTTTGGTCGCCAGGCCCCACCGAGCGAGCGAGTGCGCATAGAGGG AGTGGCCAA (SEQ ID NO: 49)pscAAV3-GRE-TTR-FIX-Padua (from Left ITR to right ITR)GRE is shown [boxed and in bold italics^.TTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGTGGGGCCTGGCGACCAAAGGTCGCCAGACGGACGTGCTTTG CACGTCCGGCCCCACC GAGC GAGC GAGT GC GC AT AGAGGGAGT GGC C AAC T C C AT C AC T| GAACAGGATGTTCljAC CGGTGGGGAGGCTGCAGGTGAACATTAACCAAGGTCACCCCAGTTATCAGAGGAGCAAACAGGAGCTAAGTCCACG TCTGTCTGCACATTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTA CTTATTCTCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCC T GGGT T GGAAGGAGGGGGT AT AAAAGC C C C T T C AC C AGGAGAAGC C GT C AC AC AGAT C C AC AAGC T C C T GGT C GAC TTAATTAAAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCC TGAAATCACTTTTTTTCAGGTTGGCTCGAGCCACCATGCAGAGGGTCAATATGATCATGGCTGAATCTCCTGGGCT60#15239971vlT19749Attorney Docket No. U1202.70169WO00 GATCACCATTTGCCTGCTGGGATACCTGCTGTCTGCTGAGTGTACAGTGTTCCTGGACCATGAGAATGCCAATAAG ATCCTGAACAGGCCCAAAAGATACAATTCTGGAAAGCTGGAGGAATTTGTGCAGGGCAACCTGGAGAGGGAATGCA TGGAGGAAAAGTGTAGCTTTGAGGAAGCTAGGGAGGTGTTTGAAAACACAGAGAGGACCACAGAATTCTGGAAGCA GTATGTGGATGGAGATCAGTGTGAGTCCAACCCCTGTCTGAATGGAGGGTCTTGCAAAGATGATATCAACTCCTAT GAGTGCTGGTGTCCTTTTGGATTTGAAGGCAAAAATTGTGAGCTGGATGTGACCTGTAACATCAAGAATGGCAGGT GTGAGCAGTTCTGTAAAAACTCTGCTGATAATAAGGTGGTCTGCAGCTGTACAGAAGGCTATAGGCTGGCTGAGAA CCAGAAGAGCTGTGAACCAGCTGTGCCCTTCCCTTGTGGGAGGGTGTCTGTCAGCCAGACCTCTAAGCTGACCAGA GCTGAGACTGTGTTCCCAGATGTGGATTATGTCAACTCCACAGAGGCTGAAACCATCCTGGACAACATCACCCAGT CTACCCAGTCCTTCAATGACTTTACCAGAGTGGTGGGAGGAGAGGATGCCAAACCAGGCCAGTTCCCCTGGCAGGT GGTCCTGAATGGGAAGGTGGATGCTTTTTGTGGGGGATCCATTGTGAATGAGAAATGGATTGTCACAGCTGCTCAC TGTGTGGAGACAGGGGTCAAGATCACTGTGGTGGCTGGAGAGCACAACATTGAGGAAACAGAACATACTGAGCAGA AGAGGAATGTGATCAGAATCATCCCTCACCATAACTACAATGCTGCTATCAACAAATATAATCATGACATTGCCCT GCTGGAACTGGATGAGCCTCTGGTGCTGAACAGCTATGTCACCCCAATCTGCATTGCTGACAAAGAGTATACCAAT ATCTTCCTGAAGTTTGGATCTGGATATGTGTCTGGATGGGGAAGGGTCTTCCACAAGGGCAGGTCTGCCCTGGTGC TGCAGTATCTGAGGGTGCCTCTGGTGGACAGAGCTACCTGCCTGCTGTCTACCAAGTTCACCATCTACAACAATAT GTTCTGTGCTGGATTTCATGAGGGAGGCAGGGACTCCTGTCAGGGGGATTCTGGAGGCCCACATGTGACAGAGGTG GAAGGCACCAGCTTCCTGACTGGCATCATCTCTTGGGGGGAGGAATGTGCTATGAAGGGGAAATATGGAATCTACA CCAAAGTGAGCAGGTATGTGAACTGGATCAAAGAGAAGACCAAACTGACCTGAGC GGC C GC AAT AAAAT AT C T T T A TTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGCAATTGTTGGCCACTCCCTCTATGCGCACTCGCTCGCTCGGT GGGGCCGGACGTGCAAAGCACGTCCGTCTGGCGACCTTTGGTCGCCAGGCCCCACCGAGCGAGCGAGTGCGCATAG AGGGAGTGGCCAA (SEQ ID NO: 50 )Capsid Proteins
[0136] AAV particles disclosed herein in some embodiments comprise capsid proteins having one or more modifications characterized by amino acid substitutions.
[0137] In some embodiments, an AAV capsid protein as disclosed herein is a VP 1 protein, a VP2 protein, or a VP3 protein. The VP1, VP2, and VP3 capsid proteins are each encoded from the same segment of the AAV genome, and differ in their N termini based on alternative mRNA splicing.
[0138] The different capsid proteins VP1, VP2, and VP3 are defined according to numbering of the full-length VP1 protein. In some embodiments, for AAV3 capsid proteins, a VP1 capsid protein is defined by amino acids 1-736 of SEQ ID NO: 3; a VP2 capsid protein is defined by amino acids 138-736 of SEQ ID NO: 3; and a VP3 capsid protein is defined by amino acids 203-736 of SEQ ID NO: 3. Numbering of AAV capsid proteins is provided according to the VP1 sequence. For example, T492 refers to the threonine at position 492 of SEQ ID NO: 3 in a VP1 protein or the corresponding threonine in a VP2 or VP3 protein. Similarly, Y444 refers to the tyrosine at position 444 of SEQ ID NO: 3 in a VP1 protein or the corresponding tyrosine in a VP2 or VP3 protein. Similarly, S262, K545, S663, and Y731 refer to the serine at position 262, lysine at position 545, serine at position 663, and tyrosine at position 731 of SEQ ID NO: 3, respectively, in a VP 1 protein, or the corresponding amino acids in a VP2 or VP3 protein.
[0139] An AAV capsid protein disclosed herein can be of any serotype, or can be a chimeric capsid protein (i.e., comprising segments from capsid proteins of two or more serotypes). In61#15239971vlT19749Attorney Docket No. U1202.70169WO00 some embodiments, a capsid protein disclosed herein is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrhlO, or AAVrh74 capsid protein. In some embodiments, an AAV capsid protein as provided herein is of serotype 2, serotype 3, serotype 6, or serotype rh74. Preferably, an AAV capsid protein provided herein is an AAV3 capsid protein. Amino acid sequences of capsid proteins of other AAV serotypes are known and can be aligned with SEQ ID NO: 3 (AAV3 capsid protein) using techniques known in the art. Examples of amino acid sequences of AAV capsid proteins of various serotypes are provided below.
[0140] Example of an amino acid sequence of wild-type AAV 1 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPVEQSP151 QEPDSSSGIG KTGQQPAKKR LNFGQTGDSE SVPDPQPLGE PPATPAAVGP201 TTMASGGGAP MADNNEGADG VGNASGNWHC DSTWLGDRVI TTSTRTWALP251 TYNNHLYKQI SSASTGASND NHYFGYSTPW GYFDFNRFHC HFSPRDWQRL301 INNNWGFRPK RLNFKLFNIQ VKEVTTNDGV TTIANNLTST VQVFSDSEYQ351 LPYVLGSAHQ GCLPPFPADV FMIPQYGYLT LNNGSQAVGR SSFYCLEYFP401 SQMLRTGNNF TFSYTFEEVP FHSSYAHSQS LDRLMNPLID QYLYYLNRTQ451 NQSGSAQNKD LLFSRGSPAG MSVQPKNWLP GPCYRQQRVS KTKTDNNNSN501 FTWTGASKYN LNGRESIINP GTAMASHKDD EDKFFPMSGV MIFGKESAGA551 SNTALDNVMI TDEEEIKATN PVATERFGTV AVNFQSSSTD PATGDVHAMG601 ALPGMVWQDR DVYLQGPIWA KIPHTDGHFH PSPLMGGFGL KNPPPQILIK651 NTPVPANPPA EFSATKFASF ITQYSTGQVS VEIEWELQKE NSKRWNPEVQ701 YTSNYAKSAN VDFTVDNNGL YTEPRPIGTR YLTRPL ( SEQ ID NO: 1 )
[0141] Example of an amino acid sequence of wild-type AAV2 capsid protein1 MAADGYLPDW LEDTLSEGIR QWWKLKPGPP PPKPAERHKD DSRGLVLPGY51 KYLGPFNGLD KGEPVNEADA AALEHDKAYD RQLDSGDNPY LKYNHADAEF101 QERLKEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEPVKTAP GKKRPVEHSP151 VEPDSSSGTG KAGQQPARKR LNFGQTGDAD SVPDPQPLGQ PPAAPSGLGT201 NTMATGSGAP MADNNEGADG VGNSSGNWHC DSTWMGDRVI TTSTRTWALP251 TYNNHLYKQI SSQSGASNDN HYFGYSTPWG YFDFNRFHCH FSPRDWQRLI301 NNNWGFRPKR LNFKLFNIQV KEVTQNDGTT TIANNLTSTV QVFTDSEYQL351 PYVLGSAHQG CLPPFPADVF MVPQYGYLTL NNGSQAVGRS SFYCLEYFPS401 QMLRTGNNFT FSYTFEDVPF HSSYAHSQSL DRLMNPLIDQ YLYYLSRTNT451 PSGTTTQSRL QFSQAGASDI RDQSRNWLPG PCYRQQRVSK TSADNNNSEY501 SWTGATKYHL NGRDSLVNPG PAMASHKDDE EKFFPQSGVL IFGKQGSEKT551 NVDIEKVMIT DEEEIRTTNP VATEQYGSVS TNLQRGNRQA ATADVNTQGV601 LPGMVWQDRD VYLQGPIWAK IPHTDGHFHP SPLMGGFGLK HPPPQILIKN651 TPVPANPSTT FSAAKFASFI TQYSTGQVSV EIEWELQKEN SKRWNPEIQY701 TSNYNKSVNV DFTVDTNGVY SEPRPIGTRY LTRNL ( SEQ ID NO: 2 )
[0142] Example of an amino acid sequence of wild-type AAV3 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWALKPGVP QPKANQQHQD NRRGLVLPGY51 KYLGPGNGLD KGEPVNEADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRILEPLG LVEEAAKTAP GKKGAVDQSP151 QEPDSSSGVG KSGKQPARKR LNFGQTGDSE SVPDPQPLGE PPAAPTSLGS201 NTMASGGGAP MADNNEGADG VGNSSGNWHC DSQWLGDRVI TTSTRTWALP251 TYNNHLYKQI SSQSGASNDN HYFGYSTPWG YFDFNRFHCH FSPRDWQRLI62#15239971vlT19749Attorney Docket No. U1202.70169WO00 301 NNNWGFRPKK LSFKLFNIQV RGVTQNDGTT TIANNLTSTV QVFTDSEYQL351 PYVLGSAHQG CLPPFPADVF MVPQYGYLTL NNGSQAVGRS SFYCLEYFPS401 QMLRTGNNFQ FSYTFEDVPF HSSYAHSQSL DRLMNPLIDQ YLYYLNRTQG451 TTSGTTNQSR LLFSQAGPQS MSLQARNWLP GPCYRQQRLS KTANDNNNSN501 FPWTAASKYH LNGRDSLVNP GPAMASHKDD EEKFFPMHGN LIFGKEGTTA551 SNAELDNVMI TDEEEIRTTN PVATEQYGTV ANNLQSSNTA PTTGTVNHQG601 ALPGMVWQDR DVYLQGPIWA KIPHTDGHFH PSPLMGGFGL KHPPPQIMIK651 NTPVPANPPT TFSPAKFASF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ701 YTSNYNKSVN VDFTVDTNGV YSEPRPIGTR YLTRNL (SEQ ID NO: 3)
[0143] Example of an amino acid sequence of wild-type AAV4 capsid protein1 MTDGYLPDWL EDNLSEGVRE WWALQPGAPK PKANQQHQDN ARGLVLPGYK51 YLGPGNGLDK GEPVNAADAA ALEHDKAYDQ QLKAGDNPYL KYNHADAEFQ101 QRLQGDTSFG GNLGRAVFQA KKRVLEPLGL VEQAGETAPG KKRPLIESPQ151 QPDSSTGIGK KGKQPAKKKL VFEDETGAGD GPPEGSTSGA MSDDSEMRAA201 AGGAAVEGGQ GADGVGNASG DWHCDSTWSE GHVTTTSTRT WVLPTYNNHL251 YKRLGESLQS NTYNGFSTPW GYFDFNRFHC HFSPRDWQRL INNNWGMRPK301 AMRVKIFNIQ VKEVTTSNGE TTVANNLTST VQIFADSSYE LPYVMDAGQE351 GSLPPFPNDV FMVPQYGYCG LVTGNTSQQQ TDRNAFYCLE YFPSQMLRTG401 NNFEITYSFE KVPFHSMYAH SQSLDRLMNP LIDQYLWGLQ STTTGTTLNA451 GTATTNFTKL RPTNFSNFKK NWLPGPSIKQ QGFSKTANQN YKIPATGSDS501 LIKYETHSTL DGRWSALTPG PPMATAGPAD SKFSNSQLIF AGPKQNGNTA551 TVPGTLIFTS EEELAATNAT DTDMWGNLPG GDQSNSNLPT VDRLTALGAV601 PGMVWQNRDI YYQGPIWAKI PHTDGHFHPS PLIGGFGLKH PPPQIFIKNT651 PVPANPATTF SSTPVNSFIT QYSTGQVSVQ IDWEIQKERS KRWNPEVQFT701 SNYGQQNSLL WAPDAAGKYT EPRAIGTRYL THHL (SEQ ID NO: 4)
[0144] Example of an amino acid sequence of wild-type AAV5 capsid protein1 MSFVDHPPDW LEEVGEGLRE FLGLEAGPPK PKPNQQHQDQ ARGLVLPGYN51 YLGPGNGLDR GEPVNRADEV AREHDISYNE QLEAGDNPYL KYNHADAEFQ101 EKLADDTSFG GNLGKAVFQA KKRVLEPFGL VEEGAKTAPT GKRIDDHFPK151 RKKARTEEDS KPSTSSDAEA GPSGSQQLQI PAQPASSLGA DTMSAGGGGP201 LGDNNQGADG VGNASGDWHC DSTWMGDRW TKSTRTWVLP SYNNHQYREI251 KSGSVDGSNA NAYFGYSTPW GYFDFNRFHS HWSPRDWQRL INNYWGFRPR301 SLRVKIFNIQ VKEVTVQDST TTIANNLTST VQVFTDDDYQ LPYWGNGTE351 GCLPAFPPQV FTLPQYGYAT LNRDNTENPT ERSSFFCLEY FPSKMLRTGN401 NFEFTYNFEE VPFHSSFAPS QNLFKLANPL VDQYLYRFVS TNNTGGVQFN451 KNLAGRYANT YKNWFPGPMG RTQGWNLGSG VNRASVSAFA TTNRMELEGA501 SYQVPPQPNG MTNNLQGSNT YALENTMIFN SQPANPGTTA TYLEGNMLIT551 SESETQPVNR VAYNVGGQMA TNNQSSTTAP ATGTYNLQEI VPGSVWMERD601 VYLQGPIWAK IPETGAHFHP SPAMGGFGLK HPPPMMLIKN TPVPGNITSF651 SDVPVSSFIT QYSTGQVTVE MEWELKKENS KRWNPEIQYT NNYNDPQFVD701 FAPDSTGEYR TTRPIGTRYL TRPL (SEQ ID NO: 5)
[0145] Example of an amino acid sequence of wild-type AAV6 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPFG LVEEGAKTAP GKKRPVEQSP151 QEPDSSSGIG KTGQQPAKKR LNFGQTGDSE SVPDPQPLGE PPATPAAVGP201 TTMASGGGAP MADNNEGADG VGNASGNWHC DSTWLGDRVI TTSTRTWALP251 TYNNHLYKQI SSASTGASND NHYFGYSTPW GYFDFNRFHC HFSPRDWQRL301 INNNWGFRPK RLNFKLFNIQ VKEVTTNDGV TTIANNLTST VQVFSDSEYQ351 LPYVLGSAHQ GCLPPFPADV FMIPQYGYLT LNNGSQAVGR SSFYCLEYFP401 SQMLRTGNNF TFSYTFEDVP FHSSYAHSQS LDRLMNPLID QYLYYLNRTQ451 NQSGSAQNKD LLFSRGSPAG MSVQPKNWLP GPCYRQQRVS KTKTDNNNSN#15239971vlT19749Attorney Docket No. U1202.70169WO00 501 FTWTGASKYN LNGRESIINP GTAMASHKDD KDKFFPMSGV MIFGKESAGA551 SNTALDNVMI TDEEEIKATN PVATERFGTV AVNLQSSSTD PATGDVHVMG601 ALPGMVWQDR DVYLQGPIWA KIPHTDGHFH PSPLMGGFGL KHPPPQILIK651 NTPVPANPPA EFSATKFASF ITQYSTGQVS VEIEWELQKE NSKRWNPEVQ701 YTSNYAKSAN VDFTVDNNGL YTEPRPIGTR YLTRPL (SEQ ID NO: 6)
[0146] Example of an amino acid sequence of wild-type AAV7 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD NGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP AKKRPVEPSP151 QRSPDSSTGI GKKGQQPARK RLNFGQTGDS ESVPDPQPLG EPPAAPSSVG201 SGTVAAGGGA PMADNNEGAD GVGNASGNWH CDSTWLGDRV ITTSTRTWAL251 PTYNNHLYKQ ISSETAGSTN DNTYFGYSTP WGYFDFNRFH CHFSPRDWQR301 LINNNWGFRP KKLRFKLFNI QVKEVTTNDG VTTIANNLTS TIQVFSDSEY351 QLPYVLGSAH QGCLPPFPAD VFMIPQYGYL TLNNGSQSVG RSSFYCLEYF401 PSQMLRTGNN FEFSYSFEDV PFHSSYAHSQ SLDRLMNPLI DQYLYYLART451 QSNPGGTAGN RELQFYQGGP STMAEQAKNW LPGPCFRQQR VSKTLDQNNN501 SNFAWTGATK YHLNGRNSLV NPGVAMATHK DDEDRFFPSS GVLIFGKTGA551 TNKTTLENVL MTNEEEIRPT NPVATEEYGI VSSNLQAANT AAQTQWNNQ601 GALPGMVWQN RDVYLQGPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI651 KNTPVPANPP EVFTPAKFAS FITQYSTGQV SVEIEWELQK ENSKRWNPEI701 QYTSNFEKQT GVDFAVDSQG VYSEPRPIGT RYLTRNL (SEQ ID NO: 7)
[0147] Example of an amino acid sequence of wild-type AAV8 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP151 QRSPDSSTGI GKKGQQPARK RLNFGQTGDS ESVPDPQPLG EPPAAPSGVG201 PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV ITTSTRTWAL251 PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ301 RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE351 YQLPYVLGSA HQGCLPPFPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY401 FPSQMLRTGN NFQFTYTFED VPFHSSYAHS QSLDRLMNPL IDQYLYYLSR451 TQTTGGTANT QTLGFSQGGP NTMANQAKNW LPGPCYRQQR VSTTTGQNNN501 SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN GILIFGKQNA551 ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS601 QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL651 IKNTPVPADP PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE701 IQYTSNYYKS TSVDFAVNTE GVYSEPRPIG TRYLTRNL (SEQ ID NO: 8)
[0148] Example of an amino acid sequence of wild-type AAV9 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY51 KYLGPGNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF101 QERLKEDTSF GGNLGRAVFQ AKKRLLEPLG LVEEAAKTAP GKKRPVEQSP151 QEPDSSAGIG KSGAQPAKKR LNFGQTGDTE SVPDPQPIGE PPAAPSGVGS201 LTMASGGGAP VADNNEGADG VGSSSGNWHC DSQWLGDRVI TTSTRTWALP251 TYNNHLYKQI SNSTSGGSSN DNAYFGYSTP WGYFDFNRFH CHFSPRDWQR301 LINNNWGFRP KRLNFKLFNI QVKEVTDNNG VKTIANNLTS TVQVFTDSDY351 QLPYVLGSAH EGCLPPFPAD VFMIPQYGYL TLNDGSQAVG RSSFYCLEYF401 PSQMLRTGNN FQFSYEFENV PFHSSYAHSQ SLDRLMNPLI DQYLYYLSKT451 INGSGQNQQT LKFSVAGPSN MAVQGRNYIP GPSYRQQRVS TTVTQNNNSE501 FAWPGASSWA LNGRNSLMNP GPAMASHKEG EDRFFPLSGS LIFGKQGTGR551 DNVDADKVMI TNEEEIKTTN PVATESYGQV ATNHQSAQAQ AQTGWVQNQG601 ILPGMVWQDR DVYLQGPIWA KIPHTDGNFH PSPLMGGFGM KHPPPQILIK651 NTPVPADPPT AFNKDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ#15239971vlT19749Attorney Docket No. U1202.70169WO00 701 YTSNYYKSNN VEFAVNTEGV YSEPRPIGTR YLTRNL (SEQ ID NO: 9)
[0149] Example of an amino acid sequence of wild-type AAV 10 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEAAKTAP GKKRPVEPSP151 QRSPDSSTGI GKKGQQPAKK RLNFGQTGES ESVPDPQPIG EPPAGPSGLG201 SGTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV ITTSTRTWAL251 PTYNNHLYKQ ISNGTSGGST NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ301 RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE351 YQLPYVLGSA HQGCLPPFPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY401 FPSQMLRTGN NFEFSYTFED VPFHSSYAHS QSLDRLMNPL IDQYLYYLSR451 TQSTGGTQGT QQLLFSQAGP ANMSAQAKNW LPGPCYRQQR VSTTLSQNNN501 SNFAWTGATK YHLNGRDSLV NPGVAMATHK DDEERFFPSS GVLMFGKQGA551 GRDNVDYSSV MLTSEEEIKT TNPVATEQYG WADNLQQAN TGPIVGNVNS601 QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL651 IKNTPVPADP PTTFSQAKLA SFITQYSTGQ VSVEIEWELQ KENSKRWNPE701 IQYTSNYYKS TNVDFAVNTE GTYSEPRPIG TRYLTRNL (SEQ ID NO: 10)
[0150] Example of an amino acid sequence of wild-type AAV 11 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPLESPQ151 EPDSSSGIGK KGKQPARKRL NFEEDTGAGD GPPEGSDTSA MSSDIEMRAA201 PGGNAVDAGQ GSDGVGNASG DWHCDSTWSE GKVTTTSTRT WVLPTYNNHL251 YLRLGTTSSS NTYNGFSTPW GYFDFNRFHC HFSPRDWQRL INNNWGLRPK301 AMRVKIFNIQ VKEVTTSNGE TTVANNLTST VQIFADSSYE LPYVMDAGQE351 GSLPPFPNDV FMVPQYGYCG IVTGENQNQT DRNAFYCLEY FPSQMLRTGN401 NFEMAYNFEK VPFHSMYAHS QSLDRLMNPL LDQYLWHLQS TTSGETLNQG451 NAATTFGKIR SGDFAFYRKN WLPGPCVKQQ RFSKTASQNY KIPASGGNAL501 LKYDTHYTLN NRWSNIAPGP PMATAGPSDG DFSNAQLIFP GPSVTGNTTT551 SANNLLFTSE EEIAATNPRD TDMFGQIADN NQNATTAPIT GNVTAMGVLP601 GMVWQNRDIY YQGPIWAKIP HADGHFHPSP LIGGFGLKHP PPQIFIKNTP651 VPANPATTFT AARVDSFITQ YSTGQVAVQI EWEIEKERSK RWNPEVQFTS701 NYGNQSSMLW APDTTGKYTE PRVIGSRYLT NHL ( SEQ ID NO: 11 )
[0151] Example of an amino acid sequence of wild-type AAV12 capsid protein1 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NGRGLVLPGY51 KYLGPFNGLD KGEPVNEADA AALEHDKAYD KQLEQGDNPY LKYNHADAEF101 QQRLATDTSF GGNLGRAVFQ AKKRILEPLG LVEEGVKTAP GKKRPLEKTP151 NRPTNPDSGK APAKKKQKDG EPADSARRTL DFEDSGAGDG PPEGSSSGEM201 SHDAEMRAAP GGNAVEAGQG ADGVGNASGD WHCDSTWSEG RVTTTSTRTW251 VLPTYNNHLY LRIGTTANSN TYNGFSTPWG YFDFNRFHCH FSPRDWQRLI301 NNNWGLRPKS MRVKIFNIQV KEVTTSNGET TVANNLTSTV QIFADSTYEL351 PYVMDAGQEG SFPPFPNDVF MVPQYGYCGV VTGKNQNQTD RNAFYCLEYF401 PSQMLRTGNN FEVSYQFEKV PFHSMYAHSQ SLDRMMNPLL DQYLWHLQST451 TTGNSLNQGT ATTTYGKITT GDFAYYRKNW LPGACIKQQK FSKNANQNYK501 IPASGGDALL KYDTHTTLNG RWSNMAPGPP MATAGAGDSD FSNSQLIFAG551 PNPSGNTTTS SNNLLFTSEE EIATTNPRDT DMFGQIADNN QNATTAPHIA601 NLDAMGIVPG MVWQNRDIYY QGPIWAKVPH TDGHFHPSPL MGGFGLKHPP651 PQIFIKNTPV PANPNTTFSA ARINSFLTQY STGQVAVQID WEIQKEHSKR701 WNPEVQFTSN YGTQNSMLWA PDNAGNYHEL RAIGSRFLTH HL ( SEQ ID NO: 12 )
[0152] Example of an amino acid sequence of wild-type AAVrhlO capsid protein:65#15239971vlT19749Attorney Docket No. U1202.70169WO00 1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP151 QRSPDSSTGI GKKGQQPAKK RLNFGQTGDS ESVPDPQPIG EPPAGPSGLG201 SGTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV ITTSTRTWAL251 PTYNNHLYKQ ISNGTSGGST NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ301 RLINNNWGFR PKRLNFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE351 YQLPYVLGSA HQGCLPPFPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY401 FPSQMLRTGN NFEFSYQFED VPFHSSYAHS QSLDRLMNPL IDQYLYYLSR451 TQSTGGTAGT QQLLFSQAGP NNMSAQAKNW LPGPCYRQQR VSTTLSQNNN501 SNFAWTGATK YHLNGRDSLV NPGVAMATHK DDEERFFPSS GVLMFGKQGA551 GKDNVDYSSV MLTSEEEIKT TNPVATEQYG WADNLQQQN AAPIVGAVNS601 QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL651 IKNTPVPADP PTTFSQAKLA SFITQYSTGQ VSVEIEWELQ KENSKRWNPE701 IQYTSNYYKS TNVDFAVNTD GTYSEPRPIG TRYLTRNL (SEQ ID NO: 13)
[0153] Example of an amino acid sequence of wild-type AAVrh74 capsid protein:1 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD NGRGLVLPGY51 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF101 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVESPVKTAP GKKRPVEPSP151 QRSPDSSTGI GKKGQQPAKK RLNFGQTGDS ESVPDPQPIG EPPAGPSGLG201 SGTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV ITTSTRTWAL251 PTYNNHLYKQ ISNGTSGGST NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ301 RLINNNWGFR PKRLNFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE351 YQLPYVLGSA HQGCLPPFPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY401 FPSQMLRTGN NFEFSYNFED VPFHSSYAHS QSLDRLMNPL IDQYLYYLSR451 TQSTGGTAGT QQLLFSQAGP NNMSAQAKNW LPGPCYRQQR VSTTLSQNNN501 SNFAWTGATK YHLNGRDSLV NPGVAMATHK DDEERFFPSS GVLMFGKQGA551 GKDNVDYSSV MLTSEEEIKT TNPVATEQYG WADNLQQQN AAPIVGAVNS601 QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL651 IKNTPVPADP PTTFNQAKLA SFITQYSTGQ VSVEIEWELQ KENSKRWNPE701 IQYTSNYYKS TNVDFAVNTE GTYSEPRPIG TRYLTRNL (SEQ ID NO: 14)
[0154] Also provided herein are nucleic acids encoding capsid proteins. A nucleic acid may comprise a sequence that encodes a capsid protein disclosed here (e.g., a capsid protein comprising one or more amino acid substitutions). A sequence encoding a capsid protein disclosed herein can be determined by one of ordinary skill in the art by known methods. A nucleic acid encoding a capsid protein may comprise a promoter or other regulatory sequence operably linked to the coding sequence. A nucleic acid encoding a capsid protein may be in the form of a plasmid, an mRNA, or another nucleic acid capable of being used by enzymes or machinery of a host cell to produce a capsid protein. Nucleic acids encoding capsid proteins as provided herein can be used to make AAV particles that can be used for delivering a gene to a cell. Methods of making AAV particles are known in the art. For example, see Scientific Reports volume 9, Article number: 13601 (2019); Methods Mol Biol. 2012; 798: 267-284; and thermofisher.com / us / en / home / clinical / cell-gene-therapy / gene-therapy / aav-production-66#15239971vlT19749Attorney Docket No. U1202.70169WO00 workflow.html. Example sequences of nucleic acids encoding capsid proteins are provided below.
[0155] Example of a nucleotide sequence encoding AAV 1 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggacttga aacctggagccccgaagcccaaagccaaccagcaaaagcaggacgacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctcgagcacgac aaggcctacgaccagcagctcaaagcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcagg agcgtctgcaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaagaagcgggttctcga acctctcggtctggttgaggaaggcgctaagacggctcctggaaagaaacgtccggtagagcagtcgccacaagag ccagactcctcctcgggcatcggcaagacaggccagcagcccgctaaaaagagactcaattttggtcagactggcg actcagagtcagtccccgatccacaacctctcggagaacctccagcaacccccgctgctgtgggacctactacaat ggcttcaggcggtggcgcaccaatggcagacaataacgaaggcgccgacggagtgggtaatgcctcaggaaattgg cattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgcacctgggccttgcccacctacaata accacctctacaagcaaatctccagtgcttcaacgggggccagcaacgacaaccactacttcggctacagcacccc ctgggggtattttgatttcaacagattccactgccacttttcaccacgtgactggcagcgactcatcaacaacaat tggggattccggcccaagagactcaacttcaaactcttcaacatccaagtcaaggaggtcacgacgaatgatggcg tcacaaccatcgctaataaccttaccagcacggttcaagtcttctcggactcggagtaccagcttccgtacgtcct cggct ct gcgcaccagggctgcctccctccgttcccggcggacgtgt teat gat tccgcaatacggct acct gacg ctcaacaatggcagccaagccgtgggacgttcatccttttactgcctggaatatttcccttctcagatgctgagaa cgggcaacaactttaccttcagctacacctttgaggaagtgcctttccacagcagctacgcgcacagccagagcct ggaccggctgatgaatcctctcatcgaccaatacctgtattacctgaacagaactcaaaatcagtccggaagtgcc caaaacaaggacttgctgtttagccgtgggtctccagctggcatgtctgttcagcccaaaaactggctacctggac cctgttatcggcagcagcgcgtttctaaaacaaaaacagacaacaacaacagcaattttacctggactggtgcttc aaaatataacctcaatgggcgtgaatccatcatcaaccctggcactgctatggcctcacacaaagacgacgaagac aagttctttcccatgagcggtgtcatgatttttggaaaagagagcgccggagcttcaaacactgcattggacaatg teat gat tacagacgaagaggaaattaaagccactaaccctgtggccaccgaaagatttgggaccgtggcagtcaa tttccagagcagcagcacagaccctgcgaccggagatgtgcatgctatgggagcattacctggcatggtgtggcaa gatagagacgtgtacctgcagggtcccatttgggccaaaattcctcacacagatggacactttcacccgtctcctc ttatgggcggctttggactcaagaacccgcctcctcagatcctcatcaaaaacacgcctgttcctgcgaatcctcc ggcggagttttcagctacaaagtttgcttcattcatcacccaatactccacaggacaagtgagtgtggaaattgaa tgggagctgcagaaagaaaacagcaagcgctggaatcccgaagtgcagtacacatccaattatgcaaaatctgcca acgttgattttactgtggacaacaatggactttatactgagcctcgccccattggcacccgttaccttacccgtcc cctgtaa (SEQ ID NO: 51 )
[0156] Example of a nucleotide sequence encoding AAV2 capsid protein: atggctgccgatggttatcttccagattggctcgaggacactctctctgaaggaataagacagtggtggaagctca aacctggcccaccaccaccaaagcccgcagagcggcataaggacgacagcaggggtcttgtgcttcctgggtacaa gtacctcggacccttcaacggactcgacaagggagagccggtcaacgaggcagacgccgcggccctcgagcacgac aaagcctacgaccggcagctcgacagcggagacaacccgtacctcaagtacaaccacgccgacgcggagtttcagg agcgccttaaagaagatacgtcttttgggggcaacctcggacgagcagtcttccaggcgaaaaagagggttcttga acctctgggcctggttgaggaacctgttaagacggctccgggaaaaaagaggccggtagagcactctcctgtggag ccagactcctcctcgggaaccggaaaggcgggccagcagcctgcaagaaaaagattgaattttggtcagactggag acgcagactcagtacctgacccccagcctctcggacagccaccagcagccccctctggtctgggaactaatacgat ggctacaggcagtggcgcaccaatggcagacaataacgagggcgccgacggagtgggtaattcctccggaaattgg cattgcgattccacatggatgggcgacagagtcatcaccaccagcacccgaacctgggccctgcccacctacaaca accacctctacaaacaaatttccagccaatcaggagcctcgaacgacaatcactactttggctacagcaccccttg ggggtattttgacttcaacagattccactgccacttttcaccacgtgactggcaaagactcatcaacaacaactgg ggattccgacccaagagactcaacttcaagctctttaacattcaagtcaaagaggtcacgcagaatgacggtacga cgacgattgccaataaccttaccagcacggttcaggtgtttactgactcggagtaccagctcccgtacgtcctcgg ctcggcgcatcaaggatgcctcccgccgttcccagcagacgtcttcatggtgccacagtatggatacctcaccctg aacaacgggagtcaggcagtaggacgctcttcattttactgcctggagtactttccttctcagatgctgcgtaccg gaaacaactttaccttcagctacacttttgaggacgttcctttccacagcagctacgctcacagccagagtctgga ccgtctcatgaatcctctcatcgaccagtacctgtattacttgagcagaacaaacactccaagtggaaccaccacg cagtcaaggcttcagttttctcaggccggagcgagtgacattcgggaccagtctaggaactggcttcctggaccct gttaccgccagcagcgagtatcaaagacatctgcggataacaacaacagtgaatactcgtggactggagctaccaa 67#15239971vlT19749Attorney Docket No. U1202.70169WO00 gtaccacctcaatggcagagactctctggtgaatccgggcccggccatggcaagccacaaggacgatgaagaaaag ttttttcctcagagcggggttctcatctttgggaagcaaggctcagagaaaacaaatgtggacattgaaaaggtca tgattacagacgaagaggaaatcaggacaaccaatcccgtggctacggagcagtatggttctgtatctaccaacct ccagagaggcaacagacaagcagctaccgcagatgtcaacacacaaggcgttcttccaggcatggtctggcaggac agagatgtgtaccttcaggggcccatctgggcaaagattccacacacggacggacattttcacccctctcccctca tgggtggattcggacttaaacaccctcctccacagattctcatcaagaacaccccggtacctgcgaatccttcgac caccttcagtgcggcaaagtttgcttccttcatcacacagtactccacgggacaggtcagcgtggagatcgagtgg gagctgcagaaggaaaacagcaaacgctggaatcccgaaattcagtacacttccaactacaacaagtctgttaatg tggactttactgtggacactaatggcgtgtattcagagcctcgccccattggcaccagatacctgactcgtaatct gtaa (SEQ ID NO: 52 )
[0157] Example of a nucleotide sequence encoding AAV3 capsid protein: atggctgctgacggttatcttccagattggctcgaggacaacctttctgaaggcattcgtgagtggtgggctctga aacctggagtccctcaacccaaagcgaaccaacaacaccaggacaaccgtcggggtcttgtgcttccgggttacaa atacctcggacccggtaacggactcgacaaaggagagccggtcaacgaggcggacgcggcagccctcgaacacgac aaagcttacgaccagcagctcaaggccggtgacaacccgtacctcaagtacaaccacgccgacgccgagtttcagg agcgtcttcaagaagatacgtcttttgggggcaaccttggcagagcagtcttccaggccaaaaagaggatccttga gcctcttggtctggttgaggaagcagctaaaacggctcctggaaagaagggggctgtagatcagtctcctcaggaa ccggactcatcatctggtgttggcaaatcgggcaaacagcctgccagaaaaagactaaatttcggtcagactggag actcagagtcagtcccagaccctcaacctctcggagaaccaccagcagcccccacaagtttgggatctaatacaat ggcttcaggcggtggcgcaccaatggcagacaataacgagggtgccgatggagtgggtaattcctcaggaaattgg cattgcgattcccaatggctgggcgacagagtcatcaccaccagcaccagaacctgggccctgcccacttacaaca accatctctacaagcaaatctccagccaatcaggagcttcaaacgacaaccactactttggctacagcaccccttg ggggtattttgactttaacagattccactgccacttctcaccacgtgactggcagcgactcattaacaacaactgg ggattccggcccaagaaactcagcttcaagctcttcaacatccaagttagaggggtcacgcagaacgatggcacga cgactattgccaataaccttaccagcacggttcaagtgtttacggactcggagtatcagctcccgtacgtgctcgg gtcggcgcaccaaggctgtctcccgccgtttccagcggacgtcttcatggtccctcagtatggatacctcaccctg aacaacggaagtcaagcggtgggacgctcatccttttactgcctggagtacttcccttcgcagatgctaaggactg gaaataacttccaattcagctataccttcgaggatgtaccttttcacagcagctacgctcacagccagagtttgga tcgcttgatgaatcctcttattgatcagtatctgtactacctgaacagaacgcaaggaacaacctctggaacaacc aaccaatcacggctgctttttagccaggctgggcctcagtctatgtctttgcaggccagaaattggctacctgggc cctgctaccggcaacagagactttcaaagactgctaacgacaacaacaacagtaactttccttggacagcggccag caaatatcatctcaatggccgcgactcgctggtgaatccaggaccagctatggccagtcacaaggacgatgaagaa aaatttttccctatgcacggcaatctaatatttggcaaagaagggacaacggcaagtaacgcagaattagataatg taatgattacggatgaagaagagattcgtaccaccaatcctgtggcaacagagcagtatggaactgtggcaaataa cttgcagagctcaaatacagctcccacgactggaactgtcaatcatcagggggccttacctggcatggtgtggcaa gatcgtgacgtgtaccttcaaggacctatctgggcaaagattcctcacacggatggacactttcatccttctcctc tgatgggaggctttggactgaaacatccgcctcctcaaatcatgatcaaaaatactccggtaccggcaaatcctcc gacgactttcagcccggccaagtttgcttcatttatcactcagtactccactggacaggtcagcgtggaaattgag tgggagctacagaaagaaaacagcaaacgttggaatccagagattcagtacacttccaactacaacaagtctgtta atgtggactttactgtagacactaatggtgtttatagtgaacctcgccctattggaacccggtatctcacacgaaa cttgtga (SEQ ID NO: 53)
[0158] Example of a nucleotide sequence encoding AAV4 capsid protein: atgactgacggttaccttccagattggctagaggacaacctctctgaaggcgttcgagagtggtgggcgctgcaac ctggagcccctaaacccaaggcaaatcaacaacatcaggacaacgctcggggtcttgtgcttccgggttacaaata cctcggacccggcaacggactcgacaagggggaacccgtcaacgcagcggacgcggcagccctcgagcacgacaag gcctacgaccagcagctcaaggccggtgacaacccctacctcaagtacaaccacgccgacgcggagttccagcagc ggcttcagggcgacacatcgtttgggggcaacctcggcagagcagtcttccaggccaaaaagagggttcttgaacc tcttggtctggttgagcaagcgggtgagacggctcctggaaagaagagaccgttgattgaatccccccagcagccc gactcctccacgggtatcggcaaaaaaggcaagcagccggctaaaaagaagctcgttttcgaagacgaaactggag caggcgacggaccccctgagggatcaacttccggagccatgtctgatgacagtgagatgcgtgcagcagctggcgg agctgcagtcgagggcggacaaggtgccgatggagtgggtaatgcctcgggtgattggcattgcgattccacctgg tctgagggccacgtcacgaccaccagcaccagaacctgggtcttgcccacctacaacaaccacctctacaagcgac tcggagagagcctgcagtccaacacctacaacggattctccaccccctggggatactttgacttcaaccgcttcca ctgccacttctcaccacgtgactggcagcgactcatcaacaacaactggggcatgcgacccaaagccatgcgggtc68#15239971vlT19749Attorney Docket No. U1202.70169WO00 aaaatcttcaacatccaggtcaaggaggtcacgacgtcgaacggcgagacaacggtggctaataaccttaccagca cggttcagatctttgcggactcgtcgtacgaactgccgtacgtgatggatgcgggtcaagagggcagcctgcctcc ttttcccaacgacgtctttatggtgccccagtacggctactgtggactggtgaccggcaacacttcgcagcaacag actgacagaaatgccttctactgcctggagtactttccttcgcagatgctgcggactggcaacaactttgaaatta cgtacagttttgagaaggtgcctttccactcgatgtacgcgcacagccagagcctggaccggctgatgaaccctct cat cgaccagt acct gtggggactgcaatcgaccaccaccggaaccaccctgaatgccgggactgccaccaccaac tttaccaagctgcggcctaccaacttttccaactttaaaaagaactggctgcccgggccttcaatcaagcagcagg gcttctcaaagactgccaatcaaaactacaagatccctgccaccgggtcagacagtctcatcaaatacgagacgca cagcactctggacggaagatggagtgccctgacccccggacctccaatggccacggctggacctgcggacagcaag ttcagcaacagccagctcatctttgcggggcctaaacagaacggcaacacggccaccgtacccgggactctgatct tcacctctgaggaggagctggcagccaccaacgccaccgatacggacatgtggggcaacctacctggcggtgacca gagcaacagcaacctgccgaccgtggacagactgacagccttgggagccgtgcctggaatggtctggcaaaacaga gacatttactaccagggtcccatttgggccaagattcctcataccgatggacactttcacccctcaccgctgattg gtgggtttgggctgaaacacccgcctcctcaaatttttatcaagaacaccccggtacctgcgaatcctgcaacgac cttcagctctactccggtaaactccttcattactcagtacagcactggccaggtgtcggtgcagattgactgggag atccagaaggagcggtccaaacgctggaaccccgaggtccagtttacctccaactacggacagcaaaactctctgt tgtgggctcccgatgcggctgggaaatacactgagcctagggctatcggtacccgctacctcacccaccacctgta ataacctgttaatcaataaaccggtttattcgtttcagttgaactttggtctccgtgtccttcttatcttatctcg tttcc (SEQ ID NO: 54 )
[0159] Example of a nucleotide sequence encoding AAV5 capsid protein: atgtcttttgttgatcaccctccagattggttggaagaagttggtgaaggtcttcgcgagtttttgggccttgaag cgggcccaccgaaaccaaaacccaatcagcagcatcaagatcaagcccgtggtcttgtgctgcctggttataacta tctcggacccggaaacggtctcgatcgaggagagcctgtcaacagggcagacgaggtcgcgcgagagcacgacatc tcgtacaacgagcagcttgaggcgggagacaacccctacctcaagtacaaccacgcggacgccgagtttcaggaga agctcgccgacgacacatccttcgggggaaacctcggaaaggcagtctttcaggccaagaaaagggttctcgaacc ttttggcctggttgaagagggtgctaagacggcccctaccggaaagcggatagacgaccactttccaaaaagaaag aaggctcggaccgaagaggactccaagccttccacctcgtcagacgccgaagctggacccagcggatcccagcagc tgcaaatcccagcccaaccagcctcaagtttgggagctgatacaatgtctgcgggaggtggcggcccattgggcga caataaccaaggtgccgatggagtgggcaatgcctcgggagattggcattgcgattccacgtggatgggggacaga gtcgtcaccaagtccacccgaacctgggtgctgcccagctacaacaaccaccagtaccgagagatcaaaagcggct ccgtcgacggaagcaacgccaacgcctactttggatacagcaccccctgggggtactttgactttaaccgcttcca cagccactggagcccccgagactggcaaagactcatcaacaactactggggcttcagaccccggtccctcagagtc aaaatcttcaacattcaagtcaaagaggtcacggtgcaggactccaccaccaccatcgccaacaacctcacctcca ccgtccaagtgtttacggacgacgactaccagctgccctacgtcgtcggcaacgggaccgagggatgcctgccggc cttccctccgcaggtctttacgctgccgcagtacggttacgcgacgctgaaccgcgacaacacagaaaatcccacc gagaggagcagcttcttctgcctagagtactttcccagcaagatgctgagaacgggcaacaactttgagtttacct acaactttgaggaggtgcccttccactccagcttcgctcccagtcagaacctgttcaagctggccaacccgctggt ggaccagtacttgtaccgcttcgtgagcacaaataacactggcggagtccagttcaacaagaacctggccgggaga tacgccaacacctacaaaaactggttcccggggcccatgggccgaacccagggctggaacctgggctccggggtca accgcgccagtgtcagcgccttcgccacgaccaataggatggagctcgagggcgcgagttaccaggtgcccccgca gccgaacggcatgaccaacaacctccagggcagcaacacctatgccctggagaacactatgatcttcaacagccag ccggcgaacccgggcaccaccgccacgtacctcgagggcaacatgctcatcaccagcgagagcgagacgcagccgg tgaaccgcgtggcgtacaacgtcggcgggcagatggccaccaacaaccagagctccaccactgcccccgcgaccgg cacgtacaacctccaggaaatcgtgcccggcagcgtgtggatggagagggacgtgtacctccaaggacccatctgg gccaagatcccagagacgggggcgcactttcacccctctccggccatgggcggattcggactcaaacacccaccgc ccatgatgctcatcaagaacacgcctgtgcccggaaatatcaccagcttctcggacgtgcccgtcagcagcttcat cacccagtacagcaccgggcaggtcaccgtggagatggagtgggagctcaagaaggaaaactccaagaggtggaac ccagagatccagtacacaaacaactacaacgacccccagtttgtggactttgccccggacagcaccggggaataca gaaccaccagacctatcggaacccgataccttacccgacccctttaa (SEQ ID NO: 55)
[0160] Example of a nucleotide sequence encoding AAV6 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggacttga aacctggagccccgaaacccaaagccaaccagcaaaagcaggacgacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggatgcagcggccctcgagcacgac aaggcctacgaccagcagctcaaagcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcagg69#15239971vlT19749Attorney Docket No. U1202.70169WO00 agcgtctgcaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaagaagagggttctcga accttttggtctggttgaggaaggtgctaagacggctcctggaaagaaacgtccggtagagcagtcgccacaagag ccagactcctcctcgggcattggcaagacaggccagcagcccgctaaaaagagactcaattttggtcagactggcg actcagagtcagtccccgacccacaacctctcggagaacctccagcaacccccgctgctgtgggacctactacaat ggcttcaggcggtggcgcaccaatggcagacaataacgaaggcgccgacggagtgggtaatgcctcaggaaattgg cattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgaacatgggccttgcccacctataaca accacctctacaagcaaatctccagtgcttcaacgggggccagcaacgacaaccactacttcggctacagcacccc ctgggggtattttgatttcaacagattccactgccatttctcaccacgtgactggcagcgactcatcaacaacaat tggggattccggcccaagagactcaacttcaagctcttcaacatccaagtcaaggaggtcacgacgaatgatggcg tcacgaccatcgctaataaccttaccagcacggttcaagtcttctcggactcggagtaccagttgccgtacgtcct cggct ct gcgcaccagggctgcctccctccgttcccggcggacgtgt teat gat tccgcagtacggct acct aacg ctcaacaatggcagccaggcagtgggacggtcatccttttactgcctggaatatttcccatcgcagatgctgagaa cgggcaataactttaccttcagctacaccttcgaggacgtgcctttccacagcagctacgcgcacagccagagcct ggaccggctgatgaatcctctcatcgaccagtacctgtattacctgaacagaactcagaatcagtccggaagtgcc caaaacaaggacttgctgtttagccgggggtctccagctggcatgtctgttcagcccaaaaactggctacctggac cctgttaccggcagcagcgcgtttctaaaacaaaaacagacaacaacaacagcaactttacctggactggtgcttc aaaatataaccttaatgggcgtgaatctataatcaaccctggcactgctatggcctcacacaaagacgacaaagac aagttctttcccatgagcggtgtcatgatttttggaaaggagagcgccggagcttcaaacactgcattggacaatg tcatgatcacagacgaagaggaaatcaaagccactaaccccgtggccaccgaaagatttgggactgtggcagtcaa tctccagagcagcagcacagaccctgcgaccggagatgtgcatgttatgggagccttacctggaatggtgtggcaa gacagagacgtatacctgcagggtcctatttgggccaaaattcctcacacggatggacactttcacccgtctcctc tcatgggcggctttggacttaagcacccgcctcctcagatcctcatcaaaaacacgcctgttcctgcgaatcctcc ggcagagtttt cggct acaaagtttgctt catt cat cacccagtattccacaggacaagtgagcgtggagattgaa tgggagctgcagaaagaaaacagcaaacgctggaatcccgaagtgcagtatacatctaactatgcaaaatctgcca aegtt gat ttcactgtggacaacaatggactt tat act gagcctcgccccattggcacccgtt acct cacccgtcc cctgtaat (SEQ ID NO: 56)
[0161] Example of a nucleotide sequence encoding AAV7 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggacctga aacctggagccccgaaacccaaagccaaccagcaaaagcaggacaacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctcgagcacgac aaggcctacgaccagcagctcaaagcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcagg agcgtctgcaagaagatacgtcatttgggggcaacctcgggcgagcagtcttccaggccaagaagcgggttctcga acctctcggtctggttgaggaaggcgctaagacggctcctgcaaagaagagaccggtagagccgtcacctcagcgt tcccccgactcctccacgggcatcggcaagaaaggccagcagcccgccagaaagagactcaatttcggtcagactg gcgactcagagtcagtccccgaccctcaacctctcggagaacctccagcagcgccctctagtgtgggatctggtac agtggctgcaggcggtggcgcaccaatggcagacaataacgaaggtgccgacggagtgggtaatgcctcaggaaat tggcattgcgattccacatggctgggcgacagagtcattaccaccagcacccgaacctgggccctgcccacctaca acaaccacctctacaagcaaatctccagtgaaactgcaggtagtaccaacgacaacacctacttcggctacagcac cccctgggggtattttgactttaacagattccactgccacttctcaccacgtgactggcagcgactcatcaacaac aactggggattccggcccaagaagctgcggttcaagctcttcaacatccaggtcaaggaggtcacgacgaatgacg gcgttacgaccatcgctaataaccttaccagcacgattcaggtattctcggactcggaataccagctgccgtacgt cct cggct ct gcgcaccagggctgcctgcctccgttcccggcggacgt ct teat gat tcctcagtacggct acct g actctcaacaatggcagtcagtctgtgggacgttcctccttctactgcctggagtacttcccctctcagatgctga gaacgggcaacaactttgagttcagctacagcttcgaggacgtgcctttccacagcagctacgcacacagccagag cct ggaccggct gat gaatcccct cat cgaccagt act tgt act acct ggccagaacacagagtaacccaggaggc acagctggcaatcgggaactgcagttttaccagggcgggccttcaactatggccgaacaagccaagaattggttac ctggaccttgcttccggcaacaaagagtctccaaaacgctggatcaaaacaacaacagcaactttgcttggactgg tgccaccaaatatcacctgaacggcagaaactcgttggttaatcccggcgtcgccatggcaactcacaaggacgac gaggaccgctttttcccatccagcggagtcctgatttttggaaaaactggagcaactaacaaaactacattggaaa atgtgttaatgacaaatgaagaagaaattcgtcctactaatcctgtagccacggaagaatacgggatagtcagcag caacttacaagcggctaat act gcagcccagacacaagttgtcaacaaccagggagcctt acct ggcatggtctgg cagaaccgggacgtgt acct gcagggtcccatctgggccaagatt cct cacacggatggcaactttcacccgt etc ctttgatgggcggctttggacttaaacatccgcctcctcagatcctgatcaagaacactcccgttcccgctaatcc tccggaggtgtt tact cct gccaagttt get tegtt cat cacacagtacagcaccggacaagtcagcgtggaaatc gagtgggagctgcagaaggaaaacagcaagcgctggaacccggagattcagtacacctccaactttgaaaagcaga70#15239971vlT19749Attorney Docket No. U1202.70169WO00 ctggtgtggactttgccgttgacagccagggtgtttactctgagcctcgccctattggcactcgttacctcacccg taatctgtaa (SEQ ID NO: 57 )
[0162] Example of a nucleotide sequence encoding AAV8 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggcgctga aacctggagccccgaagcccaaagccaaccagcaaaagcaggacgacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctggagcacgac aaggcctacgaccagcagctgcaggcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcagg agcgtctgcaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaagaagcgggttctcga acctctcggtctggttgaggaaggcgctaagacggctcctggaaagaagagaccggtagagccatcaccccagcgt tctccagactcctctacgggcatcggcaagaaaggccaacagcccgccagaaaaagactcaattttggtcagactg gcgactcagagtcagttccagaccctcaacctctcggagaacctccagcagcgccctctggtgtgggacctaatac aatggctgcaggcggtggcgcaccaatggcagacaataacgaaggcgccgacggagtgggtagttcctcgggaaat tggcattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgaacctgggccctgcccacctaca acaaccacctctacaagcaaatctccaacgggacatcgggaggagccaccaacgacaacacctacttcggctacag caccccctgggggtattttgactttaacagattccactgccacttttcaccacgtgactggcagcgactcatcaac aacaactggggattccggcccaagagactcagcttcaagctcttcaacatccaggtcaaggaggtcacgcagaatg aaggcaccaagaccatcgccaataacctcaccagcaccatccaggtgtttacggactcggagtaccagctgccgta cgttctcggctctgcccaccagggctgcctgcctccgttcccggcggacgtgttcatgattccccagtacggctac ctaacactcaacaacggtagtcaggccgtgggacgctcctccttctactgcctggaatactttccttcgcagatgc tgagaaccggcaacaacttccagtttacttacaccttcgaggacgtgcctttccacagcagctacgcccacagcca gagcttggaccggctgatgaatcctctgattgaccagtacctgtactacttgtctcggactcaaacaacaggaggc acggcaaatacgcagactctgggcttcagccaaggtgggcctaatacaatggccaatcaggcaaagaactggctgc caggaccctgttaccgccaacaacgcgtctcaacgacaaccgggcaaaacaacaatagcaactttgcctggactgc tgggaccaaataccatctgaatggaagaaattcattggctaatcctggcatcgctatggcaacacacaaagacgac gaggagcgtttttttcccagtaacgggatcctgatttttggcaaacaaaatgctgccagagacaatgcggattaca gcgatgtcatgctcaccagcgaggaagaaatcaaaaccactaaccctgtggctacagaggaatacggtatcgtggc agataacttgcagcagcaaaacacggctcctcaaattggaactgtcaacagccagggggccttacccggtatggtc tggcagaaccgggacgtgtacctgcagggtcccatctgggccaagattcctcacacggacggcaacttccacccgt ctccgctgatgggcggctttggcctgaaacatcctccgcctcagatcctgatcaagaacacgcctgtacctgcgga tcctccgaccaccttcaaccagtcaaagctgaactctttcatcacgcaatacagcaccggacaggtcagcgtggaa attgaatgggagctgcagaaggaaaacagcaagcgctggaaccccgagatccagtacacctccaactactacaaat ctacaagtgtggactttgctgttaatacagaaggcgtgtactctgaaccccgccccattggcacccgttacctcac ccgtaatctgtaa (SEQ ID NO: 58 )
[0163] Example of a nucleotide sequence encoding AAV9 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaaccttagtgaaggaattcgcgagtggtgggctttga aacctggagcccctcaacccaaggcaaatcaacaacatcaagacaacgctcgaggtcttgtgcttccgggttacaa ataccttggacccggcaacggactcgacaagggggagccggtcaacgcagcagacgcggcggccctcgagcacgac aaggcctacgaccagcagctcaaggccggagacaacccgtacctcaagtacaaccacgccgacgccgagttccagg agcggctcaaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaaaaagaggcttcttga acctcttggtctggttgaggaagcggctaagacggctcctggaaagaagaggcctgtagagcagtctcctcaggaa ccggactcctccgcgggtattggcaaatcgggtgcacagcccgctaaaaagagactcaatttcggtcagactggcg acacagagtcagtcccagaccctcaaccaatcggagaacctcccgcagccccctcaggtgtgggatctcttacaat ggcttcaggtggtggcgcaccagtggcagacaataacgaaggtgccgatggagtgggtagttcctcgggaaattgg cattgcgattcccaatggctgggggacagagtcatcaccaccagcacccgaacctgggccctgcccacctacaaca atcacctctacaagcaaatctccaacagcacatctggaggatcttcaaatgacaacgcctacttcggctacagcac cccctgggggtattttgacttcaacagattccactgccacttctcaccacgtgactggcagcgactcatcaacaac aactggggattccggcctaagcgactcaacttcaagctcttcaacattcaggtcaaagaggttacggacaacaatg gagtcaagaccatcgccaataaccttaccagcacggtccaggtcttcacggactcagactatcagctcccgtacgt gctcgggtcggctcacgagggctgcctcccgccgttcccagcggacgttttcatgattcctcagtacgggtatctg acgcttaatgatggaagccaggccgtgggtcgttcgtccttttactgcctggaatatttcccgtcgcaaatgctaa gaacgggtaacaacttccagttcagctacgagtttgagaacgtacctttccatagcagctacgctcacagccaaag cctggaccgactaatgaatccactcatcgaccaatacttgtactatctctcaaagactattaacggttctggacag aatcaacaaacgctaaaattcagtgtggccggacccagcaacatggctgtccagggaagaaactacatacctggac ccagctaccgacaacaacgtgtctcaaccactgtgactcaaaacaacaacagcgaatttgcttggcctggagcttc71#15239971vlT19749Attorney Docket No. U1202.70169WO00 ttcttgggctctcaatggacgtaatagcttgatgaatcctggacctgctatggccagccacaaagaaggagaggac cgtttctttcctttgtctggatctttaatttttggcaaacaaggaactggaagagacaacgtggatgcggacaaag tcatgataaccaacgaagaagaaattaaaactactaacccggtagcaacggagtcctatggacaagtggccacaaa ccaccagagtgcccaagcacaggcgcagaccggctgggttcaaaaccaaggaatacttccgggtatggtttggcag gacagagatgtgtacctgcaaggacccatttgggccaaaattcctcacacggacggcaactttcacccttctccgc t gat gggagggtttggaatgaagcacccgcctcctcagatcct cat caaaaacacacctgt acct gcggatcctcc aacggccttcaacaaggacaagctgaactctttcatcacccagtattctactggccaagtcagcgtggagatcgag tgggagctgcagaaggaaaacagcaagcgctggaacccggagatccagtacacttccaactattacaagtctaata atgttgaatttgctgttaatactgaaggtgtatatagtgaaccccgccccattggcaccagatacctgactcgtaa tctgtaa (SEQ ID NO: 59)
[0164] Example of a nucleotide sequence encoding AAVrhlO capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggacttga aacctggagccccgaaacccaaagccaaccagcaaaagcaggacgacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctcgagcacgac aaggcctacgaccagcagctcaaagcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcagg agcgtctgcaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaagaagcgggttctcga acctctcggtctggttgaggaaggcgctaagacggctcctggaaagaagagaccggtagagccatcaccccagcgt tctccagactcctctacgggcatcggcaagaaaggccagcagcccgcgaaaaagagactcaactttgggcagactg gcgactcagagtcagtgcccgaccctcaaccaatcggagaaccccccgcaggcccctctggtctgggatctggtac aatggctgcaggcggtggcgctccaatggcagacaataacgaaggcgccgacggagtgggtagttcctcaggaaat tggcattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgaacctgggccctccccacctaca acaaccacctctacaagcaaatctccaacgggacttcgggaggaagcaccaacgacaacacctacttcggctacag caccccctgggggtattttgactttaacagattccactgccacttctcaccacgtgactggcagcgactcatcaac aacaactggggattccggcccaagagactcaacttcaagctcttcaacatccaggtcaaggaggtcacgcagaatg aaggcaccaagaccatcgccaataaccttaccagcacgattcaggtctttacggactcggaataccagctcccgta cgtcctcggctctgcgcaccagggctgcctgcctccgttcccggcggacgtcttcatgattcctcagtacgggtac ctgactctgaacaatggcagtcaggccgtgggccgttcctccttctactgcctggagtactttccttctcaaatgc tgagaacgggcaacaactttgagttcagctaccagtttgaggacgtgccttttcacagcagctacgcgcacagcca aagcctggaccggct gat gaaccccct cat cgaccagt acct gt act acct gt ct cggactcagtccacgggaggt accgcaggaactcagcagttgctattttctcaggccgggcctaataacatgtcggctcaggccaaaaactggctac ccgggccctgctaccggcagcaacgcgtctccacgacactgtcgcaaaataacaacagcaactttgcctggaccgg tgccaccaagtatcatctgaatggcagagactctctggtaaatcccggtgtcgctatggcaacccacaaggacgac gaagagcgattttttccgtccagcggagtcttaatgtttgggaaacagggagctggaaaagacaacgtggactata gcagcgttatgctaaccagtgaggaagaaattaaaaccaccaacccagtggccacagaacagtacggcgtggtggc cgataacctgcaacagcaaaacgccgctcctattgtaggggccgtcaacagtcaaggagccttacctggcatggtc tggcagaaccgggacgtgtacctgcagggtcctatctgggccaagattcctcacacggacggaaactttcatccct cgccgctgatgggaggctttggactgaaacacccgcctcctcagatcctgattaagaatacacctgttcccgcgga tcctccaact acct tcagtcaagctaagctggcgtcgtt cat cacgcagtacagcaccggacaggtcagcgtggaa attgaatgggagctgcagaaagaaaacagcaaacgctggaacccagagattcaatacacttccaactactacaaat ctacaaatgtggactttgctgttaacacagatggcacttattctgagcctcgccccatcggcacccgttacctcac ccgtaatctgtaa (SEQ ID NO: 60 )
[0165] Example of a nucleotide sequence encoding AAVrh74 capsid protein: atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggacctga aacctggagccccgaaacccaaagccaaccagcaaaagcaggacaacggccggggtctggtgcttcctggctacaa gtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctcgagcacgac aaggcctacgaccagcagctccaagcgggtgacaatccgtacctgcggtataatcacgccgacgccgagtttcagg agcgtctgcaagaagatacgtcttttgggggcaacctcgggcgcgcagtcttccaggccaaaaagcgggttctcga acctctgggcctggttgaatcgccggttaagacggctcctggaaagaagagaccggtagagccatcaccccagcgc tctccagactcctctacgggcatcggcaagaaaggccagcagcccgcaaaaaagagactcaattttgggcagactg gcgactcagagtcagtccccgaccctcaaccaatcggagaaccaccagcaggcccctctggtctgggatctggtac aatggctgcaggcggtggcgctccaatggcagacaataacgaaggcgccgacggagtgggtagttcctcaggaaat tggcattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgcacctgggccctgcccacctaca acaaccacctctacaagcaaatctccaacgggacctcgggaggaagcaccaacgacaacacctacttcggctacag caccccctgggggtattttgacttcaacagattccactgccacttttcaccacgtgactggcagcgactcatcaac 72#15239971vlT19749Attorney Docket No. U1202.70169WO00 aacaactggggattccggcccaagaggctcaacttcaagctcttcaacatccaagtcaaggaggtcacgcagaatg aaggcaccaagaccatcgccaataaccttaccagcacgattcaggtctttacggactcggaataccagctcccgta cgtgctcggctcggcgcaccagggctgcctgcctccgttcccggcggacgtcttcatgattcctcagtacgggtac ctgactctgaacaatggcagtcaggctgtgggccggtcgtccttctactgcctggagtactttccttctcaaatgc tgagaacgggcaacaactttgaattcagctacaacttcgaggacgtgcccttccacagcagctacgcgcacagcca gagcctggaccggctgatgaaccctctcatcgaccagtacttgtactacctgtcccggactcaaagcacgggcggt actgcaggaactcagcagttgctattttctcaggccgggcctaacaacatgtcggctcaggccaagaactggctac ccggtccctgctaccggcagcaacgcgtctccacgacactgtcgcagaacaacaacagcaactttgcctggacggg tgccaccaagtatcatctgaatggcagagactctctggtgaatcctggcgttgccatggctacccacaaggacgac gaagagcgattttttccatccagcggagtcttaatgtttgggaaacagggagctggaaaagacaacgtggactata gcagcgtgatgctaaccagcgaggaagaaataaagaccaccaacccagtggccacagaacagtacggcgtggtggc cgataacctgcaacagcaaaacgccgctcctattgtaggggccgtcaatagtcaaggagccttacctggcatggtg tggcagaaccgggacgtgtacctgcagggtcccatctgggccaagattcctcatacggacggcaactttcatccct cgccgctgatgggaggctttggactgaagcatccgcctcctcagatcctgattaaaaacacacctgttcccgccga tcctccgaccaccttcaatcaggccaagctggcttctttcatcacgcagtacagtaccggtcaggtcagcgtggag atcgagtgggagctgcagaaggagaacagcaaacgctggaacccagagattcagtacacttccaactactacaaat ctacaaatgtggactttgctgtcaatactgagggtacttattccgagcctcgccccattggcacccgttacctcac ccgtaatctgtaa (SEQ ID NO: 61 )Capsid proteins with S663 and / or T492 amino acid substitutions
[0166] In some embodiments, an AAV capsid protein disclosed herein comprises amino acid substitutions at positions corresponding to S663 and / or T492 of SEQ ID NO: 3. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in SEQ ID NO: 3. It should be understood that an amino acid substitution at a position corresponding to a position of SEQ ID NO: 3 can be an amino acid substitution in a capsid protein of any serotype. The corresponding position in a capsid protein having a different baseline amino acid sequence can be determined by methods known in the art, such as by constructing structural alignments of the amino acid sequences and identifying corresponding amino acids. A “corresponding” amino acid to be substituted is one which is at the corresponding position, and may have the same amino acid identity (i.e., the amino acid at the corresponding position in the second capsid protein sequence is the same as the amino acid in the reference capsid protein sequence), or may be an amino acid with similar properties (e.g., similar hydrophobicity, size, charge, etc.) as the amino acid in the reference capsid protein. For example, an amino acid substitution at a position corresponding to T492 of SEQ ID NO: 3, or corresponding to a T492V substitution in SEQ ID NO: 3 may be a substitution at a position corresponding to position 492 of SEQ ID NO: 3 in a second capsid protein, which may also be a threonine, or which may be a similar amino acid (e.g., another amino acid with a polar uncharged side chain, such as serine, asparagine, or glutamine).
[0167] In some embodiments, an AAV capsid protein disclosed herein comprises amino acid substitutions as described in Patent Application Publication Nos. US2010 / 0104561,73#15239971vlAttorney Docket No. U1202.70169WO00 US2014 / 0050701, US2016 / 0333372, US2015 / 0133530, US2014 / 0341852, and WO2022 / 226289, the contents of each of which are herein incorporated by reference in their entireties for this purpose.Hepatocyte de-targeting capsid proteins
[0168] In some embodiments, an AAV capsid protein provided herein comprises one or more amino acid deletions or substitutions. In some embodiments, the one or more amino acid deletions or substitutions as provided herein confer / s to the AAV particle that comprises the modified capsid protein an improved hepatocyte detargeting ability (e.g., the AAV particle is delivered to hepatocytes at a reduced rate relative to an AAV particle that does not comprise the modified capsid protein), improved tropism for a particular tissue type, and / or improved transduction efficiency in particular cells or tissue type (e.g., liver sinusoidal endothelial cells).
[0169] In some embodiments, an AAV capsid provided herein is a hepatocyte de-targeting capsid protein. In some embodiments, a hepatocyte de-targeting capsid protein comprises an amino acid substitution or deletion at a position that corresponds to S262 of wild-type AAV3. SEQ ID NO: 3 provides an example of an amino acid sequence of AAV3 capsid protein.
[0170] In some embodiments, an AAV (e.g., AAV3) capsid protein comprises an amino acid deletion or substitution at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV (e.g., AAV3) capsid protein comprises an amino acid substitution at a position corresponding to Y444, T492, K545, S663, and / or Y731 of wild-type AAV3 capsid protein of SEQ ID NO: 3. In some embodiments, an AAV (e.g., AAV3) capsid protein comprises an amino acid deletion or substitution at a position corresponding to S262 of wild-type AAV3, and an amino acid substitution at a position corresponding to Y444, T492, K545, S663, and / or Y731of wild-type AAV3 capsid protein of SEQ ID NO: 3.
[0171] In some embodiments, an AAV (e.g., AAV3) capsid protein comprises any one of the following amino acid substitutions: S262D, S262F, and S262G at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 3). In some embodiments, a capsid protein as provided herein has a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 3). In some embodiments, an amino acid at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 3) is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, W, Y, or V. In some embodiments,74#15239971vlAttorney Docket No. U1202.70169WO00 an amino acid at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 3) is a negatively charged amino acid (e.g., D or E). In some embodiments, an amino acid at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 3) is an acidic polar amino acid (e.g., D or E). In some embodiments, an amino acid at a position corresponding to S262 of wild-type AAV3 (e.g., of sequence of SEQ ID NO: 1) is not neutral or polar.
[0172] In some embodiments, an AAV (e.g., AAV3) capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to T492 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to K545 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to S663 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y731 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444 and Y731 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises a deletion at a position corresponding to S262 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444, Y731, and T492 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3).
[0173] In some embodiments, an AAV (e.g., AAV3) capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild- type75#15239971vlAttorney Docket No. U1202.70169WO00 AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to T492 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to K545 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to S663 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y731 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444 and Y731 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, an AAV capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3) and an amino acid substitution at a position corresponding to Y444, Y731, and T492 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3).
[0174] In some embodiments, an amino acid substitution at a position corresponding to Y444 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is Y444F. In some embodiments, an amino acid substitution at a position corresponding to Y731 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is Y731F. In some embodiments, an amino acid substitution at a position corresponding to T492 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is T492V. In some embodiments, an amino acid substitution76#15239971vlT19749Attorney Docket No. U1202.70169WO00 at a position corresponding to K545 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is K545R. In some embodiments, an amino acid substitution at a position corresponding to S663 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is S663R or S663V. In some embodiments, an amino acid substitution at a position corresponding to Y731 of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3) is Y731F.
[0175] In some embodiments, an AAV (e.g., AAV3) capsid protein comprises an amino acid substitution at a position corresponding to S262 (e.g., S262D, S262G, or S262F) of wild- type AAV3 (e.g., as shown in SEQ ID NO: 3) and one or more (e.g., 1, 2, 3, 4, or 5) additional amino acid substitutions at one or more positions corresponding to Y444, T492, K545, S663, and / or Y731 of wild-type AAV3 (e.g., as shown in SEQ ID NO: 3). In some embodiments, the one or more additional amino acid substitutions correspond to Y444F, T492V, K545R, S663R or S663V, and / or Y731F of wild-type AAV3 capsid protein (as shown e.g., in SEQ ID NO: 3).
[0176] In some embodiments, a hepatocyte de-targeting capsid protein is an AAV capsid protein (e.g., an AAV3) comprising amino acid substitutions at positions corresponding to S262 (e.g., S262D, S262G, or S262F), Y444 (e.g., Y444F), T492 (e.g., T492V), K545 (e.g., K545R), S663 (e.g., S663R or S663V), and Y731 (e.g., Y731F) of wild-type AAV3. In some embodiments, a hepatocyte de-targeting capsid protein is an AAV capsid protein (e.g., an AAV3 capsid protein) comprising amino acid substitutions corresponding to S262D, S262G, or S262F; Y444F; T492V; K545R; S663R or S663V; and Y731F, of wild-type AAV3, and not comprising other amino acid substitutions relative to a corresponding wild-type capsid protein. In some embodiments, a hepatocyte de-targeting capsid protein is an AAV3 capsid protein comprising amino acid substitutions S262D, S262G, or S262F; Y444F; T492V; K545R;S663R or S663V; and Y731F, relative to wild-type AAV3, and not comprising other amino acid substitutions relative to a wild-type AAV3 capsid protein having an amino acid sequence of SEQ ID NO: 3.A A V Particles
[0177] According to some aspects, provided herein are AAV particles that comprise any of the nucleic acid vectors (e.g., AAV genomes) and / or modified capsid proteins disclosed herein. An AAV particle is a supramolecular assembly of 60 individual capsid protein subunits forming a non-enveloped T-l icosahedral lattice capable of protecting a single- stranded DNA genome. A 77#15239971vlT19749Attorney Docket No. U1202.70169WO00 mature AAV particle is approximately 20 nm in diameter, and its capsid is formed from three structural capsid proteins VP1, VP2, and VP3, with molecular masses of 87, 73, and 62 kDa, respectively, in a ratio of approximately 1:1:18. The 60 capsid proteins are arranged in an antiparallel P-strand barreloid arrangement, resulting in a defined tropism and a high resistance to degradation.
[0178] In some embodiments, an AAV particle comprises an empty capsid (e.g., a capsid without a cargo). In some embodiments, an AAV particle comprises a capsid encapsidating a nucleic acid (e.g., a nucleic acid vector that comprises a gene of interest, such as a nucleic acid vector disclosed herein). In some embodiments, a nucleic acid encapsidated within an AAV capsid to generate an AAV particle comprises a nucleic acid vector disclosed herein. In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising one or more mutations, e.g., one or more amino acid substitutions.
[0179] It is contemplated herein that any capsid protein mutations disclosed herein (e.g., amino acid substitutions) can be combined with any nucleic acid vector modifications disclosed herein (e.g., sequence deletions, substitutions, or insertions). For example, an AAV particle described herein may have an AAV capsid protein (e.g., a wild-type AAV capsid protein or one comprising one or more amino acid substitutions provided herein) and an AAV nucleic acid vector comprising a modification (e.g., an ITR modification provided herein).
[0180] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising one or more amino acid substitutions corresponding to S663V and T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions corresponding to S663V and T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, an AAV particle disclosed herein comprises an AAV3 serotype capsid protein comprising amino acid substitutions S663V and T492V.
[0181] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T49278#15239971vlT19749Attorney Docket No. U1202.70169WO00 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and further comprises a nucleic acid vector comprising modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of an ITR (e.g., a modification of a D-sequence of a right ITR, a left ITR, or both a right ITR and a left ITR).
[0182] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and further comprises a nucleic acid vector comprising a nucleotide sequence encoding a transgene.
[0183] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S262 (e.g., S262D, S262G, or S262F), Y444 (e.g., Y444F), T492 (e.g., T492V), K545 (e.g., K545R), S663 (e.g., S663R or S663V), and Y731 (e.g., Y731F) of wild-type AAV3. In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S262D, S262G, or S262F; Y444F; T492V; K545R; S663R or S663V; and Y731F, of wild-type AAV3. In some embodiments, an AAV particle disclosed herein comprises an AAV3 capsid protein comprising amino acid substitutions S262D, S262G, or S262F; Y444F; T492V; K545R; S663R or S663V; and Y731F.
[0184] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S262 (e.g., S262D, S262G, or S262F), Y444 (e.g., Y444F), T492 (e.g., T492V), K545 (e.g., K545R), S663 (e.g., S663R or S663V), and Y731 (e.g., Y731F) of wild-type AAV3, and further comprises a nucleic acid vector comprising modification (e.g., a deletion, a substitution, or an insertion) of a D-sequence of an ITR (e.g., a modification of a D-sequence of a right ITR, a left ITR, or both a right ITR and a left ITR).
[0185] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S262 (e.g., S262D, S262G, or S262F), Y444 (e.g., Y444F), T492 (e.g., T492V), K545 (e.g., K545R), S663 (e.g., S663R or S663V), and Y731 (e.g., Y731F) of wild-type AAV3, and further comprises a nucleic acid vector comprising a nucleotide sequence encoding a transgene.#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0186] In some embodiments, an AAV particle disclosed herein is replicative. A replicative AAV particle is capable of replicating within a host cell (e.g., a host cell within a subject or a host cell in culture). In some embodiments, an AAV particle disclosed herein is nonreplicating. A non-replicating AAV particle is not capable of replicating within a host cell (e.g., a host cell within a subject or a host cell in culture), but can infect the host and incorporate a genetic components into the host’s genome for expression. In some embodiments, an AAV particle disclosed herein is capable of infecting a host cell. In some embodiments, an AAV particle disclosed herein is capable of facilitating stable integration of genetic components into the genome of a host cell. In some embodiments, an AAV particle disclosed herein is not capable of facilitating integration of genetic components into the genome of a host cell.
[0187] In some embodiments, an AAV particle disclosed herein comprises a nucleic acid vector (e.g., an AAV genome) provided herein. In some embodiments, a nucleic acid vector (e.g., AAV genome) comprises two inverted terminal repeats (ITRs) adjacent to the ends of a sequence encoding a gene of interest (e.g., a transgene). In some embodiments, the nucleic acid vector (e.g., AAV genome) is a single- stranded DNA vector. In some embodiments, an AAV particle disclosed herein comprises one single-stranded DNA. In some embodiments, an AAV particle disclosed herein comprises two complementary DNA strands, forming a self-complementary AAV (sc AAV).
[0188] In some embodiments, a nucleic acid vector that may be comprised in an AAV particle (e.g., a WT particle or particle comprising a capsid comprising any one or more mutations as disclosed herein) comprises an ITR comprising a modification (e.g., a deletion, substitution, or insertion) of part or all of the ITR’s D-sequence. In some embodiments, part or all of the ITR’s D-sequence is substituted with a heterologous nucleotide sequence (e.g., an S-sequence, a GRE, or another heterologous sequence). In some embodiments, part or all of the ITR’s D-sequence is deleted. Further description of such modifications is provided elsewhere herein. In some embodiments, an ITR comprising a substitution, insertion, or deletion of a nucleic acid sequence as disclosed herein comprises one or more additional modifications, such as an additional substitution, modification, or deletion in another portion of the ITR.
[0189] An AAV particle disclosed herein may be of any AAV serotype (e.g., AAV serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13), including any derivative (including non-naturally occurring variants of a serotype) or pseudotype. Non-limiting examples of derivatives and80#15239971vlT19749Attorney Docket No. U1202.70169WO00 pseudotypes include AAV2-AAV3 hybrid, AAVrh.10, AAVhu.14, AAV3a / 3b, AAVrh32.33, AAV-HSC15, AAV-HSC17, AAVhu.37, AAVrh.8, CHt-P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15 / 17, AAVM41, AAV9.45, AAV2.5T, AAV-HAE1 / 2, AAV clone 32 / 83, AAVShHIO, AAV2.15, AAV2.4, AAVM41, and AAVr3.45. Such AAV serotypes and derivatives / pseudotypes, and methods of producing such derivatives / pseudotypes are known in the art (see, e.g., Mol. Ther. 2012 Apr; 20(4):699-708. doi: 10.1038 / mt.2011.287. Epub 2012 Jan 24. The AAV vector toolkit: poised at the clinical crossroads. Asokan A, Schaffer DV, Samulski RJ.). In some embodiments, the AAV particle is a pseudotyped AAV particle, which comprises a nucleic acid vector comprising ITRs from one serotype (e.g., AAV2 or AAV3) and a capsid comprised of capsid proteins derived from another serotype (i.e., a serotype other than AAV2 or AAV3, respectively). SEQ ID NOs: 1-14 provide examples of amino acid sequences of AAV capsid proteins of different serotypes. Methods for producing and using pseudotyped rAAV vectors are known in the art (see, e.g., Duan et al., J. Virol., 75:7662-7671 (2001); Halbert et al., J. Virol., 74:1524-1532 (2000); Zolotukhin et al., Methods, 28:158-167 (2002); and Auricchio et al., Hum. Molec. Genet., 10:3075-3081 (2001)).
[0190] In some embodiments, an AAV particle disclosed herein is a recombinant AAV (rAAV) particle, e.g., comprising a recombinant nucleic acid or transgene.
[0191] Any combination of modifications described herein (e.g., capsid protein modifications, ITR modifications) may result in an additive or synergistic effect, in which the beneficial properties of the resulting combination are equal to or greater than, respectively, the sum of the effects of the individual modifications. For example, an AAV particle comprising a modified capsid protein and a modified genome may have improvements in cellular / tissue delivery (e.g., specificity for a particular cell type or tissue), transduction efficiency, transgene expression, and / or packaging efficiency relative to a corresponding wild-type AAV particle that are equal to the sum of the improvements conferred by the individual capsid protein modification and the genome modification, or that are greater than the sum of the improvements conferred by the individual modifications.
[0192] AAV particles as disclosed herein, e.g., comprising modified ITRs, can be prepared by one of ordinary skill in the art by known methods.
[0193] In some embodiments, AAV particles (e.g., comprising modified genome and / or capsid protein) disclosed herein can be generated using a plasmid, such as a pSub201 plasmid, which includes sequences encoding AAV Rep and capsid proteins, and in which a gene of interest can81#15239971vlT19749Attorney Docket No. U1202.70169WO00 be inserted. The pSub201 sequence is provided below, in which the open reading frame encoding ampicillin-resistance marker is bolded and the D-sequences are underlined. The portions of the underlined D-sequences that are also bolded are the preferred portion of the D-sequences that can be replaced by a heterologous nucleotide sequence. A corresponding position for replacement by a heterologous nucleotide sequence in a different sequence can be identified by methods known in the art.CAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGT CGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTTG TAGTTAATGATTAACCCGCCATGCTACTTATCTACGTAGCCATGCTCTAGAGTCCTGTATTAGAGGTCA CGTGAGTGTTTTGCGACATTTTGCGACACCATGTGGTCACGCTGGGTATTTAAGCCCGAGTGAGCACGC AGGGTCTCCATTTTGAAGCGGGAGGTTTGAACGCGCAGCCGCCATGCCGGGGTTTTACGAGATTGTGAT TAAGGTCCCCAGCGACCTTGACGGGCATCTGCCCGGCATTTCTGACAGCTTTGTGAACTGGGTGGCCGA GAAGGAATGGGAGTTGCCGCCAGATTCTGACATGGATCTGAATCTGATTGAGCAGGCACCCCTGACCGT GGCCGAGAAGCTGCAGCGCGACTTTCTGACGGAATGGCGCCGTGTGAGTAAGGCCCCGGAGGCCCTTTT CTTTGTGCAATTTGAGAAGGGAGAGAGCTACTTCCACATGCACGTGCTCGTGGAAACCACCGGGGTGAA ATCCATGGTTTTGGGACGTTTCCTGAGTCAGATTCGCGAAAAACTGATTCAGAGAATTTACCGCGGGAT CGAGCCGACTTTGCCAAACTGGTTCGCGGTCACAAAGACCAGAAATGGCGCCGGAGGCGGGAACAAGGT GGTGGATGAGTGCTACATCCCCAATTACTTGCTCCCCAAAACCCAGCCTGAGCTCCAGTGGGCGTGGAC TAATATGGAACAGTATTTAAGCGCCTGTTTGAATCTCACGGAGCGTAAACGGTTGGTGGCGCAGCATCT GACGCACGTGTCGCAGACGCAGGAGCAGAACAAAGAGAATCAGAATCCCAATTCTGATGCGCCGGTGAT CAGATCAAAAACTTCAGCCAGGTACATGGAGCTGGTCGGGTGGCTCGTGGACAAGGGGATTACCTCGGA GAAGCAGTGGATCCAGGAGGACCAGGCCTCATACATCTCCTTCAATGCGGCCTCCAACTCGCGGTCCCA AATCAAGGCTGCCTTGGACAATGCGGGAAAGATTATGAGCCTGACTAAAACCGCCCCCGACTACCTGGT GGGCCAGCAGCCCGTGGAGGACATTTCCAGCAATCGGATTTATAAAATTTTGGAACTAAACGGGTACGA TCCCCAATATGCGGCTTCCGTCTTTCTGGGATGGGCCACGAAAAAGTTCGGCAAGAGGAACACCATCTG GCTGTTTGGGCCTGCAACTACCGGGAAGACCAACATCGCGGAGGCCATAGCCCACACTGTGCCCTTCTA CGGGTGCGTAAACTGGACCAATGAGAACTTTCCCTTCAACGACTGTGTCGACAAGATGGTGATCTGGTG GGAGGAGGGGAAGATGACCGCCAAGGTCGTGGAGTCGGCCAAAGCCATTCTCGGAGGAAGCAAGGTGCG CGTGGACCAGAAATGCAAGTCCTCGGCCCAGATAGACCCGACTCCCGTGATCGTCACCTCCAACACCAA CATGTGCGCCGTGATTGACGGGAACTCAACGACCTTCGAACACCAGCAGCCGTTGCAAGACCGGATGTT CAAATTTGAACTCACCCGCCGTCTGGATCATGACTTTGGGAAGGTCACCAAGCAGGAAGTCAAAGACTT TTTCCGGTGGGCAAAGGATCACGTGGTTGAGGTGGAGCATGAATTCTACGTCAAAAAGGGTGGAGCCAA GAAAAGACCCGCCCCCAGTGACGCAGATATAAGTGAGCCCAAACGGGTGCGCGAGTCAGTTGCGCAGCC ATCGACGTCAGACGCGGAAGCTTCGATCAACTACGCAGACAGGTACCAAAACAAATGTTCTCGTCACGT GGGCATGAATCTGATGCTGTTTCCCTGCAGACAATGCGAGAGAATGAATCAGAATTCAAATATCTGCTT CACTCACGGACAGAAAGACTGTTTAGAGTGCTTTCCCGTGTCAGAATCTCAACCCGTTTCTGTCGTCAA AAAGGCGTATCAGAAACTGTGCTACATTCATCATATCATGGGAAAGGTGCCAGACGCTTGCACTGCCTG CGATCTGGTCAATGTGGATTTGGATGACTGCATCTTTGAACAATAAATGATTTAAATCAGGTATGGCTG CCGATGGTTATCTTCCAGATTGGCTCGAGGACACTCTCTCTGAAGGAATAAGACAGTGGTGGAAGCTCA AACCTGGCCCACCACCACCAAAGCCCGCAGAGCGGCATAAGGACGACAGCAGGGGTCTTGTGCTTCCTG GGTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAGGCAGACGCCGCGG CCCTCGAGCACGTCAAAGCCTACGACCGGCAGCTCGACAGCGGAGACAACCCGTACCTCAAGTACAACC ACGCCGACGCGGAGTTTCAGGAGCGCCTTAAAGAAGATACGTCTTTTGGGGGCAACCTCGGACGAGCAG TCTTCCAGGCGAAAAAGAGGGTTCTTGAACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTCCGG GAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCC AGCAGCCTGCAAGAAAAAGATTGAATTTTGGTCAGACTGGAGACGCAGACTCAGTACCTGACCCCCAGC CTCTCGGACAGCCACCAGCAGCCCCCTCTGGTCTGGGAACTAATACGATGGCTACAGGCAGTGGCGCAC CAATGGCAGACAATAACGAGGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGCGATTCCA CATGGATGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCACC82#15239971vlT19749Attorney Docket No. U1202.70169WO00 TCTACAAACAAATTTCCAGCCAATCAGGAGCCTCGAACGACAATCACTACTTTGGCTACAGCACCCCTT GGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAAAGACTCATCAACA ACAACTGGGGATTCCGACCCAAGAGACTCAACTTCAAGCTCTTTAACATTCAAGTCAAAGAGGTCACGC AGAATGACGGTACGACGACGATTGCCAATAACCTTACCAGCACGGTTCAGGTGTTTACTGACTCGGAGT ACCAGCTCCCGTACGTCCTCGGCTCGGCGCATCAAGGATGCCTCCCGCCGTTCCCAGCAGACGTCTTCA TGGTGCCACAGTATGGATACCTCACCCTGAACAACGGGAGTCAGGCAGTAGGACGCTCTTCATTTTACT GCCTGGAGTACTTTCCTTCTCAGATGCTGCGTACCGGAAACAACTTTACCTTCAGCTACACTTTTGAGG ACGTTCCTTTCCACAGCAGCTACGCTCACAGCCAGAGTCTGGACCGTCTCATGAATCCTCTCATCGACC AGTACCTGTATTACTTGAGCAGAACAAACACTCCAAGTGGAACCACCACGCAGTCAAGGCTTCAGTTTT CTCAGGCCGGAGCGAGTGACATTCGGGACCAGTCTAGGAACTGGCTTCCTGGACCCTGTTACCGCCAGC AGCGAGTATCAAAGACATCTGCGGATAACAACAACAGTGAATACTCGTGGACTGGAGCTACCAAGTACC ACCTCAATGGCAGAGACTCTCTGGTGAATCCGGGGCCCGCCATGGCAAGCCACAAGGACGATGAAGAAA AGTTTTTTCCTCAGAGCGGGGTTCTCATCTTTGGGAAGCAAGGCTCAGAGAAAACAAATGTGAACATTG AAAAGGTCATGATTACAGACGAAGAGGAAATCGGAACAACCAATCCCGTGGCTACGGAGCAGTATGGTT CTGTATCTACCAACCTCCAGAGAGGCAACAGACAAGCAGCTACCGCAGATGTCAACACACAAGGCGTTC TTCCAGGCATGGTCTGGCAGGACAGAGATGTGTACCTTCAGGGGCCCATCTGGGCAAAGATTCCACACA CGGACGGACATTTTCACCCCTCTCCCCTCATGGGTGGATTCGGACTTAAACACCCTCCTCCACAGATTC TCATCAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTGCGGCAAAGTTTGCTTCCTTCA TCACACAGTACTCCACGGGACACGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAA CGCTGGAATCCCGAAATTCAGTACACTTCCAACTACAACAAGTCTGTTAATCGTGGACTTACCGTGGAT ACTAATGGCGTGTATTCAGAGCCTCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAATTGCTT GTTAATCAATAAACCGTTTAATTCGTTTCAGTTGAACTTTGGTCTCTGCGTATTTCTTTCTTATCTAGT TTCCATGCTCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATTAACTACAAGGAACCC CTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTC GCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCCAGCTGGCGTAATAGCGA AGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGAATTCCAGACGATT GAGCGTCAAAATGTAGGTATTTCCATGAGCGTTTTTCCTGTTGCAATGGCTGGCGGTAATATTGTTCTG GATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAGTGATGTTATTACTAATCAAAGA AGTATTGCGACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAA AACACTTCTCAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCC CGCTCTGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAG CGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGC GCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAA TCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGG TGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTT CTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTT ATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAA TTTTAACAAAATATTAACGTTTACAATTTAAATATTTGCTTATACAATCTTCCTGTTTTTGGGGCTTTT CTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGT TTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCC GGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGGCCTTTCT CACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAATATATGAGGGTTCTAAAAAT TTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGTACA ACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGAT TTATTGGATGTTGGAATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCAT ATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACC CGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGG GAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACG CCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAA TGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATA ACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCT TATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGA TGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGA83#15239971vlT19749Attorney Docket No. U1202.70169WO00 GAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATT ATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGA GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCAT AACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGC TTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCAT ACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGG CGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACC ACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTC TCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGG GAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTG GTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAG GATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTG AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTG CTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTT TCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGG CCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATA CCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAG CGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCC TGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATG GAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCG CAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCC TCTCCCCGCGCGTTGGCCGATTCATTAATG (SEQ ID NO: 62 )Examples of AAV particles comprising modified genomes and encoding transgenes
[0194] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence and (b) a nucleotide sequence encoding a transgene. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the S-sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15) and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed 84#15239971vlT19749Attorney Docket No. U1202.70169WO00 herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with an S-sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15) and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0195] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0196] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In85#15239971vlT19749Attorney Docket No. U1202.70169WO00 some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0197] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a86#15239971vlT19749Attorney Docket No. U1202.70169WO00 substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0198] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0199] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence and (b) a nucleotide sequence encoding a transgene. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR87#15239971vlT19749Attorney Docket No. U1202.70169WO00 (e.g., the D-sequence of the left ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (b) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (b) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0200] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation88#15239971vlT19749Attorney Docket No. U1202.70169WO00 factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0201] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of89#15239971vlT19749Attorney Docket No. U1202.70169WO00 either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0202] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide90#15239971vlT19749Attorney Docket No. U1202.70169WO00 sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).91#15239971vlT19749Attorney Docket No. U1202.70169WO00
[0203] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence and (c) a nucleotide sequence encoding a transgene. In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, the transgene is coagulation factor IX (FIX, e.g., human FIX). In some embodiments, the transgene is coagulation factor VIII (FVIII, e.g., human FVIII). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FIX (e.g., human FIX). In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid92#15239971vlT19749Attorney Docket No. U1202.70169WO00 sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21) and (c) a nucleotide sequence encoding FVIII (e.g., human FVIII).
[0204] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising the sequence of pscAAV3-TTR-BDD-FVIII (SEQ ID NO: 47).
[0205] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising the sequence of pscAAV3-GRE-TTR-BDD-FVIII (SEQ ID NO: 48).
[0206] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising the sequence of pscAAV3-TTR- FIX-Padua (SEQ ID NO: 49).
[0207] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein (e.g., an AAV3 capsid protein), and (ii) a nucleic acid vector comprising the sequence of pscAAV3-GRE-TTR- FIX-Padua (SEQ ID NO: 50).Examples of AAV particles comprising modified capsid proteins and modified genomes
[0208] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with an S-sequence. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the S-sequence. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a93#15239971vlT19749Attorney Docket No. U1202.70169WO00 portion of a D-sequence of an ITR with an S-sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15).
[0209] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
[0210] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid94#15239971vlT19749Attorney Docket No. U1202.70169WO00 substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
[0211] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement.
[0212] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement. In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, an AAV particle disclosed herein95#15239971vlT19749Attorney Docket No. U1202.70169WO00 is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19) or its reverse or reverse complement.
[0213] In some embodiments, an AAV particle disclosed herein comprises a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising a substitution of a portion of a D-sequence of an ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).
[0214] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid96#15239971vlAttorney Docket No. U1202.70169WO00 protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-AGAACANNNTGTTCT-3' (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).
[0215] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C. In97#15239971vlAttorney Docket No. U1202.70169WO00 some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiments, a portion or the entirety of a second D-sequence of a second ITR (e.g., the D-sequence of the right ITR) is substituted with the heterologous nucleotide sequence. In some embodiments, an AAV particle disclosed herein is an AAV3 serotype particle comprising (i) an AAV3 capsid protein comprising amino acid substitutions S663V and T492V, and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-GGTACANNNTGTYCT-3' (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence comprising, consisting essentially of, or consisting of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).
[0216] In some embodiments, an AAV particle disclosed herein comprises (i) a capsid protein comprising amino acid substitutions at one or more positions corresponding to S663 and T492 of the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3), and (ii) a nucleic acid vector comprising (a) a substitution of a portion of a D-sequence of an ITR with a GRE and (b) a substitution of a portion of a second D-sequence of a second ITR with a heterologous nucleotide sequence. In some embodiments, the amino acid substitutions correspond to S663V and / or T492V substitutions in the wild-type AAV3 capsid protein (e.g., having an amino acid sequence as provided in SEQ ID NO: 3). In some embodiments, the GRE comprises, consists essentially of, or consists of the nucleotide sequence 5'-AGAACAGGATGTTCT-3' (SEQ ID NO: 18), or its reverse or reverse complement. In some embodiments, the heterologous nucleotide sequence comprises, consists essentially of, or consists of the nucleotide sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21). In some98#15239971vlAttorney Docket No. U1202.70169WO00 embodiments, a portion or the entirety of a D-sequence of an ITR (e.g., the D-sequence of the left ITR) is substituted with the GRE. In some embodiment...
Claims
T19749Attorney Docket No. U1202.70169WO00CLAIMSWhat is claimed is:
1. An adeno-associated virus (AAV) particle comprising(i) an AAV capsid protein, and(ii) a nucleic acid vector comprising(a) a substitution of a portion of a D-sequence of an inverted terminal repeat (ITR) with a heterologous sequence, and(b) a transgene coding sequence encoding a coagulation factor.
2. The AAV particle of claim 1, wherein the AAV capsid protein is an AAV3 capsid protein.
3. The AAV particle of claim 1 or claim 2, wherein the heterologous sequence comprises an S-sequence.
4. The AAV particle of claim 3, wherein the S-sequence comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15).
5. The AAV particle of claim 3 or claim 4, wherein the S-sequence comprises, consists essentially of, or consists of the nucleic acid sequence TATTAGATCTGATGGCCGCT (SEQ ID NO: 15).
6. The AAV particle of claim 1 or claim 2, wherein the heterologous sequence comprises a glucocorticoid receptor binding element (GRE).
7. The AAV particle of claim 6, wherein the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
8. The AAV particle of claim 6 or claim 7, wherein the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence151#15239971 v1T19749Attorney Docket No. U1202.70169WO00 AGAACANNNTGTTCT (SEQ ID NO: 16), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A.
9. The AAV particle of claim 6, wherein the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
10. The AAV particle of claim 6 or claim 9, wherein the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence GGTACANNNTGTYCT (SEQ ID NO: 17), or its reverse or reverse complement, wherein each N is independently a T, C, G, or A, and wherein Y is a T or C.
11. The AAV particle of claim 6, wherein the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement.
12. The AAV particle of claim 6 or claim 11, wherein the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence AGAACAGGATGTTCT (SEQ ID NO: 18), or its reverse or reverse complement.
13. The AAV particle of claim 6, wherein the GRE comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement.
14. The AAV particle of claim 6 or claim 13, wherein the GRE comprises a nucleotide sequence comprising, consisting essentially of, or consisting of the sequence 5'-GGCACAGTGTGGTCT-3' (SEQ ID NO: 19), or its reverse or reverse complement.
15. The AAV particle of claim 1 or claim 2, wherein the heterologous sequence comprises a nucleotide sequence having fewer than 6 mismatches relative to the sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).152#15239971 v1T19749Attorney Docket No. U1202.70169WO0016. The AAV particle of claim 15, wherein the heterologous sequence comprises, consists essentially of, or consists of the nucleic acid sequence 5'-ATGTGCTTGA-3' (SEQ ID NO: 20), 5'-TCAAGCACAT-3' (SEQ ID NO: 21), or a reverse or reverse complement of either 5'-ATGTGCTTGA-3' (SEQ ID NO: 20) or 5'-TCAAGCACAT-3' (SEQ ID NO: 21).
17. The AAV particle of any one of claims 1-16, wherein the AAV capsid protein comprises amino acid substitutions at positions corresponding to S663 and / or T492 of SEQ ID NO: 3,optionally wherein the AAV capsid protein comprises amino acid substitutions corresponding to S663V and / or T492V substitutions in SEQ ID NO: 3.
18. The AAV particle of any one of claims 1-16, wherein the AAV capsid protein comprises one or more amino acid substitutions at positions corresponding to S262, Y444, T492, K545, S663, and / or Y731 of SEQ ID NO: 3,optionally wherein the AAV capsid protein comprises amino acid substitutions corresponding to S262D, S262G, or S262F; Y444F; T492V; K545R; S663R or S663V; and / or Y731F substitutions in SEQ ID NO: 3.
19. The AAV particle of any one of claims 1-18, wherein the coagulation factor comprises coagulation factor IX (FIX),optionally wherein the coagulation factor comprises human FIX (hFIX).
20. The AAV particle of claim 19, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of factor IX-Padua amino acid sequence (SEQ ID NO: 32),optionally wherein the transgene coding sequence encodes the amino acid sequence of factor IX-Padua amino acid sequence (SEQ ID NO: 32).
21. The AAV particle of claim 19 or claim 20, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of codon-optimized factor IX-Padua coding sequence (SEQ ID NO: 31),optionally wherein the transgene coding sequence comprises the sequence of codon-optimized factor IX-Padua coding sequence (SEQ ID NO: 31).153#15239971 v1T19749Attorney Docket No. U1202.70169WO0022. The AAV particle of claim 19, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_000124.1 (SEQID NO: 35),optionally wherein the transgene coding sequence encodes the amino acid sequence of NP_000124.1 (SEQID NO: 35).
23. The AAV particle of claim 19 or claim 22, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_000133.4 (SEQ ID NO: 33) or the coding sequence thereof (nucleotides 27-1412 (SEQ ID NO: 34)),optionally wherein the transgene coding sequence comprises the sequence of NM_000133.4 (SEQ ID NO: 33) or the coding sequence thereof (nucleotides 27-1412 (SEQ ID NO: 34)).
24. The AAV particle of claim 19, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_001300842.1 (SEQID NO: 38),optionally wherein the transgene coding sequence encodes the amino acid sequence of NP_001300842.1 (SEQID NO: 38).
25. The AAV particle of claim 19 or claim 24, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_001313913.2 (SEQ ID NO: 36) or the coding sequence thereof (nucleotides 27-1298 (SEQ ID NO: 37)),optionally wherein the transgene coding sequence comprises the sequence of NM_001313913.2 (SEQ ID NO: 36) or the coding sequence thereof (nucleotides 27-1298 (SEQ ID NO: 37)).
26. The AAV particle of any one of claims 1-21, wherein the nucleic acid vector comprises the sequence of pscAAV3-TTR-FIX-Padua (SEQ ID NO: 49) or pscAAV3-GRE-TTR-FIX-Padua (SEQ ID NO: 50).154#15239971 v1T19749Attorney Docket No. U1202.70169WO00 27. The AAV particle of any one of claims 1-18, wherein the coagulation factor comprises coagulation factor VIII (FVIII),optionally wherein the coagulation factor comprises human FVIII (hFVIII).
28. The AAV particle of claim 27, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40),optionally wherein the transgene coding sequence encodes the amino acid sequence of hFVIII amino acid sequence 1 (SEQ ID NO: 40).
29. The AAV particle of claim 27 or claim 28, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39),optionally wherein the transgene coding sequence comprises the sequence of hFVIII codon-optimized coding sequence 1 (SEQ ID NO: 39).
30. The AAV particle of claim 27, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_000123.1 (SEQ ID NO: 43),optionally wherein the transgene coding sequence encodes the amino acid sequence of NP_000123.1 (SEQ ID NO: 43).
31. The AAV particle of claim 27 or claim 30, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_000132.4 (SEQ ID NO: 41) or the coding sequence thereof (nucleotides 172-7227 (SEQ ID NO: 42)),optionally wherein the transgene coding sequence comprises the sequence of NM_000132.4 (SEQ ID NO: 41) or the coding sequence thereof (nucleotides 172-7227 (SEQ ID NO: 42)).
32. The AAV particle of claim 27, wherein the transgene coding sequence encodes an amino acid sequence having 0-30 amino acid mismatches relative to the sequence of NP_063916.1 (SEQ ID NO: 46),155#15239971 v1T19749Attorney Docket No. U1202.70169WO00 optionally wherein the transgene coding sequence encodes the amino acid sequence of NP_063916.1 (SEQID NO: 46).
33. The AAV particle of claim 27 or claim 32, wherein the transgene coding sequence comprises a sequence that has 0-60 nucleotide mismatches relative to the sequence of NM_019863.3 (SEQ ID NO: 44) or the coding sequence thereof (nucleotides 161-811 (SEQ ID NO: 45)),optionally wherein the transgene coding sequence comprises the sequence of NM_019863.3 (SEQ ID NO: 44) or the coding sequence thereof (nucleotides 161-811 (SEQ ID NO: 45)).
34. The AAV particle of any one of claims 1-18 and 27-29, wherein the nucleic acid vector comprises the sequence of pscAAV3-TTR-BDD-FVIII (SEQ ID NO: 47) or pscAAV3-GRE-TTR-BDD-FVIII (SEQ ID NO: 48).
35. A pharmaceutical composition comprising the AAV particle of any one of claims 1-34 and a pharmaceutically-acceptable carrier.
36. A method of treating a subject in need thereof, the method comprising administering to the subject the AAV particle of any one of claims 1-34.
37. The method of claim 36, wherein the subject has been diagnosed with a coagulopathy.
38. The method of claim 37, wherein the coagulopathy is a hemophilia.
39. A method of treating hemophilia B in a subject, the method comprising administering to the subject the AAV particle of any one of claim 1-26, or a pharmaceutical composition comprising the AAV particle of any one of claims 1-26 and a pharmaceutically-acceptable carrier.
40. A method of treating hemophilia A in a subject, the method comprising administering to the subject the AAV particle of any one of claims 1-18 and 27-34 or a pharmaceutical composition comprising the AAV particle of any one of claims 1-18 and 27-24 and a pharmaceutically-acceptable carrier.156#15239971 v1
